Hereditary deaf-blindness. Clinical and genetic aspects. by Pennings, R.J.E.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/58910
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
Hereditary Deaf-Blindness 
clinical and genetic aspects 
Ronald Pennings 

HEREDITARY DEAF-BLINDNESS 
clinical and genetic aspects 
Print: PrintPartners Ipskamp, Enschede 
Cover: The U of Usher is shown in hand alphabet on the cover, whereas the word 
Usher is shown on the rearside of this thesis. The hands belong to the parents of 
the author. 
ISBN 90-9017938-0 
© 2004 by Pennings, Ronald Johannes Elisabeth 
Hereditary Deaf-Blindness, clinical and genetic aspects. 
Thesis University Nijmegen. 
All rights reserved. No part of this publication may be reproduced in any form or 
by any means, electronically, mechanically, by print or otherwise without written 
permission of the copyright owner. 
HEREDITARY DEAF-BLINDNESS 
clinical and genetic aspects 
Een wetenschappelijke proeve 
op het gebied van 
de Medische Wetenschappen 
PROEFSCHRIFT 
Ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
op gezag van de Rector Magnificus, prof. dr. C.W.P.M. Blom, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op 
donderdag 29 april 2004 
des namiddags om 1:30 precies 
door 
Ronald Johannes Elisabeth Pennings 
geboren op 17 april 1975 
te 's-Hertogenbosch 
Promotores: Prof. Dr. C.W.R.J. Cremers 
Prof. Dr. A.F. Deutman 
Copromotor: Dr. H. Kremer 
Dr. P.L.M. Huygen 
Manuscriptcommissie: Prof. Dr. H.G. Brunner (voorzitter) 
Prof. Dr. G. Van Camp (Universiteit Antwerpen) 
Prof. Dr. C.H. van Os 
Prof. Dr. H.P.H. Kremer 
Prof. Dr. L.L.A. Monnens 
This study was supported by grants from: 
Forschung contra Blindheit - Initiative Usher syndrom - e.V. 
ZonMw (AGIKO-project) 
Nijmegen ORL Research Foundation 
Heinsius Houbolt Foundation 
Publication of this thesis was financially supported by: Audire, Oticon Nederland, Beter 
Horen, Veenhuis Medical Audio, EmiD audiologische apparatuur, Beltone Nederland, 
Stichting Atze Spoor Fonds, Zon MW, ALVA BV, Glaxo Wellcome, URSAPHARM Benelux 
BV, Kooij Optiek Hoortoestellen, Schering Plough, UCB Pharma, Mediprof & Carl Zeiss. 
tu remanebis amicus maximus perpetuo 
CONTENTS 
ABBREVIATIONS 
PREFACE AND AIMS OF THE STUDY 
page 
CHAPTER 1: GENERAL INTRODUCTION 13 
1.1 Usher syndrome 15 
1.2 Wolfram syndrome 31 
1.3 A molecular genetic approach to sensorineural 
hearing impairment 45 
1.4 A review of progressive phenotypes in nonsyndromic 79 
autosomal dominant hearing impairment. 
R ] £ Penmngs, Ρ L M Huygen, G Van Camp, CWR J Cremers 
Audiological Medicine 2003,1 47-55 
CHAPTER 2: METHODS 95 
2.1 Characterising and distinguishing progressive phenotypes in 97 
nonsyndromic autosomal dominant hearing impairment. 
Ρ h M Huygen, R J E Penmngs, CWR] Cremers 
Audiological Medicine 2003,1 37-46 
CHAPTER 3: USHER SYNDROME 111 
3.1 Variable clinical features in patients with CDH23 mutations 123 
(USHld-DFNB12). 
R/E Pennmgs, V Topsakal, L Astuto, Α Ρ M de Brouwer, M Wagenaar, 
Ρ LM Huygen, W ƒ Kimberhng, A F Deutman, H Kremer, CWR J Cremers 
Otology & Neurotology 2004, conditionally accepted 
3.2 Evaluation of visual impairment in Usher syndrome lb and 129 
Usher syndrome Ha. 
R I E Penmngs, Ρ LM Huygen, D ƒ Orten, M Wagenaar, A van Aarem, 
H Kremer, W] Kimberlmg, C W R j Cremers 
Acta Ophthalmologica Scandmavica 2004, in press 
3.3 Pure tone hearing thesholds and speech recognition scores 247 
in Dutch patients carrying mutations in the USH2A gene. 
R.J.E. Penmngs, Ρ LM. Huygen, M.D. Weston, A. van Aarem, M Wagenaar, 
WJ Kimberling, C.W.R.J. Cremers 
Otology & Neurotology 2003;24 58-63. 
3.4 Analysis of optokinetic and vestibular responses related to 161 
advancing age and increasing visual impairment in Usher 
syndrome type Ha. 
Ρ LM Huygen, R.J.E. Penmngs, M.GM. Nicolasen, A. van Aarem, M.D. Weston, 
A.F. Deutman, W.I.M. Verhagen, Η. Kremer, W.J. Kimberling, C.W.R.J. Cremers 
Experimental Brain Research 2004, submitted. 
3.5 USH2A mutation analysis in 70 Dutch families with Usher 189 
syndrome type II. 
R.J.E. Penmngs, H. te Bnnke, M D. Weston, A. Claassen, D.J Orten, H. Weekamp, 
A. van Aarem, P.L.M. Huygen, A.F. Deutman, L.H. Hoefsloot, F Ρ M. Cremers, 
C.W.R ƒ Cremers, W.J. Kimberling, H. Kremer 
Human Mutation 2004; conditionally accepted. 
3.6 Usher syndrome type III can mimic other types of 203 
Usher syndrome. 
R.J.E. Penmngs, R.R. Fields, P.L.M Huygen, A.F. Deutman, W.J. Kimberling, 
C.W.R.J. Cremers 
Annals of Otology, Rhinology & Laryngology 2003;112.525-530. 
CHAPTER 4: WOLFRAM SYNDROME 217 
4.1 Sex-related hearing impairment in Wolfram syndrome 219 
patients identified by inactivating WFS1 mutations. 
R.J E Penmngs, P.L.M. Huygen, j.M.W. van den Ouweland, K. Cryns, 
L.D. Dikkeschei, G. Van Camp, C W.R.J. Cremers 
Audiology Neuro-Otology 2004;9:51-62. 
CHAPTER 5: AUTOSOMAL DOMINANT 239 
NONSYNDROMIC LOW-FREQUENCY 
HEARING IMPAIRMENT (DFNA6/14) 
5.1 Progression of low-frequency sensorineural hearing loss 241 
(DFNA6/14-WFSÎ) 
R ƒ E Penmngs, S ƒ H Bom, Κ Cryns, Κ Flothmann, PLM Huygen, 
Η Kremer, C Van Camp, CVVRj Cremers 
Archives of Otolaryngology-Head & Neck Surgery 2003,129:421-426 
CHAPTER 6: GENERAL DISCUSSION 255 
CHAPTER 7: SUMMARY AND CONCLUSIONS 267 
Summary and conclusions 269 
Samen va tting en conclusies 2 75 
Dankwoord 283 
Curriculum Vitae 285 
List of publications 286 
ABBREVIATIONS 
ANCOVA 
ANOVA 
ARTA 
CEDOKAN 
DFNA 
DFNB 
DP 
FFS 
FAS 
FVS 
G 
HI 
IHC 
OHC 
OKAN 
OKN 
RP 
RPA 
RPE 
RPSP 
SNP 
SPV 
Τ 
ToKAN 
TFA 
USH2a 
USH2A 
USH2A 
VoKAN 
V 
VA 
VAS 
VFS 
VOR 
analysis of covariance 
analysis of variance 
age-related typical audiograms 
cumulative eye displacement during OKAN 
autosomal dominant inherited sensorineural HI 
autosomal recessive inherited sensorineural HI 
directional preponderance 
functional field score 
functional acuity score 
functional vision score 
gesampt amplitude 
hearing impairment 
inner hair cell 
outer hair cell 
optokinetic afternystagmus 
optokinetic nystagmus 
retinitis pigmentosa 
retinitis punctata albescens 
retinal pigment epithelium 
retinitis pigmentosa sine pigmento 
single nucleotide polymorphism 
slow phase velocity 
time constant 
OKAN time constant 
threshold features array 
Usher syndrome type IIa (genetic subtype) 
locus of USH?a 
gene of USH2a 
initial velocity of OKAN 
initial velocity 
visual acuity 
visual acuity score 
visual field score 
vestibulo-ocular reflex 
PREFACE AND AIMS OF THIS STUDY 
Preface 
This thesis is part of the ongoing Nijmegen Usher syndrome research project, 
which is directed by Cor Cremers. In this project, families and individual patients 
with Usher syndrome are contacted and examined to evaluate their clinical 
features. In addition, blood samples are taken from the patients and their relatives 
to perform linkage studies and mutation analysis of Usher syndrome genes. These 
genetic studies are performed at the Center for the Study and Treatment of Usher 
syndrome, in the Boys Town National Research Hospital in Omaha, USA (Bill 
Kimberling) and, since 2000, DNA samples of Usher syndrome families are also 
analysed at the Department of Human Genetics of the UMC St Radboud at 
Nijmegen, the Netherlands (Hannie Kremer, Heleen te Brinke, Lies Hoefsloot and 
Frans Cremers). The first Nijmegen PhD thesis on Usher syndrome has been 
written by Annelies van Aarem (1996, Heterogeneity in the Usher syndrome) and 
the second PhD study was written by Mariette Wagenaar (2000, The Usher 
syndrome, a clinical and genetic correlation). 
This is the third thesis, bearing on the third Usher syndrome project that started in 
april 2001. It was facilitated by a grant from the German foundation Forschung 
Contra Blindheit- Initiative Usher syndrom (Mr. And Mrs. Ger & Angelika König). 
At the beginning of this project, the PhD student involved had to learn how to 
perform a family study. A family with low-frequency hearing impairment was 
examined and within two months mutations in the Wolfram syndrome 1 gene 
(WFS1) were found to be responsible for the hearing impairment (DFNA6/14) in 
that family. As Wolfram syndrome, similar to Usher syndrome, is a deaf-blindness 
syndrome, it was decided to study families with this syndrome as well. This was 
done in close cooperation with the Department of Medical Genetics of the 
University of Antwerp in Antwerp, Belgium (Guy Van Camp & Kim Cryns), and 
the Department of Clinical Chemistry of the Isaia Clinics in Zwolle, the 
Netherlands (Bert Dikkeschei & Jody van den Ouweland). In May 2003, the fourth 
Nijmegen Usher syndrome research project has started (Rutger Plantinga). This 
project will study the genotype-phenotype correlation in Finnish Usher syndrome 
type III patients and is performed in close cooperation with Finnish scientists, who 
have examined many of these patients exhibiting progressive hearing loss 
(Leenamaija Kleemola) and who have cloned the USH3 gene (Eeva-Marja Sankila). 
Aims of the study 
1. To develop in more detail a useful method to analyse audiometrie data and 
thus to classify and distinguish families with hearing impairment in order to 
guide future linkage and gene identification studies. 
2. To further delineate the phenotype of several genetic subtypes of Usher 
syndrome, hereby focusing on audiometrie, ophthalmological and vestibular 
examination results. 
3. To perform linkage and mutation analysis of the ÜSH2A gene in Dutch 
Usher syndrome type II families in order to support the DNA diagnostics 
and genetic counselling of Usher syndrome families. 
4. To evaluate and analyse the audiovestibular features ofWolfram syndrome 
patients and their relatives. 
5. To evaluate and analyse the audiometrie findings associated with 
DFNA6/14. 
The general introduction is divided into four sections. In the first two sections 
specific attention is paid to Usher syndrome and Wolfram syndrome. The 
historical perspective, clinical characteristics and genetic characteristics are 
described for these two syndromes. In the third section, a molecular genetic 
approach to sensorineural hearing impairment is given, in which the currently 
identified genes are classified and described according to their function in the 
inner ear. The last section is a review of progressive phenotypes in nonsyndromic 
autosomal dominant hearing impairment that was published in Audiological 
Medicine. 
The results of this study are presented in five different chapters. Chapter 2 
describes a method to analyse audiometrie data. Chapter 3 presents the 
phenotype-genotype correlation studies performed on several different groups of 
genotyped Usher syndrome patients (USHlb, USHld, USH2a en USH3). Chapter 
4 presents the audiovestibular findings in 11 Wolfram syndrome patients and 
Chapter 5 shows the results of audiovestibular examinations in two new 
DFNA6/14 families. In Chapter 6 the results of this PhD study are discussed and 
related to the aims of this study. Finally, in Chapter 7 the summary and 
conclusions of this study are presented in English and in Dutch. 

CHAPTER 1 
GENERAL INTRODUCTION 

1.1
USHER SYNDROME

INTRODUCTION 
HISTORICAL PERSPECTIVE OF USHER SYNDROME. 
In the second part of the 19th century, the first reports on hereditary causes of 
deafness and blindness were published. One of the first pioneers in research of the 
deaf was Sir William Wilde, an Irish otologist. In 1853, about a decade before the 
introduction of Mendel's laws, William Wilde was the first to describe autosomal 
dominant inheritance of hearing impairment (HI) in Irish families.1 In 1857, 
Donders, the famous Dutch ophthalmologist, described the bone spicule 
formation we now know as retinitis pigmentosa (RP).2 Alfred Graefe was the first 
ophthalmologist who noticed the combination of deafness and RP in 3 related 
patients and suspected a hereditary cause. His uncle, the famous ophthalmologist 
Albrecht von Graefe, described these three cases in his scientific journal in 1858.3 
During the 19th century, the first large studies of populations with HI were 
conducted and it was noted that in many cases the HI was accompanied by other 
disorders such as ophthalmological diseases, mental retardation, epilepsy and 
Polydactyly.4-5 Liebreich, another German ophthalmologist, performed systematic 
examinations on a large group of 341 deaf inhabitants of Berlin. The proportion of 
RP in this group of deaf patients was high, and remarkably, even higher in 
consanguineous Jewish families.4 
At that time, Gregor Johann Mendel, a monk and biologist from Brno who 
performed studies on pea pod plants, publishes his "Versuche über Pflanzen-
Hybriden", which later became the basis for the establishment of modern 
genetics.6 In this work he proposed the principles of heredity and introduced the 
concept of dominantly and recessively inherited genes to explain how 
characteristic features can be repressed in one generation, but appear in the next. 
Although his work already had been published in 1866, it was relatively 
unappreciated until the beginning of the 20th century. 
Arthur Hartmann, a German otologist, was one of the first to describe an indirect 
(recessive) inheritance pattern of HI in his book on deaf-mutes published in 1880.7 
A chapter on deafness and blindness again accurately stressed the combination of 
profound deafness and RP and its relation to consanguineous marriages. He also 
emphasised the difficulties in educating individuals with visual as well as HI and 
promoted the oral method for the education of hearing impaired individuals, 
which at that time was not generally accepted. In 1919, De Wilde was one of the 
first Dutch doctors who reported on individuals with a combination of HI and 
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visual impairment in the Netherlands. He concluded that 38 of 167 (22%) Dutch 
RP patients also suffered from HI; 13 of them had been born in consanguineous 
marriages.8 
The syndromal combination of HI and RP was finally named after the Scottish 
ophthalmologist Charles Howard Usher (1865-1942), born 7 years (!) after the first 
description of deafness and RP in a patient and two of his sibs by Albrecht von 
Graefe. Charles Usher was the fourth son in a prominent Edinburgh family. After 
studying at Cambridge University he got his medical degree at the St Thomas 
Hospital in London. He was very dedicated to 
his work and spent much time on performing 
extensive family studies, especially in the 
Highlands of Scotland. Influenced by his mentor 
Edward Nettleship, an eminent ophthalmologist 
of that time, he decided to study a population of 
visually impaired patients.9 The results of these 
elaborate studies were described in his book 
entitled "On the inheritance of retinitis pigmentosa, 
with notes of cases", which was published in 
1914.10 In this book he only briefly mentioned 
that 19 of 69 RP patients to some degree had HI. 
After his presentation in 1935 of the Bowman 
Lecture "On a few hereditary eye affections", in 
Charles Usher (1865-1942)
 w h i c h s e v e r a l f a m i i i e s w i t h eye disorders were 
presented to a large group of scientists, his name became an eponym for the 
syndromal combination of RP and HI.11 This is very remarkable, because in his 
Bowman lecture he did not mention the association of HI and RP. Regarding 
history, it should have been more appropriate to name the syndrome after Alfred 
Graefe or after Liebreich. 
In the past century, the studies on Usher syndrome were conducted from two 
clinical perspectives. The studies by Usher,10 Bell,12 Nettleship,13 Von Wibaut14 and 
Kjerrumgaard15 were performed from an ophthalmological perspective, i.e. data 
on groups of RP patients were collected and it was evaluated how many of them 
also were hearing impaired. The studies performed from an otological perspective 
merely focused on the examination of large groups of deaf patients attending 
schools for the deaf, who in addition had RP. In three Scandinavian countries. 
18 
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Norway,16 Sweden17 and Denmark,18 examinations of large groups of deaf 
individuals were performed on a national scale and two observational studies, by 
Hallgren19 in 1959 and Nuutila20 in 1970, comprised nationwide evaluations of 
Usher syndrome patients in Sweden and Finland, respectively. 
Hallgren was the first to report on the prevalence of Usher syndrome; it was 
estimated to be about 3 per 100,000 inhabitants.19 This estimate was based on his 
study of the Swedish deaf population and on the international literature available 
at that time. At present, the prevalence of Usher syndrome is estimated to range 
from 3.5 - 6.2 per 100,000.20-26 It accounts for about 3-6 % of the congenital types of 
deafness, about 18% of the pigmentary retinopathies and over 50% of all patients 
with deafblindness.27 
Already in 1922 Julia Bell, one of the first prominent female geneticists, was the 
first to report on a difference in the degree of HI in Usher syndrome.12 She 
emphasised that there were two groups of patients, one in which HI was profound 
and a second one in which the patients suffered from a moderate to severe type of 
HI. Hallgren in 1959 suggested that these two clinical types of Usher syndrome 
might be caused by two different genes.19 In his studies, Hallgren also described 
psychiatric problems in Usher syndrome patients and for some time this was 
regarded as a separate type of Usher syndrome, which was referred to as the 
Hallgren syndrome. To date, psychiatric illness is no longer defined as a key 
feature in any of the known types of Usher syndrome. 
Whereas Julia Bell already emphasised the clinical heterogeneity of Usher 
syndrome in 1922, several other studies also reported on the variability in clinical 
features. In 1977, this finally led to the original classification described by 
Davenport and Omenn (Table 1, adjusted to recent findings).28 Although mental 
retardation and psychosis at that time were suspected to be part of the syndrome, 
Davenport and Omenn decided to exclude these features from the classification, 
because they regarded them to be secondary to the inherent double sensory 
deprivation. 
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GENETIC AND CLINICAL FEATURES OF USHER SYNDROME 
Usher syndrome is divided into three clinical types (Table 1). These three clinical 
types are further divided into several genetic subtypes on the basis of the 
identification of loci and genes as is shown in Table 2. In the next paragraphs, the 
genetic characteristics are described, followed by a detailed description of the 
audiological, vestibular and ophthalmological features of the 3 clinical types of 
Usher syndrome. 
Table 1. Original clinical classification by Davenport and Omenn (1977) ^ adjusted to recent 
findings. 
Hearing impairment Visual impairment Vestibular function 
Usher type I Severe to profound congenital RP onset before Vestibular areflexia 
deafness puberty 
Usher type II Moderate to severe hearing RP onset after puberty Normal/variable 
loss 
Usher type III Progressive hearing loss RP Variable 
RP: retinitis pigmentosa. 
Genetic characteristics of Usher syndrome 
Since the beginning of the eighties of the past century, family studies have been 
initiated with the purpose of mapping and identifying the genes involved in 
Usher syndrome. The first locus for Usher syndrome (USH2A) was localised to 
chromosome lq41 by Kimberling et al. in 1990.29 In the past decade several genes 
were linked and cloned and it was proven that Usher syndrome was more 
heterogeneous than originally had been thought. At present, 11 loci, including 7 
identified genes, are known to be involved in Usher syndrome.30 In Table 2, the 
presently known to be involved loci and genes are shown for the different types of 
Usher syndrome. 
Several useful reviews on the molecular genetics of Usher syndrome have 
appeared recently.46"49 Some of the genes found to be involved in Usher syndrome 
are also involved in nonsyndromic types of hearing loss or RP. For example, 
MY07A, the gene involved in Usher syndrome lb (USHlb), also harbours 
mutations in families with DFNA11,50 a nonsyndromic dominant type of 
sensorineural HI, as well as in families with DFNB2,51 a nonsyndromic recessive 
type of sensorineural HI. Other genetic subtypes of Usher syndrome and 
nonsyndromic types of HI caused by mutations in the same gene are Usher 
20 
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syndrome le (USHlc) and DFNB18,52 and Usher syndrome Id (USHld) and 
DFNB12.36 In the USH2A gene a frequent mutation (Cys759Phe) causes about 4.5% 
of the cases of nonsyndromic recessive RP.53 The most recent knowledge on the 
function of the proteins of the known Usher syndrome genes and the functional 
complexes they form is described in the section "A molecular genetic approach to 
sensorineural hearing impairment". 
Table 2. Genetic subtypes of Usher syndrome. 
Type 
Type I 
Type II 
Type III 
Genetic 
subtype 
USHla 
USHlb 
USHlc 
USHld 
USHle 
USHlf 
USHlg 
USH2a 
USH2b 
USH2c 
USH3 
Chromosomal 
location 
14q32 
l lql3.5 
l lp lS . l 
lOq 
21q 
10q21-22 
17q24-15 
lq41 
3p23-24.2 
5ql4.3-21.3 
3q21-25 
Gene 
-
MY07A 
USH1C 
CDH23 
-
PCDH75 
SANS 
USH2A 
-
-
USH3 
Mouse 
model 
-
Shakeri 
-
Waltzer 
-
Ames 
Waltzer 
Jackson 
shaker 
-
-
-
-
OMIM τ 
276900 
276903 
276904 
601067 
602097 
602083 
607696 
276901 
276905 
605472 
606397 
References 
12 
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45 
OMIM: Online Mendelian Inheritance in Man 31 
Hearing impairment 
Usher syndrome type I is characterised by congenital severe to profound HI. The 
patients have a disturbed speech-language development and most of them will 
have their education at schools for the deaf. Because their visual handicap will 
more and more affect their normal daily activities with increasing age, these 
patients will benefit from early cochlear implantation followed by an intensive 
auditory rehabilitation program.54-55 The rehabilitation of Usher syndrome patients 
requires little extra effort when compared to other prelingually deaf patients and 
all of them reported considerable advantages in hearing abilities and social life.55 It 
was shown that Usher syndrome patients have better logopedie results when they 
receive their cochlear implant at younger ages.56 Histopathologic studies of the 
cochlear nuclei in 2 Usher syndrome type I patients have shown that these patients 
with long-term sound deprivation only have minor degenerative changes in the 
dorsal and ventral cochlear nucleus and therefore will benefit from cochlear 
implantation because the central auditory system is intact.57 
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Usher syndrome type I patients with 
congenital severe to profound HI can 
clearly be distinguished from Usher 
syndrome type II patients, who have a 
congenital moderate to severe HI that 
is more prominent in the high-
frequency range This is shown in 
Figure 1 by the Age Related Typical 
Audiograms (ARTA) of Usher 
syndrome IIa (USH2a) patients and 
USHlb patients 5 8 5 9 Usher syndrome 
type II patients can communicate by 
telephone at least up to the age of 50-
60 years and will benefit from hearing 
aids Currently, it is debated as to 
whether or not Usher syndrome type II 
shows progression of HI Previously, 
the suggestion of USH2a patients 
showing progressive HI was made in the reports by Wagenaar et a l 5 9 and van 
Aarem et a l 6 0 In Chapter 3 3 of this thesis, it is demonstrated that a selected 
sample of USH2a patients, all identified by mutation analysis, shows progression 
of HI by about 0 5 dB/year, which in the low frequencies cannot be attributed to 
presbyacusis alone 5 8 
Hmam-Aifa et al reported that the HI in a Tunisian family with USH2a was 
significantly worse than the HI in the only currently known Usher syndrome type 
lib (USH2b) family also originating from Tunisia6 1 In addition, they also stated 
the HI in these two families to be non-progressive In the future, when more genes 
for Usher syndrome type II will be cloned, it will be possible to evaluate the 
associated HI in different genetic subtypes 
ι r 
1 2 4 8 kHz 
Frequency 
Figure 1 ARTA for USHlb and USH2a ^ 
Age in italics (year) 
Besides Usher syndrome type I and II, Usher syndrome type III can be 
distinguished, mainly by its characteristic progression of HI Although Usher 
syndrome type III is considered to be a rare type (2%) of Usher syndrome, it was 
noticed that in Finland about 40% of the Usher syndrome patients are having this 
progressive type of H I 6 2 The first study of this patient group was performed by 
22 
INTRODUCTION 
Karjalainen et al. 63, who examined 18 patients with progressive HI. This study 
was expanded by Pakarinen and Sankila, in order to clone the responsible gene for 
Usher syndrome type III and to describe the clinical features of this type of Usher 
syndrome. In an elaborate, relatively unknown study, Pakarinen et al.64 described 
42 Usher syndrome type III patients. They stated that HI in Usher syndrome type 
III most often has a postlingual onset and progresses to severe to profound HI in a 
variable duration of 5 to 30 years. Thus, at higher ages these patients have a 
hearing loss that resembles Usher syndrome type I but, unlike Usher syndrome 
type I patients, most of them communicate by speech.64 On the basis of this work, 
Sankila et al. were able to map the ÌJSH3 gene to chromosome 3q ft5 and to clone 
the LÌSH3 gene in 2001.66 A founder mutation (Y100X) in this gene was responsible 
for most of the Finnish Usher syndrome type III patients, which were all identified 
by progressive HI. In the Netherlands, Usher syndrome type III is rare. The 
clinical examination results of the first and so far only Dutch USH3 family are 
reported in Chapter 3.6 of this thesis.67 
Visual impairment 
The visual impairment in Usher syndrome is caused by RP (Figure 2). Synonyms 
are pigmentary retinopathy and tapetoretinal degeneration, however, RP is now 
most commonly used in literature. The term retinitis is semantically incorrect, 
because retinitis refers to 
inflammation of the retina, which is 
unusual for the disease. The term 
pigmentosa refers to the 
characteristic melanin depositions 
in the retina in more advanced 
stages of RP. The intraretinal 
deposition of pigment and arterio-
lar narrowing characterise the 
fundus appearance in patients with 
RP and are prerequisites for the 
diagnosis. As the deterioration of 
retinal photoreceptors progresses, 
cells and pigment particles from the 
retinal pigment epithelium detach from Bruch's membrane and accumulate in the 
thinner retina where they form pigmented bone-spicule formations around the 
Figure 2. Retinitis pigmentosa of the right eye 
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thin-walled blood-vessels.67-68 On funduscopy, bone spicules can be clearly seen, 
especially in the mid-periphery of the retina they are most prominent. In addition, 
with the developing atrophy of the retina, the retinal blood vessels tend to 
attenuate and the disk will develop a waxy appearance (Figure 2). Atypical forms 
of RP have also been reported in Usher syndrome patients. Retinitis pigmentosa 
sine pigmento, i.e. RP without the characteristic pigment depositions and retinitis 
punctata albescens, i.e. the presence of multiple scattered white dots in the mid-
periphery of the retina, were seen in the Dutch Usher syndrome type III family.69 
Retinitis punctata albescens was also described in another Dutch Usher syndrome 
patient,70 in whom we recently identified a mutation in the Usher syndrome type 
Ha gene.71 In his thesis (1976), Cremers already described a brother and sister with 
Usher syndrome type I and retinitis pigmentosa sine pigmento.72 
RP presents with nyctalopia (nightblindness) in the first decade of life or during 
early adolescence. This is mainly due to degeneration of the rods in the retina, 
however, in the following decades progressive deterioration of rods as well as 
cones gradually and increasingly affects vision. As the disease progresses over the 
years, constriction of the visual fields leads to tunnel vision.68 In addition, visual 
acuity starts to deteriorate, related to a loss of cones in the central retina. Visual 
acuity can be disturbed not only by degeneration of cones in the retina, but also by 
the development of posterior subcapsular cataract. This type of cataract can be 
removed by surgery, however, not all patients will benefit from such treatment 
due to the poor visual acuity that is seen in some of them.68 To evaluate the 
deterioration of visual field size, Goldmann perimetry is used. Before signs of RP 
can be seen on funduscopy, subnormal electroretinogram values may already 
indicate RP at young age.73 The early diagnosis of RP by electroretinography was 
first advocated by Vernon et al.74 Their recommendation was based on the finding 
that the electroretinogram may detect the presence of retinal disease secondary to 
RP before the onset of signs or symptoms of this disorder.74 
Several studies have emphasised a more unfavourable course in Usher syndrome 
type I than in Usher syndrome type Π. 7 5 7 7 It is also emphasised that night 
blindness starts several years later in Usher syndrome type II than in Usher 
syndrome type I.78 However, other studies were not able to detect significant 
differences in this regard between Usher syndrome type I and II, although they 
described an apparently worse outcome in Usher syndrome type I patients.79·80 
Unfortunately, these studies only comprised cross-sectional analyses of data in 
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patients who were selected on the basis of clinical findings and not on the basis of 
mutation analysis. In Chapter 3.2 of this thesis, we identified no difference in 
progression of visual field size and visual acuity in cross-sectional analysis 
between USHlb and USH2a. Longitudinal analysis of several USH2a patients, 
however, suggested a later onset age and a higher rate of deterioration in these 
patients.81 It is important to mention that not all Usher syndrome patients will 
become blind, however, the prevalence of blindness increases with age. About 
40% of the patients will be blind by the fifth decade, 60% by the sixth decade and 
75% by the seventh decade of life, whereas the patients who are not blind by the 
latter ages will have developed severe visual impairment. 
In patients with Usher syndrome type III, a high proportion of hypermetropia 
with a high degree of astigmatism was found in refraction tests.64·82 This was 
found to be more frequent in Usher syndrome type III than in the general 
population. In addition, most of the progression of visual deterioration occurred 
below the age of 40 and was continuous up to that age. Visual acuity was severely 
impaired by the age of 37 and the visual fields were constricted without peripheral 
islands at an average age of 30 years.82 
Vestibular impairment 
Patients with Usher syndrome type I have vestibular areflexia by definition (Table 
1). These patients have delayed motor milestones and most of them are not able to 
walk independently at age below 18 months. Therefore, children with profound 
HI and delayed motor milestones should be tested for vestibular areflexia. This is 
best done by using a rotatory chair, while the child is seated on a parent's lap. 
Patients with vestibular areflexia also have difficulties in learning to ride a bicycle. 
Vestibular areflexia in Usher syndrome lb patients and in the related mouse model 
(shakeri) is caused by peripheral dysfunction of the labyrinth and malfunction of 
vestibular hair cells.83-85 In the section on "A molecular genetic approach to 
sensorineural hearing impairment" it is described that the proteins encoded by the 
USHlb, USHlc, USHld and USHlg genes interact and thus shape the stereocilia 
of the inner ear hair cells. These proteins are likely to have a similar function in 
vestibular sensory epithelia and therefore, similarly to the cochlea, normal 
function is disturbed, by abnormal protein expression. 
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Although vestibular function in Usher syndrome type II has always been 
designated as "normal", in Chapter 3.4 it is shown that this is often not the case.86 
Over 15 years of vestibular examinations of Usher syndrome type II cases has 
shown that the results of optokinetic nystagmus (OKN) and vestibulo-ocular 
reflex (VOR) examinations were seldom normal.86 Variable vestibular findings 
have been reported in Usher syndrome type III patients.64 In about 50% of them a 
reduced response on caloric testing was found.66 Recently, Otterstedde et al. 
proposed a new classification for Usher syndrome type I.89 Their clinically 
identified Usher syndrome type I patients with profound HI were divided into a 
group with vestibular areflexia (n=17) and a group with normal vestibular 
function (n=9).89 However, no mutation or linkage analysis was performed to 
genetically classify these patients and thus it could have been possible that these 9 
patients from Germany were in fact Usher syndrome type III patients with early, 
severe progression of HI and intact vestibular responses. 
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WOLFRAM SYNDROME

INTRODUCTION 
HISTORICAL PERSPECTIVE OF WOLFRAM SYNDROME 
In 1938, Wolfram and Wagener reported on a family with 6 children, 4 of them 
having the combination of diabetes mellitus and optic atrophy 1 In 3 sibs the 
diabetes mellitus preceded the optic atrophy, however, the youngest sib first 
presented with optic atrophy On the basis of these findings they concluded that 
the optic atrophy could not have been caused by the disturbance of the sugar 
metabolism This was the first publication that reported on the association of 
diabetes mellitus and progressive optic atrophy Several years later, Tunbridge 
(1956) reported on a personal communication with Wagener that three of the sibs 
reported on in 1938 also had subnormal hearing as tested by watch ticks Two of 
the children were re-examined and their optic atrophy had progressed to complete 
blindness Wagener also stated that two sibs had developed a cord bladder2 In the 
next decades, many case reports on similar patients were published and over the 
years it became apparent that the combination of diabetes mellitus, optic atrophy, 
diabetes insipidus and sensorineural HI was one that belonged to a rare 
syndrome In 1977, Cremers et al ^ described 3 additional cases from the 
Netherlands and presented a review of 88 cases described in the international 
literature In this publication, the syndromic association was referred to as 
Wolfram syndrome, to acknowledge the original publication in 1938 ^ Another 
important study on Wolfram syndrome was performed by Barrett et al in 19954 
They performed a UK nationwide study and included 45 patients with Wolfram 
syndrome, which illustrates the rarity of the syndrome In the next paragraphs, the 
clinical and genetic features of Wolfram syndrome will be outlined 
CLINICAL CHARACTERISTICS OF WOLFRAM SYNDROME 
Wolfram syndrome is also known by the acronym DIDMOAD, which stands for 
Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness It shows 
autosomal recessive inheritance and is rare, with an estimated general prevalence 
of 1 in 770,000 in the UK4 The syndrome is caused by mutations in the WFS1 
gene,5 6 which encodes wolframin 
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Diabetes mellitus 
Diabetes mellitus has a median age of presentation of 6 years and is non-
autoimmune, insulin-deficient and non-HLA linked3 4 Remarkably, Wolfram 
syndrome patients seem relatively resistant to microvascular complications7 The 
reason for this is unclear, however, a hypothesis is that the decreased levels of sex 
steroid hormones in these patients protect against diabetic retinopathy by 
decreasing vascular permeability8 Although the diabetes mellitus presents in an 
atypical fashion, it is clearly related to the loss of ß-cells in the islets of Langerhans 
m the pancreas, which results in reduced production of insulin 9 In addition, it has 
recently been shown that wolframin is required to maintain normal rates of β -cell 
proliferation w 
Optic atrophy 
Progressive optic atrophy presents with reduced visual acuity and loss of colour 
vision (blue-yellow) at a median age of 11 years 3 4 At about 18-19 years, optic 
atrophy in most cases has progressed to complete blindness4 8 1 1 In Wolfram 
syndrome, optic atrophy is not secondary to retinal pathology It is part of a more 
generalised degeneration of neural structures 8 1 2 In addition to optic atrophy, in 
about 65% cataract is found, however, this is only mild and not contributing to the 
loss of vision1 3 Pathology examinations have revealed atrophy not only of the 
optic nerve, but of the entire visual pathway with degeneration of retinal ganglion 
cells, loss of nerve fibers in the optic nerves, optic chiasm and central optic tracts1 4 
Diabetes insipidus 
Diabetes insipidus in Wolfram syndrome patients is of hypothalamic origin and 
responds to vasopressin treatment It manifests in about 75% of the patients in the 
second decade of life at a median age of 14 years 1 4 Polyuria is often presumed to 
be secondary to diabetic hyperglycemia and it therefore may take long before the 
actual diagnosis is made 4 In addition, atony of the urinary tract may be suggestive 
for the presence of renal diabetes insipidus, which may obscure the hypothalamic 
origin1 5 Some studies suggest that hypothalamic diabetes insipidus occurs in 
nearly all Wolfram syndrome patients 1 6 On postmortem examination, the 
hypothalamus shows loss of vasopressin neurons in the supraoptic and 
paraventricular nuclei 1 2 However, not only loss of vasopressin neurons occurs in 
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Wolfram syndrome but in another Dutch study it was shown that there is also a 
defect in vasopressin precursor processing.17 
Deafness - Hearing impairment 
HI is estimated to occur in 51-62% of the Wolfram syndrome patients.4·718 It 
manifests mostly in the second decade of life at a median age of 15-16 years.3-4 The 
hearing loss is most prominent in the high-frequency range, however, in case of 
progressive HI the low frequencies also tend to be affected.319 Ohata et al. 
reported an increased risk for hearing loss in heterozygous carriers of WFSI 
mutations in a Wolfram syndrome family.20 However, in their study the type of HI 
was not described and thus it cannot be determined whether or not it was similar 
to DFNA6/14, a low-frequency type of HI, which is caused by heterozygous 
mutations in the WFSI gene.2122 In Chapter 4.1 of this thesis, the results of 
audiovestibular examinations in 11 Wolfram syndrome patients from the 
Netherlands are presented.23 The audiovestibular examination results of 2 Dutch 
DFNA6/14 families are described in Chapter 5.1 of this thesis and are briefly 
mentioned in the review in the last section of this introduction.24-25 
Urological abnormalities 
Dilatation of the urinary tract is a common feature in Wolfram syndrome. 
Although it is not covered by the acronym DIDMOAD, it manifests mainly in the 
second decade in 52-58% of the Wolfram syndrome patients.3-4<1H.The median onset 
age is 15-20 years.418 Patients often complain about incontinence and a high 
urinary frequency, which may be caused by the hypothalamic diabetes insipidus 
and/or a poorly managed diabetes mellitus.4 Hydronephrosis and/or 
hydroureters are present in about 75% of the Wolfram syndrome patients with 
urinary anomalies.18-26 It has been hypothesised that hydronephrosis may be 
caused by the high urine output, however, Tekgül et al. reported that severe 
hydronephrosis did not improve on desmopressin therapy. Bladder dysfunction 
in Wolfram syndrome presents in a wide spectrum, with a large atonic bladder 
and a low-capacity, high-pressure bladder with sphincteric dyssynergia as the 
most common manifestations. Therefore, bladder dysfunction is thought to be a 
primary feature of the syndrome instead of a secondary feature.26 
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Neuropsychiatrie abnormalities 
Central nervous system abnormalities are found in Wolfram syndrome patients 
with a median age of onset at 30 years4 There is much variability in the 
presentation of these abnormalities Truncal ataxia, which causes unsteady gait 
and falling, is the most common finding and is seen in approximately 30% of the 
patients418 Another common finding is central respiratory dysfunction and apnea, 
which is the cause of death in 39% of the cases in one report918 Additional 
neurological features reported in Wolfram syndrome include seizures, startle 
myoclonus, reduced limb reflexes, nystagmus, dysarthria, anosmia, ageusia and 
hemiparesis, peripheral neuropathy and developmental disabilities 9 27 The variety 
of neurological abnormalities reflects the underlying neurodegeneration, which 
can manifest anywhere in the central nervous system Magnetic resonance 
imaging studies of Wolfram syndrome patients have shown widespread 
neurodegeneration28 29 Also in postmortem examinations of Wolfram syndrome 
patients, neurodegeneration of many regions of the brain and widespread axonal 
pathology that parallels the neurodegeneration is a common finding14 30 
Neurodegeneration may also be involved in the psychiatric features of Wolfram 
syndrome In about 60% of reviewed cases in the USA, psychiatric findings were 
reported and consisted of episodes of severe depression, psychosis or organic 
brain syndrome, as well as impulsive verbal and physical agression In 25% of 
these cases the psychiatric symptoms were very severe and in 18% admission to a 
psychiatric hospital was required 11 Mental illness is not only common in Wolfram 
syndrome patients but also their mutation-carrying relatives may be affected The 
prevalence of mental illness in heterozygous carriers of WFS1 mutations is 26-fold 
higher than in non-carriers32 33 
Hypogonadism 
Hypogonadism is a frequent finding in male Wolfram syndrome patients27 The 
relative prevalence of hypogonadism m male Wolfram syndrome patients varies 
from 33-70% 41834 Most of the affected men have small, soft atrophic testes and 
histopathology studies have shown evidence of fibrosis and tubular atrophy18 
Most patients have reduced fertility, however, several female patients had 
succesful pregnancies and gave birth to healthy unaffected children18 35 
Hypogonadism in Wolfram syndrome has been attributed to hypothalamic 
dysfunction with correspondingly low or normal gonadotropin levels36 However, 
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more recent studies have suggested that hypogonadism is merely caused by 
primary gonadal atrophy and not by hypothalamic dysfunction.4·11·18·27'37 
Other clinical manifestations 
Several case reports have shown that Wolfram syndrome patients may also 
develop cardiac abnormalities. Features include Fallot's tetralogy, pulmonary 
valve stenosis, sinus tachycardia and atrial and ventricular arrythmias.18 Anosmia 
is a relatively frequent finding in Wolfram syndrome patients and occurs in about 
9% of the patients.18 Autopsy findings have shown that the underlying cause is 
atrophy of the olfactory bulbs and tracts.14 Gastrointestinal motility disturbances 
have been reported in about 24% of the Wolfram syndrome patients. Symptoms 
include constipation with faecal impaction as well as chronic diarrhoea.4 
Hypothyroidism is also reported in several Wolfram syndrome patients, however, 
it does not appear to be a frequent finding.38 
Mortality 
The median age at death is estimated to be 30 years (25-49 years).4 Causes of death 
include central respiratory failure, renal failure secondary to infection, 
hypoglycaemic coma, pneumonia, status epilepticus, suicide related to psychiatric 
disease, or death related to severely advanced neurodegeneration.41118 
GENETIC CHARACTERISTICS OF WOLFRAM SYNDROME 
In the early nineties of the past century, it has been hypothesised that 
mitochondrial deletions and/or mutations were responsible for Wolfram 
syndrome (OMIM 222300). This was based on the similarity of Wolfram syndrome 
features to symptoms due to mitochondrial mutations including deafness, 
diabetes mellitus, optic atrophy, psychiatric disorders and thrombocytopenia.39J,4 
Several studies have identified abnormalities in the mitochondrial genome in 
patients with Wolfram syndrome. Rötig et al.45 found a deletion of mitochondrial 
DNA in a patient, diagnosed with Wolfram syndrome. However, this patient in 
addition developed a failure to thrive, cerebellar ataxia, nightblindness, 
progressive external ophthalmoplegia, an extrapyrimidal syndrome and mental 
retardation. At 13 years of age, she had severe amyotrophy, inability to stand and 
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walk, RP and major difficulty in swallowing. These symptoms were caused by a 
7670 bp deletion in the mitochondrial genome and skipped the genes COX1, 
COX2, ATPase6, ATPaseS, COX3, ND3, ND4L, ND4 and part of ND5.45 A study by 
Barrientos et al.46 demonstrated a heteroplasmic mitochondrial DNA deletion of 
8.5 kb in 23% of the copies of the mitochondrial DNA in lymphocytes and about 
5% in tissues studied from relatives. The patient was diagnosed with Wolfram 
syndrome on the basis of the presence of the four main symptoms. The authors 
suggested that Wolfram syndrome in this family was caused by a nuclear genetic 
defect inherited in an autosomal recessive mode that predisposes to a 
mitochondrial DNA deletion, which may contribute to the clinical manifestations 
in the homozygous individual.46 To explain the mitochondrial genomic deletions, 
which show maternal inheritance in an autosomal recessively inherited syndrome, 
Bu & Rotter hypothesised a dual genome defect model.47 As Wolfram syndrome 
shows autosomal recessive inheritance and most of the clinical features seem to 
relate to an ATP supply defect often seen in mitochondrial disorders, they 
proposed that nuclear genetic defects or mitochondrial genetic defects can 
independently lead to the same disorder.47 
In 1998, after linkage of the critical region to chromosome 4pl6.1,48·49 two groups 
reported cloning of the Wolfram syndrome 1 gene (PVFS2).5'6 In a more recent 
study by Barrett et al.50, the mitochondrial genome was evaluated in a large 
patient group but no mtDNA mutations or abnormal mitochondrial function were 
found. In 16 of 17 examined families loss of functions mutations in the WFSl gene 
were identified.50 The WFSl gene consists of 8 exons encompassing 33.4 kb of 
genomic DNA and encodes wolframin consisting of 890 amino acids with an 
apparent molecular weight of 100 kD. Wolframin is a transmembrane protein with 
nine transmembrane domains.48-49 Several studies of large patient groups have 
identified many mutations in WFSl. Until recently, no real mutational hotspot or 
clustering of mutations were observed.5154 However, in a Spanish cohort of 12 
different Wolfram syndrome families, an insertion of 16 base pairs in exon 4 was 
found to cause the disease in 6 families.55 Mutation analysis of the WFSl gene 
identifies mutations in about 90% of the patients.54 Most of the identified 
mutations are inactivating or truncating mutations, which suggests that loss of 
wolframin function is the main cause of the disease.56 Only a few patients were 
reported to have homozygous or compound heterozygous missense mutations in 
WFSl. Remarkably, these patients have optic atrophy, diabetes mellitus and in 
some cases HI, however, diabetes insipidus and other Wolfram symptoms are 
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lacking.51-56 In our clinical study of Wolfram syndrome patients, 2 sisters were 
described with compound heterozygous missense mutations in WFS1 and mild 
features of Wolfram syndrome.23-52 It therefore seems possible that missense 
mutations in the WFS1 gene cause a mild variant of Wolfram syndrome, however, 
patients with a homozygous missense mutation in WFS1 and a more severe 
phenotype have also been reported.57 
In 2000, El-Shanti et al.58 examined 16 Wolfram syndrome patients from 4 different 
families and found that 3 families were not linked to the WFS1 locus, but to a 
second locus, designated WFS2 on chromosome 4q22-24. These patients have a 
Wolfram syndrome-like phenotype without evidence of diabetes insipidus but 
with profound upper gastrointestinal tract ulceration and bleeding.58 A prolonged 
bleeding time due to abnormal platelet aggregation was found in these patients.59 
Several studies focused on a possible role of the WFS1 gene in diabetes mellitus or 
psychiatric disorders. Two studies have shown that sequence variants in PVFS1 
may be involved in the pathogenesis of type 2 diabetes mellitus in patients from 
the UK and Spain.60-61 Awata et al.62 have shown that especially R456H and the 
single nucleotide polymorphisms H611R and I720V are significantly correlated 
with type I diabetes mellitus.62 However, whether these sequence variants in 
WFS1 really cause type I or II diabetes mellitus, still remains to be elucidated.56 
Following the report that Wolfram syndrome heterozygotes are 26-fold more 
likely to require psychiatric hospitalisation when compared to non-carriers and 
the fact that Wolfram syndrome heterozygotes may constitute approximately 25% 
of individuals hospitalised with depression and suicide attempts,31-61 some studies 
examined whether or not wolframin plays a major role in affective disorders. 
Several studies have shown that rare coding variants in exon 8 of the WFSì gene 
may be potential risk alleles for psychiatric disease.55-56-6467 However, it is still not 
possible to draw firm conclusions on the basis of these results, because of the very 
low frequencies of these variants.56 
In 2001, two different research groups identified mutations in the WFSI gene as 
the cause of a nonsyndromic autosomal dominantly inherited type of low-
frequency HI, named DFNA6/14.21'22 Mutation analysis of WFSÎ in patients with 
low-frequency sensorineural HI revealed heterozygous mutations in most 
patients. Thus, mutations in this gene are a major cause of low-frequency HI.68 So 
far, there is still no explanation as to why the HI in DFNA6/14 merely affects the 
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low frequencies and in Wolfram syndrome the high frequencies. In addition, the 
mutations responsible for DFNA6/14 seem to be non-inactivating mutations, 
which are located in the C-terminal domain of the protein.68 
At this moment, only little is known about the function of wolframin. Takeda et 
al.69 showed that it has a predominant subcellular localization to the endoplasmic 
reticulum in cultured cells and has neuronal expression in rat brain tissue. No 
colocalization of wolframin with mitochondria was seen. In rat brain, wolframin 
was found to be predominantly present in specific neurons in the hippocampus 
CAI, amygdaloid areas, olfactory tubercle and the superficial layer of the 
allocortex. These sites of expression may be involved in the psychiatric, 
behavioural and emotional abnormalities characteristic of this syndrome. It was 
hypothesised that wolframin plays a role in membrane trafficking, protein 
processing or calcium homeostasis in the endoplasmic reticulum.69 In the inner 
ear, wolframin is expressed in the canalicular reticulum, a specialised form of the 
endoplasmic reticulum, which is believed to be involved in the transcellular 
movements of ions. For this reason, Cryns et al. suggested that wolframin plays a 
role in inner ear ion homeostasis maintained by the canalicular reticulum.70 
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1.3
A MOLECULAR GENETIC 
APPROACH TO SENSORINEURAL 
HEARING IMPAIRMENT

INTRODUCTION 
HISTORICAL PERSPECTIVE AND INTRODUCTION 
Adam Politzer, nowadays regarded as one of the pioneers in Otology, was born in 
1835 in Albertirsa, about 35 kilometres from Budapest. He studied medicine in 
Vienna and received his doctorate in 1859. After this he started working at the 
laboratory of Carl Ludwig, where he performed research on the physical 
principles of the auditory system. It was at this laboratory that he developed the 
politzerisation technique, which made him famous.1 In his second edition of the 
"Lehrbuch der Ohrenheilkunde", published in 1887, he emphasised that many 
individuals suffer from HI that is caused by genetic factors.2 Being a well-known 
otologist, he made heredity as one of the etiological factors of HI an accepted 
concept in modern western otology. Politzer realised that genetics played an 
important role in HI on the basis of studies published in 1880 by his colleague 
Arthur Hartmann, who recognised indirect (recessive) and direct (dominant) 
transmission of deafness.3 Hartmann performed a detailed study of deafmute 
individuals, visited schools and centres for the deaf and presented pedigrees of 
families with hereditary deafness. He was also one of the first to emphasise the 
importance of histopathological examinations of the temporal bones of patients 
with HI. 
Of all sensory disorders, HI is the most prevalent one. HI or deafness is seen in 
1:1000 neonates. In more than 50% of the prelingual cases, the HI is caused by 
genetic factors.4'5-6 The prevalence of postlingual deafness in western Europe, with 
an average hearing threshold > 25 dB, is about 1% in young adults, 10% at age < 
60 years and almost 50% at 80 years.6 Over the age of 65, sensorineural HI is 
caused by genetic as well as environmental factors. The proportion of HI due to 
environmental causes, such as infectious disease is decreasing with improving 
medical treatments. Of all hereditary cases of HI, about 30% is syndromic and 70% 
is nonsyndromic.7 In 75% of these cases with nonsyndromic sensorineural HI there 
is an autosomal recessive pattern of inheritance and in about 20% the inheritance 
is autosomal dominant. X-linked inheritance is seen in about 5% and 
mitochondrial HI in less than 1%.4"8 Autosomal dominantly inherited 
nonsyndromic sensorineural HI subtypes have the prefix DFNA followed by a 
number that represents the order of identification. In the majority of the DFNA 
patients, onset of HI is postlingual and most subtypes show progression of HI. So 
far, 20 genes have been identified for autosomal dominant sensorineural HI (Table 
1) and 20 genes for nonsyndromic autosomal recessive sensorineural HI (Table 
2)/26,27 w hi c h have the prefix DFNB. 
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Table 1. Locus, location and gene with related phenotype, in nonsyndromic types of autosomal dominant sensorineural HI (DFNA). 
Locus Location Gene Phenotype 
DFNA1 
DFNA2 
DFNA3 
DFNA4 
DFNA5 
DFNA6/14/38'' 
DFNA7 
DFNA8/12'' 
DFNA9 
DFNA10 
DFNA11 
DFNA13 
DFNA15 
DFNA16 
DFNA17 
DFNA18 
DFNA19 
DFNA20/26<: 
DFNA21 
DFNA22 
DFNA23 
DFNA24 
DFNA25 
DFNA27 
DFNA28 
DFNA29 
DFNA30 
DFNA31 
5q31 
lp24 
13ql2 
19ql3 
7pl5 
4pl6.3 
Iq21-q23 
Ilq22-q24 
14ql2-ql3 
6q22-q23 
Ilql2.3-q21 
6p21 
5q31 
2q24 
22q 
3q22 
10 
(pericentr) 
17q25 
6p21 
6ql3 
14q21-q22 
4q 
12q21-q24 
4ql2 
8q22 
15q25-q26 
HDIA1 
GJB3 
K.CNQ4 
G]B2 
GJB6 
Posthngual, low-freq., progressive all freq.9 
Postlingual, high-freq., onset 20-40yrs.10 
Postlingual, high-freq., progressive all freq.9 
Prelingual or postlingual, variable presentation and onset, downsloping audiogram.' 
DFNA5 Posthngual, high-freq., onset 5-15 yrs.9 
WFS1 Prelingual, low-freq, slow or non-progressive.9 
TECTA Prelingual, mid-frequency, stable but progressive in some cases.9 
COCH Posthngual, high-freq , progressive all freq., midlife onset (40-50 yrs), vestibular dysfunction 
(Menière-like).9 
EYA4 Posthngual, all freq., progressive, onset 20-60 yrs.9 
MY07A Postlingual, all freq., progressive, onset 10-20 yrs.9 
COL1ÌA2 Prelingual, mid/high-freq., progressive.9 
POÌÌ4F3 Postlingual, all freq., progressive, onset 20-40 yrs.9 
MYH9 Posthngual, high-freq , onset 10 yrs, moderate-severe at 30 yrs.9 
ACTG1 Posthngual, downsloping, progressive, onset 10-20 yrs.9 
ΜΥΌ6 Postlingual, all freq., progressive, onset 8-10 yrs. n 
TFCP2L3 Posthngual, all freq., progressive, onset I s ' decade. 1 2 
Reserved 
Reserved 
DFNA32 
DFNA33 
DFNA34 
DFNA35 
DFNA36 
DFNA37 
DFNA39 
DFNA40 
DFNA41 
DFNA42 
DFNA43 
DFNA44 
DFNA45 
DFNA46 
DFNA47 
DFNA48 
DFNA49 
DFNA50 
DFNA51 
l l p l 5 
lq44 
9ql3-q21 
lp21 
4q213 
16pl2 
12q24-qter 
2pl2 
3q28-q29 
9p21-p22 
12ql3-ql4 
9q21 
-
Reserved 
-
Reserved 
TMCl 
-
DSPP 
-
Reserved 
-
Reserved 
Reserved 
-
MYOIA 
Reserved 
Reserved 
-
Postlingual, high-freq., highly progressive all freq., onset ls l decade.13 
Not specified hearing loss, associated with dentinogenesis imperfecta.14 
Postlingual,slowly progressive, onset Is'-S"1 decade.15 
a
 DFNA6 and DFNA14 were originally reported as non-overlapping, however, re-evaluation of the original DFNA6 family showed a phenocopy and 
subsequently the locus was relocated at the DFNA14 locus. DFNA38 was reserved as a new locus, however, it would have been more appropriate to 
use the previous loci DFNA6/14. 
b
 DFNA8 was first linked to chromosome 15ql5-q21, however, later this linkage was withdrawn and the locus relocated to the DFNA12 locus. 
c
 DFNA20 and DFNA26 are overlapping loci and are possibly caused by mutations in the same gene 
Table 2. Locus, location and gene with related phenotype, in nonsyndromic types of autosomal recessive sensorineural HI (DFNB). 
Locus Location Gene Phenotype 
DFNB1 
DFNB2 
DFNB3 
DFNB4 
DFNBS" 
DFNB6 
DFNB7/11 
DFNB8/10= 
DFNB9b 
DFNB12 
DFNB13 
DFNB14 
DFNB15C 
DFNB16 
DFNB17 
DFNB18 
DFNB19 
DFNB20 
DFNB21 
DFNB22 
DFNB23 
DFNB24 
DFNB25 
DFNB26i 
DFNB27 
DFNB28d 
DFNB29 
DFNB30 
DFNB31 
DFNB32 
DFNB33 
13ql2 
l lq l3 .5 
17pll.2 
7q31 
14ql2 
3pl4-p21 
9ql3-q21 
21q22 
2p22-p23 
10q21-q22 
7q34-36 
7q31 
3q21-q25/19pl3 
15q21-q22 
7q31 
I lpl4-pl5.1 
18pll 
llq25-qter 
l l q 
16pl2.2 
10pll.2-p21 
l lq23 
4pl5.3-pl2 
4q31 
2q23-q31 
22ql3 
21q22 
10pl2.1 
9q32-34 
Ipl3.3-p22 1 
9q34.3 
Prelingual, severe-profound, occasional mild.9 C]B2 
G]B6 
MY07A Prelingual, severe-profound, vestibular dysfunction.9 
MY015 Prelingual, profound.9 
SLC26A4 Prelingual, downsloping, progressive, enlarged vestibular aquaduct. Allelic with Pendred syndrome.9 
TMIE Prelingual, severe-profound deafness.16 
TMCI Prelingual, profound.13 
TMPRSS3 Prelingual, profound, or onset 10-12 yrs and profound within 4-5 yrs.17 
OTOF Prelingual, profound, possible association with auditory neuropathy.9 
CDH23 Prelingual, profound, in some: atypical RP, and vestibular dysfunction.9 
STKC Postlingual, all freq moderate-severe, non-progressive, onset 3-5 yrs. Sometimes prelingual profound.18 
USH1C Prelingual profound, vestibular dysfunction.19 
TECTA Prelingual, severe-profound.9 
OTOA Prelingual, moderate-severe.20 
CLDN24 Prelingual profound.9 
MY03A Postlingual, downsloping, progressive.21 
WHRN Prelingual, profound.22·23 
DFNB34 
DFNB35 
DFNB36 
DFNB37 
DFNB38 
DFNB39 
DFNB40 
n.s. 
14q24.1-q24.3 
6ql3 
22qll.21-12.1 
7q22.1 
Reserved 
-
Reserved 
MY06 
Reserved 
Reserved 
-
SLC26A5 
Prelmgual, profound.24 
Prelingua 1, se vere-prof( 
a
 DFNB5 was reported originally as DFNB4. 
b
 DFNB9 was reported originally as DFNB6. 
c
 DFNB15 has identical LOD scores at both chromosomal locations. 
d
 DFNB28 is located distally to MYH9. 
e
 DFNB8 and DFNBIO first were thought not to overlap, however, both conditions are caused by mutations in the same gene (TMPRSS3) 
' DFNB26 is suppressed by the dominant modifier DFNMl. n.s.: non-specified locus. 
CHAPTER 1 
All identified DFNA and DFNB subtypes are shown in Table 1 and Table 2, 
respectively. Not only the loci and genes are shown in these tables, but a short 
description of the phenotype is also given when the gene involved has been 
identified and the phenotype was specified. Nonsyndromic autosomal recessive 
HI is often characterised by severe to profound congenital HI with prelingual or 
congenital onset.28 
At this moment, over 400 syndromes with HI are listed in the OMIM (Online 
Mendelian Inheritance in Man) database.29'30 For some of these syndromes the 
gene or genes involved have been cloned. With the identification of genes 
involved in syndromic and nonsyndromic HI and the unravelling of their function 
in the inner ear, the understanding of the molecular basis of auditory function has 
improved. In the next paragraphs, a selection of the currently identified 
syndromic and nonsyndromic sensorineural HI genes, their function and the 
associated phenotype are presented. These genes are categorised according to the 
known or presumed function and/or sites of expression in the inner ear. 
Mutations in different genes that encode proteins with a related function in the 
inner ear may lead to a similar type of HI. An example of this is the similarity in 
HI seen in DFNA8/12, caused by mutations in the TECTA gene and that of 
DFNA13, caused by mutations in the COL11A2 gene.31-32 In both conditions, a 
relatively stable mid-frequency hearing loss, sometimes combined with 
progressive high-frequency HI, is found. Both genes encode extracellular matrix 
proteins that are part of the tectorial membrane. Thus, phenotypic characterisation 
may be of assistance in the identification of the mutated gene in a new hereditary 
HI family trait. The HI in such a family can be analysed and compared to the 
known types of HI and an impression of the function of the gene involved can 
thus be made on the basis of similarities in phenotype. 
HAIR CELL STRUCTURE AND FUNCTION 
The highly organised epithelium in the organ of Corti consists of supporting cells 
and rows of sensory hair cells that are specialised in the transduction of 
mechanical energy into electrical energy, i.e. the mechanoelectrical transduction 
process. The apex of the hair cells carries the stereocilia. These are covered by an 
acellular gelatinous membrane, the tectorial membrane. Sound waves elicit motion 
of the basilar membrane that is located at the base of the organ of Corti. This 
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motion leads to deflection of the stereocilia of the outer hair cells against the 
tectorial membrane. This deflection opens the transduction channels in the 
stereocilia and thus the hair cells are depolarised. This way, mechanical energy is 
transduced into electrical energy. The hair cells are positioned in a single row of 
inner hair cells (IHC) and three rows of outer hair cells (OHC). The IHC have 
strong afferent connections but few efferente and the OHC have little afferent 
innervation and receive significant efferent feedback. The IHC transduce and 
transmit auditory information via their afferent synapses, whereas the OHC also 
transduce auditory signals but merely provide mechanical feedback and amplify 
the auditory stimuli sensed by the IHC, thus establishing the process of cochlear 
amplification.33-34 Several genes are involved in the normal structure and function 
of the hair cells and their stereocilia. In Table 3, some deafness genes and encoded 
proteins are listed. 
Table 3 Deafness genes expressed in hair cells 
Gene 
MYH9 
MYOÌA 
MY03A 
MY06 
MY015 
HDIA 
ACTG1 
STRC 
OTOF 
SLC26A5 
WHRN 
MY07A 
usmc 
CDH23 
SANS 
PCDH15 
Localisation 
22qn 2 
12ql3-ql5 
lOpll 1 
6ql3 
1 7 p l l 2 
5q31 
17q25 
15ql5 
2p23-p22 
7q221 
9q32-q34 
l l q l 3 5 
l l p l S 1 
10q21-q22 
17q24-q25 
10q21-q22 
OMIM3» 
160775 
601478 
606808 
600970 
602666 
602121 
102560 
606440 
603681 
604943 
607928 
276903 
605242 
605516 
607696 
605514 
Protein 
Myosin heavy chain Ha 
Myosin la 
Myosin Ilia 
Myosin VI 
Myosin XV 
Diaphanous 
Gamma achn 1 
Stereocilm 
Otoferlm 
Prestin 
Whirlm 
Myosin Vila 
Harmonm 
Otocadhenn 
SANS 
Protocadhenn 15 
Disease 
MYH9-related disease * 
DFNA17 
DFNA48 
DFNB30 
DFNA22 
DFNB37 
DFNB3 
DFNA1 
DFNA20/26 
DFNB16 
DFNB9 
NSRAN 
DFNB (n a ) 
DFNB31 
DFNAll 
DFNB2 
USHlb 
DFNB18 
USHlc 
DFNB12 
USHld 
USHlg 
USHlf 
·, MYH9-related disease May-Hegghn anomaly, Sebastian syndrome, Fechtner syndrome, Epstein 
syndrome and Alport-hke syndromes, NSRAN nonsyndrormc recessive auditory neuropathy 
n.a.: not assigned, OMIM Online Mendehan Inheritance in Man ^ 
Several myosins play an essential role in hearing. These motor molecules bind to 
actin and hydrolyse ATP. They contain a motor domain, which is attached to a tail 
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through a flexible neck region. To date, six different myosin-encoding genes are 
known to be involved in nonsyndromic HI, MYOIA, MY03A, MY06, MY07A, 
MY015 and MYH9. MYH9 encodes the myosin Ha heavy chain protein, a 
conventional nonmuscle myosin, whereas the remaining genes encode 
unconventional myosins. Mutations in MYH9 result in a spectrum of autosomal 
dominant platelet disorders (Fechtner syndrome, May-Hegglin anomaly, 
Sebastian syndrome, Epstein syndrome and Alport-like syndromes), which are 
mainly characterised by giant platelets and thrombocytopenia. Depending on the 
syndrome other features are characteristic leukocyte inclusions (Döhle-like 
bodies), nephritis, deafness and cataracts.35 In addition, mutations in this gene 
cause DFNA17, which is characterised by severe progression of HI.36 
The genes encoding the motor molecules myosin la, myosin Ilia, myosin VI and 
myosin XV are all expressed in the cochlea and the proteins are likely to have a 
specific function in the hair cells. Mutations in MYOM cause DFNA48, which may 
be a frequent type of sensorineural HI.15 Still little is known about the DFNA48 
phenotype and the function of myosin Ia. DFNB30 is caused by mutations in the 
MY03A gene.21 The expression of myosin Ilia is higly restricted to the hair cells in 
the cochlea and the photoreceptors of the retina and thus may be involved in 
Usher syndrome as well.37 HI in the DFNB30 family started to increase in the 
second decade of life and by age 50 it was severe in the high and mid frequencies 
and moderate in the low frequencies.21 DFNA22 and DFNB37 are both caused by 
mutations in the MY06 gene. Myosin VI is expressed in the IHC and OHC of the 
cochlea as well as in the retina, which makes also this gene a candidate Usher 
syndrome gene.11·24 DFNA22 shows progressive and postlingual HI with onset 
during childhood. At the age of 50, all affected individuals are profoundly hearing 
impaired.11 Recessive mutations in MY06 lead to profound congenital deafness, 
designated DFNB37, in 3 Pakistani families.24 Mutations in the MY015 gene cause 
DFNB3 and lead to congenital profound sensorineural HI in 2% of the inhabitants 
of an Indonesian village.38 Myosin XV is presumed to play a role in the proper 
development of the sensory epithelium of the inner ear.39 
Mutations in the HDIA gene were found to cause DFNA1,40 the first locus that was 
found for autosomal dominant sensorineural HI. The patients from the DFNA1 
family from Costa Rica have progressive low-frequency HI and so far no other 
families with this type of HI are known.41 It is hypothesised that the HDM 
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encoded protein diaphanous is involved in the regulation of actin polymerisation 
in hair cells.40 
Recently, van Wijk et al.42 identified mutations in the gamma actin 1 (ACTGî) gene 
in a Dutch DFNA20/26 family. Gamma actin 1 is present in the stereocilia, 
cuticular plate and zonula adherens and thus constitutes an important structural 
element of the inner ear hair cells. The identified mutation probably leads to 
impairment of actin polymerization. The severity of progression in HI in the 
DFNA20/26 family resembled the progression described for DFNA1 (HDIAl), 
DFNA17 (MYH9) and DFNA22 (MY06), which also are functionally related to 
actin in the cochlear hair cells.42 
Another gene whose product is involved in the maintenance and elongation of the 
sterocilia of both IHC and OHC is WHRN. Recessive mutations in this gene cause 
profound prelingual HI (DFNB31) in a Palestinian family from Jordan.22 WHRN 
encodes whirlin, which is a PDZ domain-containing molecule that is suggested to 
act as an organiser of submembranous molecular complexes that control the 
coordinated actin polymerisation and membrane-growth of stereocilia.23 
Another important protein for the maintenance of hair cell integrity is stereocilin, 
encoded by the STRC gene. Stereocilin is exclusively expressed in the hair cells of 
the inner ear and mutations in STRC cause DFNB16.1H Stereocilin and otoancorin, 
encoded by OTGA and involved in DFNB22, share sequence similarities and are 
though to be responsible for the attachment of acellular gels to both sensory and 
nonsensory cells of the inner ear.43 Otoancorin is, however, classified as an 
extracellular matrix protein and is therefore shown in Table 5 listing the 
extracellular matrix proteins. 
Otoferlin is the protein that is encoded by the OTOF gene. Mutations in this gene 
lead to DFNB9 and/or to NSRAN (nonsyndromic recessive auditory 
neuropathy).44 Speech perception in DFNB9 patients is more disturbed than 
would be expected from the degree of HI. Otoferlin is expressed in the IHC. The 
exact role otoferlin plays in the inner ear is still unclear, although it has been 
suggested to be involved in membrane trafficking activated by increased local 
Ca2+ concentration.44 
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In contrast to otoferlin, which is expressed in the IHC of the cochlea, prestin is 
expressed in the OHC of the cochlea.25 Prestin is a motor protein which senses the 
membrane potential and drives rapid length changes in OHC and is therefore part 
of the elusive cochlear amplifier system.25 It belongs to the solute carrier 26 family 
(SLC26), that encodes anion transporters and related proteins. SLC26A5 is the 
encoding gene and mutations have been identified to cause nonsyndromic 
recessive HI. So far, a DFNB-locus has not been assigned.45 
Usher syndrome type I genes 
Several Usher syndrome type I genes have so far been identified and experimental 
data suggest that the proteins of MY07A, USH1C, CDH23 and SANS form a 
complex that is essential for normal stereocilia development and function.46-47 This 
functional complex will be described, after the separate description of these genes. 
Mutations in MY07A are responsible for DFNA11, DFNB2 and Usher syndrome 
type lb.4851 USHlb is the most frequent subtype of Usher syndrome type I, with an 
estimated prevalence of about 40-50% of all Usher syndrome type I cases. USHlb 
and DFNB2 show congenital profound HI,50·51 whereas the HI in DFNA11 is much 
milder (Table I).49 The mutation in MY07A that leads to DFNA11 has been 
suggested to have a dominant negative effect that leads to defective dimers. Thus, 
25% of the dimers still have two copies of wild-type myosin Vila.49 In USHlb and 
DFNB2 both alleles are mutated, but there is still no explanation for the difference 
in retinal phenotype.50·51 
Immunofluorescence studies of myosin Vila in rat tissue have shown that it is 
expressed in the apical stereocilia and in the cytoplasm of the IHC and OHC of the 
cochlea.52 In the absence of myosin VIIA, the stereocilia are disorganised, whereas 
the lateral links and tip links between the stereocilia and the shape of the 
kinocilium in the vestibular hair cells appear to be normal.5354 The hair cell 
bundles need to be displaced beyond their physiological operating range to open 
the mechanotransducer channels. Therefore, it has been suggested that myosin 
Vila plays a key role in adjusting the tension of the tip-link/transduction channel 
complex.2954 In conclusion, myosin Vila probably participates in anchoring and 
holding membrane-bound elements to the rigid actin core of the stereocilium and 
is therefore required for the normal gating of transducer channels. 
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In the eye, myosin Vila is expressed in the apical actin-rich domain of the retinal 
pigment epithelium and in the connecting cilia of the rod and cone photoreceptor 
cells.55-57 In the retinal pigment epithelium (RPE), myosin Vila is involved in the 
transport of melanosomes in an apical direction and in normal phagocytosis of 
ingested photoreceptor outer segment disks, because the ingested phagosomes are 
not cleared normally from the RPE apical processes into the cell body.58-60 
The gene involved in Usher syndrome Ie, USH1C, was identified by two different 
research groups.61-62 USH1C consists of 28 exons, of which 20 are constitutive and 
8 are alternatively spliced. It encodes a PDZ-domain containing protein named 
harmonin.61 Recent studies have shown that mutations in USH1C cause USHlc in 
populations of different ethnic backgrounds.19-61 -64 Mutations in the USH1C gene 
not only cause USHlc, but also DFNB18.19 In the inner ear, harmonin is present in 
the organ of Corti, mainly in the cuticular plate and stereocilia, and in the 
vestibular hair cells.46-61 So far, only little is known about the expression and 
function of harmonin in the eye. However, as Cadherin 23 and harmonin are 
shown to interact,65 it may well be possible that harmonin, like Cadherin 23, is 
expressed in the photoreceptor layer of the eye.65 
CDH23 encodes Cadherin 23 and is the gene involved in USHld and DFNB12.66<67 
Mutation analysis of CDH23 in a large number of families with USHld or DFNB12 
has revealed that in USHld most mutations lead to truncation of the protein, 
whereas only missense mutations that alter the protein are detected in DFNB12 
families.66-6872 In addition, it was shown that some DFNB12 patients have 
asymptomatic RP-like abnormalities in the retina.6K'69'71 The clinical features of 3 
USHld families and 1 DFNB12 family are described in Chapter 3.1 of this thesis.71 
Studies in the waltzer mouse have shown that Cdh23 is expressed in the 
neurosensory epithelia containing cochlear and vestibular hair cells and that 
stereocilia organisation is disrupted during hair cell differentiation.73 Cadherin 23 
is a member of the Cadherin superfamily of cell-cell adhesion molecules.73 Based 
on experimental data it has been hypothesised that Cadherin 23 is present at the 
surface of the growing stereocilia and through homophilic interaction it forms 
transient lateral links that interconnect the stereocillia from their emergence to 
their final maturation.46 Modelling of DFNB12 mutations in CDH23 showed that 
these missense mutations directly impair the calcium binding of the extracellular 
Cadherin domains.69 Calcium provides rigidity to the elongated structure of 
Cadherin molecules and enables homophilic lateral interactions. It is therefore 
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hypothesised that mutations at these sites are likely to impair the interactions of 
Cadherin 23 either with Cadherin 23 or with other proteins.69 CDH23 is expressed 
in the photoreceptor layer of the retina, however, its exact retinal function still 
remains to be elucidated.65-72 
Usher syndrome type Ig (USHlg) is caused by mutations in the SANS gene, the 
most recently identified Usher syndrome type I gene.47 The SANS protein contains 
three ankyrin domains and a sterile alpha motif, lts C-terminal tripeptide presents 
a class I PDZ-binding motif. SANS and harmonin interact and therefore SANS is 
suggested to be part of the complex that shapes the hair cell bundle. So far, 
nothing is known about the function of SANS in the retina.47 
^C ^ fc^H^B<e __/^9( )C3^| Bfil 
Figure 1. Schematic presentation of the interactions between myosin Vila (USHlb), harmonin 
(USHlc), Cadherin 23 (USHldj and SANS (USHlg) in the stereocilia of the hair cells (adapted with 
permission from Weil et al.*7) 
The proteins of the four previously described genes (MY07A, USH1C, CDH23 and 
SANS) are involved in a functional network that is responsible for the correct 
cohesion of the hair bundles, as is shown in Figure l.4647 Boëda et al. proposed the 
following molecular scenario.46 Myosin Vila first transports harmonin isoform b to 
its stereociliar localisation. Then, harmonin b binds the Cadherin 23-containing 
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interstereociliar links to the actin filament cores of the developing stereocilia. 
These early connections between growing stereocilia seem to be critical for the 
correct and coherent shaping of the hair cell bundle. A failure in this process 
therefore leads to the observed disorganisation of the hair bundles.46 In addition, it 
also seems likely that in this functional network other USH1 genes will play 
important roles. SANS was the first gene for which this was suggested to be the 
case as it directly interacts with harmonin.47 Hypothetically, these proteins may 
also interact in the retina and form a similar functional complex in the 
photoreceptor cell layer. Dysfunction of this complex may thus cause RP. 
Usher syndrome type If (USHlf) is caused by mutations in PCDH15, which 
encodes protocadherin 15.74·75 Together with USHld, USHlf is believed to be the 
second most frequent cause of Usher syndrome type I. The USH1F locus shows 
overlap with the DFNB23 locus, however, so far no disease-causing mutations in 
PCDH15 have been reported in DFNB23 families.26 Protocadherin 15 has 11 
Cadherin repeats, which probably are involved in Ca2* dependent cell adhesion, at 
least one transmembrane domain and a cytoplasmic domain. Expression studies 
have shown that it is not only expressed in the retina and in the hair cells of the 
cochlea, but also in many other tissues.7477 Because there are no additional 
symptoms found in patients with USHlf, it is suggested that there may be a level 
of redundancy in some tissues that is provided by other types of protocadherins.75 
Protocadherin 15 may also be part of the myosin Vlla-cadherin 23-SANS-
harmonin complex since the ames waltzer mice with a mutation in Pcdhl5 present 
with disorganised stereocilia as well. So far, the function of protocadherin 15 in the 
retina is relatively unknown. 
ION HOMEOSTASIS AND K+ RECYCLING 
The inner ear consists of a bony labyrinth and a membranous labyrinth. The 
cochlea comprises three parallel ducts: the scala tympani, the scala media and the 
scala vestibuli. The scala tympani and scala vestibuli are filled with perilymph, a 
fluid that is rich in Na+ and low in K+. The scala media is filled with endolymph, 
rich in K+ and low in Na+ ions. The scala media is separated from the scala 
tympani by the basilar membrane and from the scala vestibuli by Reissner's 
membrane. Deflection of the hair cell stereocilia in the direction of the largest 
stereocilium results in the mechanical opening of apical cation-selective channels. 
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K+ ions flow from the endolymph into the hair cell and cause depolarisation. The 
depolarisation of the hair cell opens voltage-gated Ca2+ channels and the Ca2+ 
influx triggers a neurotransmitter release that stimulates the auditory nerve 
endings, which then transfers the signal to the brain. The apical influx of K+ ions is 
coupled to a K+ efflux in the basolateral membrane of the hair cells. The K+ ions 
are transported back to the endolymph through a mechanism of gap junctions and 
pumps that is called the fibrocyte gap junction system. Within the cochlea this 
system consists of supporting cells, fibrocytes, basal and intermediate cells of the 
stria vascularis. Finally, the K+ ions are released into the endolymph through the 
marginal cells of the stria vascularis (Figure 2). This recycling process of K+ is 
essential to repolarise the hair cells and to prevent cytotoxic effects on the hair 
cells due to a high K+ concentration. Ion homeostasis of the endolymph is crucial 
for optimal function of the hair cells and several gene products have been found to 
be involved in this process. This paragraph describes some of the genes involved 
in ion homeostasis in the inner ear (Table 4).27·33-34 
Figure 2. Presentation of the cochlear duct and the proposed K+ recycling pathways from the 
cochlear hair cells to the endolymph.(«rfijptei and modified with permission from Steel and Kros29) 
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Four genes encoding gap junction proteins involved in endolymph homeostasis, 
have been identified: GJA1, GJB2, GJB3 and GJB6. Gap junction proteins are 
intercellular channels that enable the passage of small ions and metabolites.78 A 
complete intercellular channel consists of two connexons and each connexon 
consists of six connexins (hexamer). Mutations in these gap junction genes cause 
dominant and recessive nonsyndromic HI but may also cause syndromic HI 
(Table 4). Mutations in the GJB2 gene encoding CX26, seem to account for 
recessive nonsyndromic HI in almost 50% of all patients in Southern Europe.27-79 A 
lower percentage, about 10-20%, is found in Northern Europe.80 The by far most 
prevalent mutation in CX26 is the 35delG mutation, which leads to a severely 
shortened, non-functional protein.80 
Table 4 Deafness genes involved in ion homeostasis/K* cycling 
Gene Localisation OMIM30 Protein Disease 
Gl Al 
G/B2 
6q21-q23 2 
13qll-ql2 
121014 
121011 
CX43 
CX26 
G/B3 
G]B6 
l p351 
13ql2 
603324 
604418 
CX31 
CX30 
Recessive HI 
DFNA3 
DFNB1 
Keratitis-Ichtyosis-deafness syndrome 
Palmoplantar hyperkeratosis and deafness 
Palmoplantar keratoderma and deafness 
Vohwinkel's syndrome 
DFNA2 
Neuropathy and HI 
Recessive HI 
DFNA3 
DFNB1 
KCNQ1 
KCNQ4 
KCNE1 
SLC19A2 
SLC26A4 
CLDNU 
ATP6B1 
BSND 
l l p l 5 5 
lp34 
21q22 1-
q22.2 
lq23 3 
7q31 
21q22 3 
2cen-ql3 
lp31 
607542 
603537 
176261 
603941 
605646 
605608 
192132 
602522 
KvLQTl 
KCNQ4 
IsK 
THTR-1 
Pendrm 
Claudm 14 
ATP6B1 
Barttm 
Jervell and Lange-Nielsen syndrome 1 
DFNA2 
Jervell and Lange-Nielsen syndrome 2 
Thiamine-responsive megaloblastic anemia with 
diabetes mellitus and deafness 
DFNB4 
Pendred syndrome 
DFNB29 
Renal tubular acidosis and HI 
Bartter syndrome and HI 
OMIM Online Mendehan Inheritance in Man x 
Also potassium channels are involved in ion homeostasis of the inner ear. 
Currently, three genes encoding potassium channel proteins are involved in HI: 
KCNQ1, KCNQ4 and KCNE1. KCNQ4 mutations are causative for a progressive 
type of high-frequency HI entitled DFNA2, whose phenotype is described in the 
last section of this introduction.81 KCNQ1 and KCNE1 both are involved in the 
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Jervell and Lange-Nielsen syndrome, a rare autosomal recessive disorder 
characterised by congenital deafness and long QT interval.82 Dominant mutations 
lead to the Romano-Ward syndrome, which is characterised by syncope and a 
prolonged QT interval without associated HI.27 
Recessive mutations in the SLC26A4 gene cause DFNB4 and Pendred syndrome.83 
Pendred syndrome is characterised by HI and goiter. These patients have an 
enlarged vestibular aqueduct, as well as an enlarged endolymphatic sac and duct 
on CT and MRI scans. Progression and fluctuation of hearing is reported in 
childhood or adolescence and seem to relate to head injury, infection or delayed 
secondary hydrops.84-85 Pendrin is a transmembrane protein that functions as a 
sodium-independent cotransporter of chloride and anions.86 Another member of 
the solute carrier families is also known to be involved in inner ear ion 
homeostasis: SLC19A2.87 This gene has an entirely different function because it is a 
thiamine transporter gene. Mutations in this gene cause the autosomal recessive 
Rogers syndrome more commonly referred to as Thiamin-Responsive 
Megaloblastic Anaemia syndrome (TRMA) characterised by megaloblastic 
anaemia, diabetes mellitus and sensorineural HI. This disease responds in varying 
degrees to thiamine administration.87 
Recessive mutations in the CLDN24 gene cause DFNB29. This gene encodes 
claudin 14, which is a tight-junction protein.88 The main function of tight junctions 
is to maintain epithelial cell polarity and to selectively modulate paracellular 
permeability between extracellular compartments. Tight junctions in the cochlear 
duct are necessary to compartimentalise the endolymph and to provide structural 
support to the auditory neuroepithelium.88 
Two genes are not only involved in inner ear ion homeostasis but also in renal 
disorders. The first gene, ATP6B1, encodes the Bl-subunit of H+-ATPase and 
mutations in this gene cause autosomal recessive distal renal tubular acidosis 
combined with progressive HI.89 The protein probably plays a role in maintaining 
the correct pH of the endolymph and mutations in this gene lead to an increase in 
pH and subsequently to hearing loss due to impaired hair cell function. The 
protein is expressed in the cochlea as well as the endolymphatic sac.89 Bartter 
syndrome is a heterogeneous, autosomal recessive salt-losing nephropathy. The 
fourth, antenatal type of Bartter syndrome presents with sensorineural HI and 
renal failure and is caused by mutations in the BSND gene, which encodes 
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barttin.90 Barttin is an essential ß-subunit of the CIC-Ka and CIC-Kb chloride 
channels. It is expressed in the basoiaterai membranes of renal tubules and in the 
potassium-secreting epithelia of the inner ear and is crucial for renal salt 
absorption and potassium recycling in the inner ear.91 
TRANSCRIPTION FACTORS 
Transcription factors are gene regulatory proteins. These proteins have DNA 
binding capacity to short recognisable nucleotide sequences. Transcription factors 
control RNA transcription and genes can be switched on or off by activation or 
repression. Important transcription factors control many other genes in a 
coordinated sequential cascade thereby regulating fundamental developmental 
processes such as segmentation, induction, differentiation, migration and 
apoptosis. Mutations in transcription factor genes may result in isolated 
malformations or in multiple congenital syndromes.92 In the present section, some 
of the transcription factors with a function in the inner ear are described (Table 5). 
Table 5. Deafness genes that encode transcription factors involved in the cochlea 
Gene 
POU3F4 
POU4F3 
EYAÌ 
EYA4 
PAX3 
MITF 
SOX10 
TFCP2L3 
GATA3 
SALL1 
Localisation 
Xq21.1 
5q31 
8ql3.3 
6q23 
2q35 
3pl4.1-
pl2.3 
22ql3 
8q22 
10pl5 
16ql2.1 
OMIM30 
300039 
602460 
601653 
603550 
606597 
156845 
60???9 
-
131320 
602218 
Protein 
POU3F4 
POU4F3 
EYA1 
EYA4 
PAX3 
MITF 
SOX10 
TFCP2L3 
GATA3 
SALL1 
Disease 
DFN3 (Stapes Gusher syndrome) 
DFNA15 
Branchio-oto-renal syndrome (BOR) 
Branchio-oto syndrome 
DFNA10 
Waardenburg syndrome 1 
Waardenburg syndrome 3 
Craniofacial-deafness-hand syndrome 
Waardenburg syndrome 2 
Tietz syndrome 
Waardenburg syndrome 4 
Peripheral neuropathy with hypomyelination and 
deafness 
Yemenite deaf-blmd hypopigmentation 
DFNA28 
Hypoparathyroidism, deafness and renal dysplasia 
Townes-Brocks syndrome 
OMIM: Online Mendelian Inheritance in Man.30 
Two genes encode POU domain transcription factors and the POU domains are 
involved in high-affinity binding to DNA target sites. POU3F4 plays a crucial role 
in the patterning of the mesynchymal compartment of the inner ear. Mutations in 
63 
CHAPTER 1 
POU3F4 are responsible for DFN3, an X-linked type of HI that shows mixed 
conductive and perceptive HI.9 3 The conductive part of the HI is caused by 
congenital fixation of the stapedial footplate. Perilymphatic gusher appears when 
the stapedial footplate is opened in order to replace the fixed stapes, therefore 
DFN3 is also referred to as the stapes gusher syndrome.94 The widened vestibule 
associated with DFN3 can contribute to an air-bone gap in the pure tone 
audiogram as the result of leakage of sound energy on its way from the stapedial 
footplate to the inner ear hair cells. Another POU domain containing protein is 
encoded by POLZ4F3. Mutations within this gene cause DFNA15.95 The phenotype 
of DFNA15 is more extensively described in the last section of this introduction.81 
Waardenburg syndrome is an autosomal dominantly inherited syndrome that is 
known for its clinical and genetic heterogeneity. Four clinically different types are 
distinguished (WS1-WS4). In general, the major symptoms of Waardenburg 
syndrome are congenital sensorineural HI, pigmentation abnormalities of the iris 
(heterochromia iridis), white forelock and hypopigmentation of the skin.96 So far, 
mutations in 6 different genes have been identified. Four genes encode 
transcription factors (PAX3, MITF, SLUG and SOXIO)97"100 and two genes (EDN3 
and EDNRB) encode a ligand (endothelin 3)101 and its receptor (endothelin 
receptor B)102. Mutations in the latter two genes cause WS4 and are described in 
the paragraph on receptors and ligands. WS1 and WS2 are by far the most 
common types of the syndrome. WS1 is caused by mutations in ΡΛΧ3, and WS2 is 
caused by mutations in the MITF and SLUG gene.97-99 WS3 is also caused by 
mutations in the PAX3 gene and mutations in SOXIO are responsible for 
WS4 100,103 w s i and WS3, also known as the Klein-Waardenburg syndrome, can be 
distinguished from WS2 and WS4 on the basis of lateral displacement of the 
medial canthi combined with dystopia of the lacrimal punctae and 
blepharophimosis. Also, WS3 shows upper limb defects.96 MITF and ΡΛΧ3 are 
both involved in the migration and differentiation of neural crest cells. During 
embryogenesis, part of these cells develop into melanocytes and migrate to their 
final position in various organs. It has been suggested that absence of melanocytes 
causes a white forelock, iris pigmentation abnormalities and in the stria vascularis 
it may lead to sensorineural HI. 1 0 4 
Another family of transcription factors involved in syndromic and nonsyndromic 
HI is the family of ΕΥΑ genes. These genes are named after the eyes absent (Eya) 
gene of Drosophila. Mutations in EYA1 are responsible for Branchio-Oto-Renal 
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syndrome (BOR) and Branchio-Oto syndrome (BO).105106 BOR is an autosomal 
dominant syndrome that is characterised by 1 hearing loss (of conductive, 
perceptive or mixed origin) 2 second branchial arch fistula or cyst/preauricular 
sinus including ear pits 3 malformed auricles, ear canal, middle and/ or inner ear 
and 4 renal anomalies ranging from mild hypoplasia to complete agenesis. 
Stenosis of the nasolacrimal duct is also common in these patients.107108 Recently, a 
long-term follow-up study of BOR syndrome patients reported that HI has a 
progressive and fluctuating character.109 This study demonstrated that these 
patients also may have an enlarged vestibular aqueduct and cochlear hypoplasia, 
which can be seen on CT scans.109 The BO syndrome shows similar features as 
seen in BOR syndrome, however, without renal anomalies. 
The Townes-Brocks or REAR (Renal-Ear-Anal-Radial) syndrome is another 
syndrome that resembles BOR syndrome. REAR shows autosomal dominant 
inheritance with variable expression. Major symptoms are renal malformations, 
external ear anomalies (lop ear, microtia, preauricular pits or tags), sensorineural 
HI, imperforate anus and preaxial Polydactyly or triphalangeal thumbs. The 
syndrome is caused by mutations in SALL1. This gene encodes a zinc finger 
transcription factor.110 Mutations in the GATA3 gene, another zinc finger 
transcription factor, are responsible for the syndromic association of 
Hypoparathyroidism, Deafness and Renal dysplasia, also referred to as HDR 
syndrome.111 The last transcription factor gene shown in Table 5 is TFCP2L3. 
Mutations in this gene are responsible for a progressive, late onset type of 
nonsyndromic sensorineural HI, DFNA28.12 The function of this transcription 
factor in the cochlea is still poorly understood. 
EXTRACELLULAR MATRIX PROTEINS 
Several extracellular matrix proteins are essential for normal inner ear function. A 
number of these will be described in this paragraph. The tectorial membrane is an 
acellular gelatinous mass overlying the hair cells. When the basilar membrane is 
moved due to a sound wave, the sterocilia of the OHC bend against the tectorial 
membrane. The tectorial membrane is made of noncollageneous glycoproteins and 
collagens. One of the important glycoproteins is encoded by the a-tectorin gene 
TECTA, which is mutated in DFNA8/12 and DFNB21.112<113 The HI known for 
DFNB21 is characterised by severe to profound prelingual hearing loss at all 
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frequencies.113 A genotype-phenotype correlation study of HI in DFNA8/12 
families has shown that mutations in the zona pellucida domain of a-tectorin are 
associated with stable mid-frequency HI, whereas mutations in the zonadhesin 
domain seem to relate to progressive high-frequency HI. 1 1 4 Otoancorin is the 
protein encoded by the OTOA gene. Recessive mutations in this gene cause 
DFNB22, which is characterised by prelingual moderate to severe sensorineural 
HI.2 0 Otoancorin is suggested to ensure the attachment of the inner ear acellular 
gels to the apical surface of the underlying nonsensory cells.20 
Table 6 Deafness genes encoding extracellular matrix components of the cochlea (tectorial 
membrane/basement membrane) 
Gene 
TECTA 
OTOA 
COLUAl 
COLllAl 
COL2A1 
COL4A3 
COL4A4 
COL4A5 
COCH 
USH2A 
NDP 
Localisation 
Ilq22-q24 
16pl2.2 
lp21 
6p21.3 
12ql3.11-
ql3.2 
2q36-q37 
2q36-q37 
Xq22 3 
14ql2-ql3 
lq41 
Xpll.4 
OMIM30 
602574 
607038 
120280 
120290 
120140 
120070 
120131 
303630 
603196 
276901 
310600 
Protein 
a-tectorin 
Otoancorin 
Collagen 
H a l 
Collagen 
11α2 
Collagen 2 αϊ 
Collagen 4a3 
Collagen 4a4 
Collagen 4a5 
Cochlin 
Usherin 
Norrin 
Disease 
DFNA8/12 
DFNB21 
DFNB22 
Stickler syndrome 2 
Marshall syndrome 
DFNA13 
Stickler syndrome 3 
Oto-spondylo-mega-epiphyseal dysplasia 
(OSMED) 
Weissenbacher-Zweymuller syndrome 
Stickler syndrome 1 
Alport syndrome, recessive 
Alport syndrome, dominant 
Alport syndrome, recessive 
Alport syndrome, dominant 
Alport syndrome, X-linked dominant 
DFNA9 
USH2a 
N o m e disease 
Coats' disease 
OMIM: Online Mendelian Inheritance in Man.1 0 
Collagens are important components of the tectorial membrane and the basement 
membranes in the inner ear. Six different collagen genes are currently known to be 
involved in syndromic and nonsyndromic sensorineural HI COL2A1, COL4A3, 
COL4A4, COL4A5, COLUAl and COLUAl (Table 6). Stickler syndrome is caused 
by mutations in collagen genes. The original description by Stickler et al. 
concerned a family with progressive myopia, retinal detachment and blindness, as 
well as premature degenerative changes in various joints.115 Later on, mild HI, 
radiographic abnormalities, the Pierre-Robin sequence and typical orofacial 
features were added to the description of this syndrome.1 1 6 1 1 7 The syndrome 
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shows autosomal dominant inheritance. Stickler syndrome is classified into three 
genetic subtypes on the basis of mutations in three different genes: COL11A1, 
COU1A2 and COL2AL118 Mutations in COL11A2 are also responsible for 
DFNA13, a nonsyndromic type of HI characterised by nonprogressive, 
presumably congenital mid-frequency sensorineural HI. In some families there is 
an additional high-frequency hearing loss.119 The mid-frequency hearing loss in 
DFNA13 resembles that of DFNA8/12 and this probably relates to the fact that 
both proteins are components of the tectorial membrane. 
Mutations in three collagen 4 genes (COL4A3, COL4A4 and COL4A5) are 
responsible for Alport and related syndromes (Table 5).120 The most characteristic 
symptom of this syndrome is nephropathy, characterised by microscopic 
hematuria and proteinuria, leading to end-stage renal failure in virtually all 
affected male patients with X-linked Alport syndrome, which is the most 
prevalent type. In approximately 55% of the male and 45% of the female patients, 
slowly progressive sensorineural HI is seen. In addition, X-linked Alport 
syndrome patients tend to develop ocular lesions. Anterior lenticonus, in which 
the central portion of the lens protrudes into the anterior chamber, is virtually 
pathognomonic for this condition. Corneal abnormalities have also been reported 
in these patients.121 Alport syndrome is an inherited disorder of the basement 
membranes. The X-linked type of Alport syndrome is caused by mutations in 
COL4A5 and the autosomal recessively inherited type of Alport syndrome is 
caused by mutations in COL4A3 and COL4A4. In addition, heterozygous 
mutations in COL4A3 and COL4A4 were reported to cause autosomal dominant 
Alport syndrome, which is characterised by slow progression towards impaired 
renal function.120 
Another type of an autosomal dominantly inherited progressive high-frequency 
HI (DFNA9) is caused by mutations in the COCH gene.122 This characteristic type 
of HI is relatively often seen in the Netherlands and Belgium and its characteristic 
features, mid-life onset of progressive HI starting in the high frequencies and 
progressive vestibular dysfunction, are described in the review in the next section 
of this introduction.81 COCH encodes cochlin, an extracellular matrix protein, and 
is expressed in fibrocytes of the spiral limbus and the spiral ligament in the 
cochlea, as well as in the fibrocytes of the connective tissue stroma underlying the 
sensory epithelium of the crista ampullaris.123 The exact function of this protein in 
the inner ear is still unknown. Recent studies have shown that mutant cochlins are 
67 
CHAPTER 1 
not retained intracellularly and can be secreted by the cells through the 
Golgi/endoplasmic reticulum secretory pathway and that DFNA9 mutations 
probably lead to incorrect integration of cochlin into the extracellular matrix.124-125 
Usherin, another extracellular matrix protein that is present in the cochlear 
basement membranes, is encoded by the USH2A gene. Mutations in this gene are 
responsible for USH2a.126 This the most prevalent genetic subtype of all types of 
Usher syndrome and is believed to account for about 80-85% of all Usher 
syndrome type II cases.127129 Usherin is located in the basement membranes of the 
cochlea and retina, as well as in those of other tissues.130-131 By in situ hybridisation 
USH2A transcripts were only shown to be present in the perinuclear cytoplasm of 
the photoreceptor cells in the outer nuclear layer of the retina in humans, mice and 
rats.132 However, with antibodies against usherin the protein could not be detected 
in this layer. In the Usher syndrome type Ha retina, the number of photoreceptors 
is reduced, the rods and cones are diminished in numbers with shorter outer 
segments, and there is virtual absence of both photoreceptors in the peripheral 
retina.132 
Norrie disease is an X-linked syndrome, which main characteristic feature is 
congenital bilateral blindness due to a prominent intraocular mass 
(pseudoglioma). In addition, there is partial avascularity of the retina. Additional 
features are deafness and mental retardation. Patients with Norrie disease show 
progressive HI in all frequencies, but more severely in the high-frequency range, 
leading to profound deafness. The onset age varies widely from 4 months to 45 
years. In two-thirds of the patients, mental retardation or psychotic features are 
seen.133 Norrie disease is caused by mutations in the NDP gene.134 Studies of a 
knock-out mouse model (Ndp) have shown that the primary lesion is located in the 
stria vascularis of the inner ear. Abnormal vasculature and finally a loss of two-
thirds of the vessels can be seen in this region. Therefore, it was concluded that 
one of the main functions of norrin is to regulate the interaction of the cochlea 
with its vasculature.135 
RECEPTORS AND LIGANDS 
Autosomal dominantly inherited Waardenburg syndrome type IV (WS4), also 
known as the Shah-Waardenburg syndrome, is caused by heterozygous mutations 
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in SOX20.100 Homozygous or compound heterozygous mutations in the 
endothelin receptor Β gene (EDNRB) and in EDN3 encoding its ligand endothelin 
3 also cause WS4, however, with autosomal recessive inheritance.1 0 1 1 0 2 WS4 is 
characterised by the WS2 features combined with Hirschsprung disease and is 
part of a heterogeneous group of rare neurocristopathies in which aberrant 
migration of the neural crest cells results in absence or abnormal location of enteric 
neurons and melanocytes.101 Recent studies have shown that the endothelin 
signalling pathway is involved in the migration of neural crest-derived 
melanocytes and enteric neuron precursors.136 
Table 6. Other deafness genes involved in sensorineural HI. 
Gene Location OMIM'10 Protein Disease 
RECEPTORS AND LIGANDS 
EDN3 20ql3.2- 131242 Endothelin 3 Waardenburg syndrome 4 
ql3.3 Hirschprung disease 
EDNRB 13q22 131244 Endothehn receptor Β Waardenburg syndrome 4 
Hirschprung disease 
CELLULAR TRAFFICKING PROTEINS 
T/MM8A Xq22 300356 Deafness dystonia peptide Deafness dystonia syndrome or 
DFNA5 
WFS7 
TMC1 
ΓΜ7Ε 
TMPRSS3 
ÜSH3 
DSPP 
7pl5 
4pl6.1 
9ql3-q21 
3p21 
21q22.3 
3q21-q25 
4q21.3 
600994 
606201 
606706 
607237 
605511 
606397 
125485 
UNKNOWN FUNCTION 
DFNA5 
Wolframin 
TMC1 
TMIE 
Transmembrane protease 
serine 3 
Clarin-1 
Dentin 
sialophosphoprotein 
Mohr-Tranebjaerg syndrome 
DFNA5 
DFNA6/14/38 
Wolfram syndrome 
DFNA36 
DFNB7/n 
DFNB6 
DFNB8/10 
USH3 
DFNA39 
OMIM· Online Mendelian Inheritance in Man. 
CELLULAR TRAFFICKING PROTEINS 
Mutations in the DDP1 gene (Deafness-Dystonia Peptide) cause DFN1, which was 
later renamed as deafness-dystonia syndrome or Mohr-Tranebjaerg syndrome.137 
The sensorineural HI is accompanied by dystonia, fractures, mental retardation 
and ocular features, which gradually lead to cortical blindness.138 Ocular features 
include myopia, decreased visual acuity, constricted visual fields and an abnormal 
electroretinogram. DDP1 is located on the X chromosome and the protein is 
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thought to be involved in the import of carrier proteins into the mitochondria and 
insertion into the mitochondrial inner membrane. Therefore, the DDP1 protein is 
likely to affect mitochondrial oxidative phosphorylation.1 3 9 1 4 0 
GENES WHOSE FUNCTION CURRENTLY IS UNKNOWN 
In the past years the number of genes known to be involved in syndromic and 
nonsyndromic sensorineural HI has increased considerably. For some of these 
genes, the function of the protein is still unknown. DFNA5, whose phenotype is 
described in the last section of this introduction,81 is one of these genes.141 The 
exact function of the WFSI product wolframin, which is involved in Wolfram 
syndrome (Chapter 4.1) and DFNA6/14 (Chapter 5.1), is also still unknown. It has, 
however, been hypothesised to play an important role in endolymph homeostasis, 
maintained by the canalicular reticulum, a specialised type of endoplasmic 
reticulum in the inner ear.142 The USH3 gene is mutated in Usher syndrome type 
III.1 4 3 This type of Usher syndrome is differentiated from other clinical types of 
Usher syndrome by progressive HI. The protein encoded by the USH3 gene is 
named clarin-1. Although still little is known about the protein function of the 
gene, it may play a role in synapse function between hair cells and cochlear 
ganglion cells. This suggestion was made on the basis of remote similarity to 
stargazin.144-145 Several other genes with a currently unknown function are shown 
in Table 6. Clinical and genetic studies will reveal the function of these proteins in 
the nearby future. 
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HI is the most common sensory disorder worldwide. Congenital HI, which can be 
caused by genetic as well as environmental factors, is seen in one of 1,000 
newborns.1 More than 50% of these cases is caused by single gene mutations. 
Environmental factors play an important role in postlingual HI, but also this type 
can be caused by mutations in single genes. Autosomal recessive sensorineural HI 
is the main cause of the more profound, mostly prelingual, types of sensorineural 
HI, whereas autosomal dominant sensorineural HI is generally characterised by a 
lesser degree of impairment with, usually, postlingual onset and progression of 
impairment.2-3 
At this moment, 40 chromosomal loci (DFNA1-40) and 14 genes 
(DFNA1/D/APH1, DFNA2/ÎCCNQ4, DFNA2/G/B3, DFNA3/G/B2, DFNA3/G/B6, 
DFNA5/DFNA5, DFNA6/14(/38)/WFSI, DFNA8/12/TECTA, DFNA9/COCH, 
DFNA10/EYA4, DFNA11/MY07A, DFNA13/COLnA2, DFNA15/POÜ4F3, 
DFNA17/MYH9) are known to be involved in non-syndromic autosomal 
dominant sensorineural HI.4 Many of these are described elsewhere in this issue. 
Despite the broad interest in and the extensive research on the genotypes 
involved, adequate description of the corresponding phenotypes is often still 
lacking, or lagging behind. 
This review focuses on phenotype features of progressive types of nonsyndromic 
autosomal dominant sensorineural HI. The loci DFNA1, DFNA2, DFNA4, DFNA5, 
DFNA6/14(/38), DFNA7, DFNA9, DFNA10, DFNA15, DFNA16, DFNA17, 
DFNA20/26 and DFNA21 are included. For these loci we created "Age Related 
Typical Audiograms" (ARTA) that cover the relevant age range and constitute a 
convenient "fingerprint" characterizing these progressive phenotypes. 
ARTA were derived on the basis of our own raw data underlying previous 
reports, data found in sufficient detail in previous reports, or data based on 
personal communication (details below). The preparation and analyses of these 
ARTA are also described in this issue.5 
Data pertaining to speech recognition performance only included data based on 
our previously described analyses of %Correct scores, derived from individual 
monaural performance-intensity plots, using phonetically balanced word lists. 
Relevant score parameter values were obtained by performing regression analysis 
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on scores relating to either the patient's age or level of HI, as assessed by the pure 
tone average at the frequencies 1, 2 and 4 kHz (PTAi^i kHz). Details of the analyses 
can be found in the original reports. 
Frequency 
Figure 1. ARTA for DFNA1, DFNA2, DFNA4, DFNA5, DFNA6/14, DFNA7, DFNA9, DFNA15, 
DFNA16, DFNA17, DFNA20/26 and DFNA21. ARTA derived from single-family data, except 
when labeled as "mean" (DFNA2, DFNA6/14, DFNAIO; as indicated in the text). Italics indicate 
age (year). Data points are only included when no cross-sectional regression analysis was 
performed for producing ARTA. 
AGE-RELATED PURE TONE THRESHOLDS 
Low-frequency sensorineural hearing impairment 
DFNA1/D7APH1 
In 1992 Leon and co-workers identified the first locus for autosomal dominant 
sensorineural HI on chromosome 5q31.6 This locus was determined in a large 
Costa Rican family that traces back to 1754 whose phenotype was already 
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described in 1981.7 In 1997 Lynch et al. found DFNA1 to be associated with 
mutations in the human homologue (DIAPH1) of the Drosophila gene diaphanous.8 
HI began in childhood and initially mainly affected the lower frequencies. Severe 
progression occurred in the second and third decades of life, involving mid and 
high frequencies. In adults, hearing loss was profound (up to about 100 dB HL), 
affecting all frequencies (Figure). Some subjects initially complained about 
tinnitus. No signs of vestibular dysfunction could be elicited on formal testing.9 
DFNA6/14(/38)/WFSl 
Already in 1968 the Vanderbilt University Hereditary Deafness Study Group 
described a large family characterised by low-frequency sensorineural HI with 
autosomal dominant inheritance. The locus for this family was designated DFNA6 
and mapped to chromosome 4pl6.3 in 1995.10 A third locus (DFNA14) for low-
frequency sensorineural HI was mapped close to the DFNA6 region, however, 
without apparent overlap.11 Recently, Bespalova et al. described seven DFNA6/14 
families to harbour mutations in the WFSÌ gene.12 A key recombinant in the 
original American DFNA6 family that excluded the DFNA14 region was in fact 
based on a phenocopy. Simultaneously, Young et al. identified mutations in WFSI 
within a locus designated DFNA38 that was mapped for a trait with an apparently 
fairly similar phenotype.13 The raw data of the American DFNA6 family showed 
predominant involvement of the 0.25-1 kHz frequencies (Figure). Analysis of these 
data showed significant progression only at the higher frequencies, however, not 
beyond presbyacusis.14 The phenotype of the original Dutch DFNA14 family was 
described by Kunst et al.,15 who demonstrated the presence of significant 
progression in sensorineural HI that, however, could be attributed to 
presbyacusis. A second Dutch family was later described (data not shown) that 
appeared to have significant progression in sensorineural HI, even after correction 
for presbyacusis.14 Recent findings confirmed progression of sensorineural HI 
beyond presbyacusis (data not shown) in two additional Dutch families.16 
Flat-threshold sensorineural hearing impairment 
DFNA4 
In 1995 DFNA4 was introduced as the fourth locus for autosomal dominant 
inherited sensorineural HI, mapped to chromosome 19ql3.17 Despite an extensive 
search, the responsible gene is currently still unknown. 
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The affected persons from this family showed a progressive type of sensorineural 
HI covering all frequencies (Figure), that was said to be fluctuating, and started in 
the second decade of life, leading to severe-to-profound hearing loss by the age of 
40. 
DFNA21 
DFNA21 is one of the loci whose phenotype was described simultaneously with 
the results of linkage analysis.18 Linkage data indicated a position telomeric to the 
DFNA13 locus on chromosome 6p21-22; the responsible gene is still unknown. 
The trait showed progressive non-specific mid-frequency sensorineural HI with 
childhood to late adolescence onset (Figure). Progression of sensorineural HI was 
fairly similar for all frequencies, with a pooled value of 1.0 dB/year. 
Oculovestibular function was found to be normal. 
High-frequency hearing impairment 
O¥NA2/KCNQ4 
At this moment, two deafness genes are known to exist within the DFNA2 region 
on chromosome lp34: KCNQ4 and G/B3.4'19 As yet, only the phenotypes of traits 
with mutations in KCNQ4 have been thoroughly described. DFNA2 is linked to 
the short arm of chromosome l20-21 and the responsible gene KCNQ4 coding for a 
potassium channel was detected in 1999.22'23 Several different mutations have been 
found in different DFNA2/ÎCCNQ4 families,2227 but the fact that one mutation 
(W276S) has been found repeatedly in different, presumably unrelated families28-29 
suggests the possibility of a hotspot mutation in the KCNQ4 gene.30 
DFNA2/ÎCCNQ4 is generally characterised by a progressive downsloping pure-
tone audiogram (Figure) and its phenotype features have been described for 
several families originating from Belgium, the Netherlands, Japan and the USA by 
De Leenheer et al.27 The Figure shows ARTA obtained from averaging the age-
related threshold data of 6 DFNA2/KCNQ4 families,20'26-28'2931-32' threshold data 
communicated personally by Drs Shelley Smith, Margriet Verstreken and Floris 
Wuyts in 2000 and Zoreh Talebizadeh in 2001 as outlined in Chapter 2.1 of this 
thesis.5 
Speech recognition scores of one of the four currently known Dutch DFNA2 
families were analysed by De Leenheer et al.29 Speech recognition was in 
agreement with pure-tone audiograms and showed no deterioration before the 
fourth decade. Only after a high level of pure tone sensorineural HI had been 
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reached, speech recognition started to deteriorate Bom et al therefore suggested 
that relative sparing of outer hair cell function with the associated fine-tuning 
mechanisms might be held responsible for this fmding ^ 
Vestibular hyperreactivity appeared to be present in the two DFNA2/ÌCCNQ4 
families in whom vestibular function has been thoroughly assessed28 29 We 
suggest this can be associated with the expression of (mutated) KCNQ4 in central 
vestibular pathways M 
DFNA5/DFNA5 
DFNA5 was mapped to chromosome 7pl5 in 1995 and, after refining the locus, 
Van Laer et al reported finding the DFNA5 gene35 37 The only currently known 
DFNA5 trait occurs in a large Dutch family, its phenotype was described already 
in the late sixties of the past century 1 Μ 2 The pure tone audiogram showed a Z-
shaped configuration (Figure) Onset was determined at between 5 and 15 years of 
age Progression was most pronounced in the first three decades of life and then 
gradually slowed down Original data were obtained (personal communication by 
Dr Egbert Huizing, 2000) and re-analysed by De Leenheer et al ^ The lower 
frequencies showed a lower maximum rate of deterioration (1 dB/year) than did 
the higher frequencies (1-4 dB/year)3 
Relatively good speech recognition scores were reported by De Leenheer et a l 4 4 At 
a given level of sensorineural HI, the scores of the DFNA5 patients were nearly 
similar to those reported for DFNA2/XCNQ4 patients29 and much better than in 
DFNA933 or presbyacusis patients 2 9 It was speculated that outer hair cell function 
was relatively well preserved4 4 
Vestibular function was formally tested in four members of one branch of the 
original DFNA5 family and found to be normal ** 
DFNA7 
DFNA7 has been mapped to chromosome lq21-23 in one Norwegian family with 
22 affected individuals The responsible gene is not yet known 4 5 The trait showed 
postlingual onset affecting the higher frequencies The lower frequencies were 
relatively well preserved (Figure) and a useful hearing capacity was thus 
maintained until old age Periods of rapid progression of hearing loss were seen 
mainly at young ages and could be asymmetrical All patients had 100% speech 
recognition unaided and no signs of vestibular dysfunction could be detected on 
bithermal caloric testing4 6 
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DFNA9/COCH 
DFNA9/COCH is currently the only form of nonsyndromic autosomal dominant 
sensorineural HI that includes the feature of substantial vestibular impairment3·47 
DFNA9 was found to be linked to chromosome 14ql2-ql348'49 and COCH was 
identified as the gene carrying the disease-causing mutations.^054 Previously 
performed temporal bone studies demonstrated typical histopathological 
features.55-56 Several clinical reports antedated the linkage reports on 
DFNA9/COCH.57 62 The same mutation is found in a number of Western 
European DFNA9/COCH families, probably originating from a single common 
ancestor.53 In addition, other mutations have been identified in American and 
Australian families.52'63-64 DFNA9 shows a flat to gently downsloping pure tone 
threshold with limited or no loss in the low-frequency range in the first three to 
four decades of life, followed by progression establishing downsloping pure tone 
threshold characteristics and eventually profound deafness with residual hearing 
only at the lower frequencies (Figure). 
Bom et al. evaluated speech recognition scores in DFNA9/COCH patients and 
compared them to scores obtained for patients with OFIS^/KCNCM.13 DFNA2 
and DFNA9 patients at modal ages appeared to have fairly similar pure tone 
audiograms, but exhibited a substantial difference in speech recognition 
performance. At a given level of sensorineural HI, the DFNA9 patients showed 
poorer speech recognition scores than the DFNA2 patients. It was speculated that 
such differences relate to differences in intracochlear pathology, especially the 
degree of functional impairment of inner and outer hair cells.33 Widespread inner-
ear pathology is found in the case of DFNA9,65 which is reflected not only in 
relatively poor speech recognition performance, but also in the development of 
vestibular hyporeflexia and, eventually, areflexia. 
Typical for DFNA9/COCH are the most impressive vestibular findings that have 
been documented in several families, where the patients developed vestibular 
hyporeflexia ultimately leading to complete vestibular areflexia from the age of 
about 40 year onwards.50'55'57-6670 Up to now, this is the only DFNA locus 
associated with vestibular areflexia. In the course of progression, patients may 
have episodes of Ménière-like symptoms, sometimes associated with vestibular 
hyperreactivity.50-55'66'6870 Presumably, such episodes are associated with transient 
asymmetry in peripheral vestibular function.67·69 
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DFNA10/EYA4 
In 1996 DFNAIO was mapped to chromosome 6q22.3-23.2 based on linkage 
analysis results in a large American family.71 Later refinement was achieved by an 
additional Belgian family.72 In 2001, Wayne et al. found mutations in the 
transcriptional activator EYA4 to be responsible for DFNAIO in both families.73 
DFNAIO is phenotypically characterised by mid- and high-frequency 
sensorineural HI progressing mainly during the first few decades of life.7476 The 
ARTA in the Figure is the result of an average of the data pertaining to both 
currently known families. Presumably, onset was postlingual, as individuals were 
only affected after having developed normal speech and language assessment. De 
Leenheer et al. showed that the additional deterioration of sensorineural HI 
occurring after the age of 30 could not be distinguished from presbyacusis.74 
Verstreken et al. reported the presence of tinnitus in 35% of the affected Belgian 
family members.76 A thorough phoneme recognition score analysis was also 
performed and it demonstrated that by the age of 67 years speech recognition is 
about 50%.74 
DFNA15/POÜ4F3 
The responsible gene in an Israeli Jewish family is located at the DFNA15 locus on 
chromosome 5q31 and is a transcription factor named POL/4F3.77 HI in this family, 
caused by POU4F3 mutations, was described by Frydman et al.78 They noticed 
progressive high-frequency sensorineural HI starting at between 18 and 30 years 
of age. Pure tone audiograms showed a downsloping configuration and 
sensorineural HI gradually progressed involving all frequencies (Figure). 
DFNA16 
The DFNA16 locus has been mapped to chromosome 2q23-24.3 and several 
candidate genes have been suggested to exist by Kasai et al.79 DFNA16 is 
characterised by repeated episodes of fluctuating progressive high-frequency 
sensorineural HI (Figure). Normal hearing anamnestically was present until 9-10 
years of age. DFNA16 is the first type of sensorineural HI that appears to respond 
to steroid treatment; all affected mothers reported having experienced (increased) 
tinnitus and hearing loss after delivery.80 
DFNA17/MYH9 
MYH9 is a nonmuscle-myosin heavy-chain gene that shows mutations in one 
family linked to DFNA17.81 This trait is characterised by progressive high-
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frequency sensorineural HI that begins at about 10 years of age. Initially, it only 
involves the higher frequencies, but by the age of 30 years affected individuals 
have developed severe to profound sensorineural HI at all frequencies (Figure). 
Histopathological study has identified cochleosaccular degeneration (Scheibe 
type).82 
DFNA20/26 
DFNA20 and DFNA26 have both been mapped to chromosome 17q25. It is very 
likely that both loci are caused by mutations in the same gene.4-83 Sensorineural 
HI in DFNA20 shows relatively late onset and most prominent progression at the 
high frequencies.84 The phenotype of a Norwegian family linked to DFNA26 was 
described in 1968 by Teig (data underlying the ARTA in Figure) and demonstrated 
primary involvement of the higher frequencies to be present already at young ages 
and progression with secondary involvement of the lower frequencies.85 
Table 1 Speech recognition scores for DFNA2, DFNA5, DFNA9 and DFNAIO related to age and 
HI. 
Speech recognit ion scores related to· 
DFNA2/fCCNQ4 
DFNAS/DFMS 
DFNA9/COCH 
DFNA10/EYA4 
Age (year) 
Onset age Deterioration rate 
(year) 
34 
16 
43 
43 
(%/year) 
0 3 
0 7 
1 8 
1 8 
PTA, 
Onset level 
(dB HL) 
65 
41 
45 
53 
MkH, (dB HL) 
Deterioration gradient 
(%/dBHL) 
05 
04 
12 
14 
Onset age and onset level are related to 90% phoneme recognition score Deterioration rate and 
deterioration gradient relate to (average, maximum) slope in score against age and score against 
P T A M kHz plots, respectively Values for DFNAIO are calculated from the original plots 
PHONEME RECOGNITION SCORE RELATED TO AGE AND LEVEL 
OF IMPAIRMENT 
As can be seen in the Figure, some similarity in pure tone threshold features 
(ARTA) exists between DFNA2, DFNA5, DFNA9 and DFNAIO. As described in 
part in the separate sections above, analyses of speech recognition scores (Table) 
have revealed some intriguing differences between some of these traits.33·44'74 The 
low onset age for score deterioration in DFNA5 underlines the rapid deterioration 
in this trait; onset age for pure tone hearing loss was 5-15 year! However, the rate 
of score deterioration was relatively low in this trait, not much higher than in 
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DFNA2 that showed later onset of deterioration in speech recognition (Table 1). 
Both DFNA9 and DFNA10 showed a relatively late onset of deterioration of 
speech recognition, then followed by a similar, considerably higher rate of 
progression than was found in DFNA2 or DFNA5.44 Both DFNA9 and DFNA1074 
showed a fairly similar development in terms of phoneme recognition score 
related to the level of sensorineural HI, with a relatively low onset level and a 
relatively high deterioration gradient. Patients with DFNA5 showed a similar 
onset level, but a lower, i.e. more favourable, deterioration gradient. A similar 
relatively low deterioration gradient was found in DFNA2 patients where it was 
combined, however, with a higher onset level, which indicates that at a similar 
level of impairment, they showed higher scores than the DFNA5 patients. At 
comparable levels of HI, DFNA5 patients thus showed speech recognition scores 
in between those of DFNA9 patients, who had relatively poor scores, and those of 
DFNA2 patients, who had relatively good scores.44 
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METHODS 

2.1
CHARACTERISING AND 
DISTINGUISHING PROGRESSIVE 
PHENOTYPES IN NONSYNDROMIC 
AUTOSOMAL DOMINANT 
HEARING IMPAIRMENT
P.L.M. Huygen 
R.J.E. Pennings 
C.W.R.J. Cremers
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METHODS 
INTRODUCTION 
This report introduces the use of a newly derived method developed especially for 
convenient and comprehensive phenotype presentation of, and comparison 
across, progressive HI disorders. It includes construction, starting from regression 
analysis (threshold on age) of age-related threshold data, of "Age Related Typical 
Audiograms" (ARTA). ARTA are featuring in a combination plot with an 
audiogram-Iike format that covers the relevant age range and constitutes a 
"fingerprint" characterizing these progressive phenotypes. The method also 
includes transformation of age-related threshold data (from a regression plot or 
ARTA) into a one-dimensional so-called "threshold features array", that can be 
used for statistical testing on age-related threshold features across HI traits. Given 
such an array, it is possible to make a reasonable reconstruction of the 
corresponding ARTA and regression lines for the trait. This indicates that the 
information content of the threshold features array, despite its one-dimensionality, 
is high enough to justify its use as a tool for testing on phenotype features across 
traits. To outline the use of ARTA and the threshold features array, we focused on 
autosomal dominant non-syndromic progressive HI traits linked to (DFNA) loci 
for which sufficient data were available or could be obtained. This includes 
DFNA2, DFNA5, DFNA6/14, DFNA9, DFNA10, DFNA15, DFNA21 and DFNA26. 
MATERIAL AND METHODS 
Age Related Typical Audiograms (ARTA) 
Many of the patients and families covered by the present paper have been 
previously described, or their description is currently in press. ARTA were 
derived from regression analysis (air conduction threshold on age), as previously 
described (DFNA2, DFNA9, DFNA10, DFNA14 and DFNA21), or performed by 
ourselves on reported data (DFNA2, DFNA6/14, DFNA15 and DFNA26). Some 
raw threshold data became available by personal communication, as specified 
below. 
Sources of the used threshold data were as follows: DFNA2: Marres et al.1 (family 
A); De Leenheer et al.2 (family Β); Kunst et al.3 (family C); Ensink et al.4 (family D); 
personal communications of raw data, in 2000, by Dr Shelley Smith (family E, 
underlying the report by Coucke et al.5) and Drs Margriet Verstreken and Floris 
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Wuyts (Belgian family, also underlying the report by Coucke et al.5) and, in 2001, 
by Dr Zoreh Talebizadeh (family F, underlying the report by Talebizadeh et al.6). 
DFNA5: original reports by Huizing et al.7"9 and van den Wijngaart et al.10·11 on a 
family later linked to this locus (Van Camp et al.12); raw data obtained from Dr. 
Egbert Huizing (personal communication, 2000) and re-analysed by De Leenheer 
et al.13 DFNA6/14: (see Hereditary Hearing Loss Homepage14), Vanderbilt 
University Hereditary Deafness Study Group,1 5 (DFNA6), Kunst et al.16 
(DFNA14). DFNA9: raw data underlying the report by Bom et al.17 DFNAIO: De 
Leenheer et al. 1 8 1 9 (family A), Verstreken et al.20 (family Β). DFNA15: Frydman et 
al.21 DFNA21: Kunst et al.22 DFNA26: Teig23 (family recently linked to the same 
locus as DFNA20 by Fagerheim et al.24). 
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Figure 1 (Α-C) Figure illustrating the method used to transform age-related threshold findings 
obtained in regression plot (A) into ARTA (B) and from there into a threshold features array (C) 
Data of family D in Fig 3 The number of data points in (A) is counted for 3 frequency classes, ι e 
the low frequencies (If, 0 25-0 5 kHz), the mid frequencies (mf, 1-2 kHz) and the high frequencies 
(A/, 4-8 kHz) for each class of hearing impairment, mild, moderate and severe The counts of data 
points per cell (bold) are included in the corresponding cells (identification, a-i) as indicated in top 
right comer of each cell) in the ARTA panel (B) The one-dimensional threshold features array is 
included in (B) and the count (#) per cell is plotted in (C) Italic figures 0 and 70 in (B) indicate age 
Part of the ARTA included, have already been presented in a different format in 
previous original or review papers. The present format is a "smoothed" one, the 
curves having been obtained by applying non-linear regression analysis (Prism 
3.02 software, GraphPad, San Diego, CA, US) to approximate the original ARTA. 
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Second-order or third-order polynomials were used for that purpose, or an 
equation describing a dose-response curve with variable slope, of which details 
have been described previously by Bom et al.25 
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Figure 2. ARTA for the single-family loci DFNA5, DFNA9, DFNA15, DFNA21 
and DFNA26. Italics indicate age (year). 
Tlireshold Features Array (TFA) 
An indirect method for statistical testing between threshold-by-age data across 
loci relating to the threshold predicted for each frequency by regression analysis at 
fixed ages (0, 10, 20, 30, 40, 50, 60 and 70 years. Figure 1A), or the equivalent 
ARTA data derived from the latter (Figure IB) was developed. A 3x3 table was 
constructed for each complete data set thus obtained that indicates the number of 
(predicted) data points within the separate 9 cells of this table (Figure IB). Data 
classification involved the following frequency classes: low frequency (If, 0.25-5 
kHz), mid frequency (mf, 1-2 kHz) and high frequency (hf, 4-8 kHz). Three HI 
classes were distinguished: mild (< 40 dB HL), moderate (40-80 dB HL) and severe 
(> 80 dB HL). The 9 cells of this 3x3 table were designated a-i in such a way that 
cell a (top left in panel Β of Figure 1) contained the number of data points 
pertaining to mild HI at 0.25-0.5 kHz (Ifl and cell i contained the number of data 
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Figure 3 ARTA for a relevant selection of DFNA2 families covering several 
different (or similar, in families A and B) mutations m the KCNQ4 gene 
Mutations in families Α-F affect the potassium channel pore region, the Belgian 
family has an inactivating mutation 
points pertaining to severe HI at 4-8 kHz (hß. The contents of all these cells thus 
established a one-dimensional (n=9) array (Figure IB), which we called the 
"threshold features array". This was used for plotting (Figure 1C) and testing 
purposes in order to compare between phenotypes. Testing between threshold 
features arrays for the different loci was performed by applying conventional chi-
square tests. 
RESULTS 
Figure 2 shows the single-family DFNA loci. Figures 3 and 4 relate to multi-family 
loci. It can be concluded from Figure 3 that chi-square tests applied on threshold 
features arrays of the DFNA2/KCNQ4 traits caused by mutations affecting the 
KCNQ4 channel pore region (families Α-F) did not reveal any significant 
difference. However, if such tests included the Belgian family harboring a KCNQ4 
inactivating mutation (Figure 3, bottom panel), the corresponding test results 
indicated significant differences. 
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Figure 5. Plots of threshold features arrays for cell count in cells a-i. Plots were 
superposed for DFNA6 and DFNA14 (top left panel), the two DFNA10 traits 
(families A and Β in Fig. 4 designated here as a and b in top right panel), as well 
as combinations of loci in apparent phenotype clusters (bottom panels). For 
DFNA2, the affixed a-f relate to families Α-F. Horizontal bars above the plotted 
counts indicate the age class (0-30 year or 40-70 year, italics) to which the counts 
plotted below each bar pertain. The Ρ value in each panel shows the result of 
the chi-square test across all traits included in the plot. 
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Figure 5 shows plots derived from a number of relevant threshold features arrays. 
The shape of these plots indicates that the threshold features array to some extent 
reflects the ARTA. For example, the plot for DFNA6/14 (Figure 5, top left panel) 
shows culmination of the cell count in cell d, i.e. the cell that pertains to moderate 
HI in the low-frequency range (Figure IB). This is in line with the observation that 
can be made in Figure 4 (top panels) that all audiogram lines of the ARTA in 
DFNA6/14 start out from a moderate threshold level in the If range. For the 
cluster of DFNA2, DFNA5 and DFNA26 (Figure 5, bottom left panel), 3 peaks are 
found in the threshold feature array: in cells a (mild, If), e (moderate, mf) and i 
(severe, hf), i.e. corresponding to the predominantly diagonal pattern seen in the 
ARTA (Figure 3). As indicated in this panel (Figure 5, bottom left), the thresholds 
predicted for ages 0-30 are mainly represented by cells a-e and those for ages 40-70 
by cells d-i. These latter observations were made by preparing separate threshold 
features arrays and plots (data not shown) for the separate age classes 0-30 year 
and 40-70 year. 
The information content of the threshold features array is substantial: following a 
few basic rules for calculation (details not shown), it can be demonstrated that it is 
possible to reconstruct ARTA, or threshold against age plots, from a given 
threshold features array with a precision of within about 10-20 dB (data not 
shown). The observation that major phenotype characteristics of a given trait locus 
are thus reflected in its compact one-dimensional threshold features array 
suggests that the latter is a suitable tool for testing on major HI features across 
DFNA traits within a chi-square test setting. 
Table 1 Apparent similarity of pure tone threshold features according to chi-square test between 
threshold features arrays (Yes, Ρ > 0 05, Yes', Ρ < 0 05 but close to 0 05) 
Locus D F N A 2 a D F N A 5 D F N A 6 / 1 4 D F N A 9 DFNA10 DFNA15 DFNA21 
DFNA5 Yes 
DFNA6/14 
DFNA9 Yes 
DFNA10 Yes 
DFNA15 Yes' 
DFNA21 
DFNA26 Yes Yes 
a
, Belgian trait with inactivating mutation excluded 
Table 1 shows the crude results of chi-square tests in pairwise comparisons 
involving threshold features arrays in terms of fair similarity. There was no 
significant difference detected between DFNA6 and DFNA14 or between the two 
Yes 
Yes 
Yes Yes 
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DFNAIO traits. Other combination plots and the corresponding Ρ values in Figure 
5 illustrate that two different phenotype clusters could be distinguished: one 
comprising 6 DFNA2 families (Α-F), the DFNA5 family and the DFNA26 family 
(Figure 5, bottom left panel), the other comprising the same DFNA5 family as well 
as the families with DFNA9, DFNAIO, DFNA15 and DFNA21 traits (Figure 5, 
bottom right panel). As DFNA5 (bold line) forms part of both these clusters, its 
phenotype features probably are intermediate between those of the two 
phenotypes covered by these clusters and are not too different from both of them. 
DISCUSSION 
Soon after their introduction, ARTA have turned out to be extremely useful in the 
characterisation of progressive DFNA types. ARTA prepared for several different 
traits (Figures 2-4) show that it is fairly easy to get a first impression of which 
traits have fairly similar or dissimilar features. It may, indeed, be much more 
difficult to compare the original regression lines in the threshold-against-age plots 
across different traits. The main problems that can be met with the latter type of 
plots are that progression is non-linear, regression lines or curves cross one 
another, and the results of formal statistical tests pertaining to the original age-
related threshold data depend very much on the numbers of observations and the 
degree of variability involved. Typically, the lines or curves depicted in ARTA 
never cross, a feature that accounts for their fingerprint-like appearance. The 
numbers of observations involved when comparing across ARTA for different 
traits are (preferably) always the same, so that each trait has the same weight in 
any comparison test. 
For any further use of ARTA, the problem is how to formalise comparisons 
between ARTA in pairwise or simultaneous comparisons. To this purpose, we 
designed the threshold features array to transform the data point entries of either 
the ARTA or the original regression plots into a one-dimensional array. The array 
entries can be used for plotting purposes; superposition of such plots (Figure 5) 
obviously avoids superposition of different sets of curves constituting the ARTA, 
which can be very confusing if a number of traits are involved (Figure 6). 
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Figure 6 Superposed ARTA for the DFNA2/ÎCCNQ4 families Α-F of Figure 3 are shown 
in the left panel Averaging of original threshold data resulted in the data points shown 
in the right ARTA panel, together with the newly fitted curves Similar to Figure IB, the 
corresponding counts (bold figures) in cells a-i are shown and entered in the threshold 
features array on the right, that is typical of DFNA2/i;CNQ4 traits with an affected 
potassium channel pore region and can be used for future testing on hearing impairment 
features of newly identified traits 
Perhaps even more important is that such arrays are easy to use in pairwise or 
simultaneous testing across the corresponding traits, employing standard chi-
square methods (programs and tables). "Averaged" ARTA and threshold features 
arrays can be derived which represent normative, typical values to be expected for 
a specific trait (Table 2). An example is shown in Figure 6. The left panel shows the 
superposition of the ARTA plots for all the present DFNA2 traits (families Α-F in 
Figure 3) with mutations affecting the KCNQ4 channel pore region. Averaging of 
data entries as per age and frequency produced the data points depicted in the 
right ARTA panel of Figure 6. The curves were fitted to these points with third-
degree polynomials. Similar to Figure 1, the corresponding threshold features 
array is shown on the right. This array can be used as being normative for the 
phenotype of DFNA2/ÎCCNQ4 mutations affecting the potassium channel pore 
region. If an apparently similar phenotype is encountered in a new family, the 
threshold features array for the latter can be derived similarly and the two arrays 
can be entered in a chi-square test for goodness of fit. The expected values (counts 
per cell) for the DFNA2/ KCNQ4 phenotype are those shown in Figure 6 and Table 
2 and the observed values are those pertaining to the trait to be tested. If the chi-
square value (goodness of fit) does not detect a significant difference (P < 0.05) 
between the known phenotype and the new trait, it seems worth the effort to 
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undertake linkage analysis and or mutation analysis for this trait, guided by this 
finding. 
Using this method, our most recently identified DFNA2/ÎCCNQ4 family (family Β 
of Figure 3), in fact, was predicted to be a KCNQ4 family before genetic analysis 
took place.2 
Table 2 Threshold features arrays (cell count for cells a-i) for the traits under study that can be 
used m conventional chi-square tests Averages pertain to norm values It should be noted that a 
conventional chi-square test can be used for testing across separate arrays, but that a chi-square test 
for goodness of fit should be used if (average) norm values are applied as representing expected 
values Prior to performing a conventional chi-square test on a given contingency table, that can be 
constructed by combining any arrays, cells should be combined where necessary according to 
general rules described for chi-square tests in most textbooks on statistics 
Trait (Family) 
DFNA2 (A) 
DFNA2 (B) 
DFNA2 (C) 
DFNA2 (D) 
DFNA2 (E) 
DFNA2(F) 
Average DFNA2 
DFNA2, Belgian family 
DFNA5 
DFNA6 
DFNA14 
Average DFNA6/14 
DFNA9 
DFNA10 (A) 
DFNA10 (B) 
Average DFNA10 
DFNA15 
DFNA21 
DFNA26 
Cella 
9 
6 
11 
10 
7 
9 
9 
16 
8 
0 
0 
0 
11 
7 
10 
9 
12 
12 
7 
Cellb 
7 
1 
7 
4 
0 
6 
5 
11 
5 
10 
6 
6 
11 
6 
9 
6 
10 
10 
2 
Celle 
1 
1 
2 
0 
0 
1 
1 
0 
2 
10 
12 
11 
8 
6 
7 
6 
8 
9 
0 
Celld 
7 
8 
5 
6 
9 
7 
7 
0 
8 
16 
16 
16 
5 
9 
6 
7 
4 
4 
7 
Celle 
6 
9 
8 
11 
14 
9 
8 
3 
8 
6 
10 
10 
5 
10 
7 
10 
5 
6 
5 
Cell f 
8 
7 
7 
10 
9 
8 
8 
6 
4 
6 
3 
5 
2 
5 
7 
7 
4 
6 
5 
Cell g 
0 
2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
2 
Cell h 
3 
6 
1 
1 
2 
1 
3 
2 
3 
0 
0 
0 
0 
0 
0 
0 
1 
0 
9 
Cell 
7 
8 
7 
6 
7 
7 
7 
10 
10 
0 
1 
0 
6 
5 
2 
3 
4 
1 
11 
It is obvious that the quality of any normative threshold features array increases 
with the number of genotyped traits it is based on, provided these traits 
correspond to fairly similar phenotypes. In the present material, fairly 
homogeneous phenotypes were found across the entries for families Α-F with 
DFNA2/ÎCCNQ4 (mutations affecting the channel pore region), the entries for 
locus DFNA6/14, and those for DFNA10. 
A potentially serious problem is the existence of similarity in phenotype of 
different genotypes, such as is suggested to be the case by the presence in Figure 5 
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of a phenotype cluster of DFNA2, DFNA5 and DFNA26, as well as a phenotype 
cluster comprising DFNA5, DFNA9, DFNA10, DFNA15 and DFNA 21. It seems 
possible that mutations in different genes lead to very similar phenotypes. If a lack 
of specificity in phenotype is evident from evaluation by ARTA and the threshold 
features array, additional distinguishing phenotype features can be very 
important. For example, although the DFNA2 and DFNA5 traits included in our 
analyses showed fairly similar features, it is clear that these traits have different 
onset age and progression characteristics. DFNA2 patients are likely to have 
considerable congenital offset threshold levels, especially at the higher 
frequencies,2 in contrast to DFNA5 patients, who do not have any clear HI 
symptoms or elevated thresholds before the postlingual age of onset.13 In addition, 
DFNA5 patients typically show non-linearity of progression, which is most rapid 
in the initial stages and then gradually slows down, whereas DFNA2 patients 
show steady, linear progression. Onset age is also different between DFNA5 (5-15 
year) and DFNA9 (about 40 year). It may also be important to know whether or 
not a given trait exhibits progression beyond presbyacusis. Other distinguishing 
phenotype features include speech recognition scores and vestibular dysfunction 
(for example in DFNA9). Finally, when attempting to distinguish between 
phenotypes, one should be aware of the relevant genetic epidemiological evidence 
available. That is, it can be very helpful in a given classification task to realize that 
many, if not most of the documented trait loci, are amazingly rare, each having 
been identified only in a single family. Notable exceptions are the multi-family loci 
DFNA2 and DFNA9, whereas the number of families linked to other loci, for 
example DFNA6/14(/38), is still increasing.14 
Features relating to progression in HI can be assessed in more detail than has 
usually been the case up to now.26 An easy and convenient way to accomplish this 
is to establish ARTA and threshold features arrays that can be compared and 
tested across the different traits in a formal and semi-automatic way. Typical 
threshold features arrays can be established in the case of multiple occurrences of 
a given genotype (Figure 6). Such data can then be used in a normative way (i.e. 
defining expected values) to test (for example, in chi-square tests) whether or not a 
given phenotype is likely to be similar to already firmly established phenotypes. 
Based on his phenotypic findings, the clinician can direct the geneticist to search 
for mutations in a specific gene or perform linkage on a specific genotype. While 
performing such a task, it should always be kept in mind that different genotypes 
may have strikingly similar phenotypes. 
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The ARTA and threshold features arrays, representing the various types of DFNA, 
so far confirm the correlation between specific genotype and phenotype. 
Therefore, detailed phenotypic analyses have important consequences, especially 
when performing research in families affected by hereditary HI. The created 
ARTA and threshold features array of the investigated families can be used to 
compare the type of HI, the age of onset, the possible progression of HI and the 
influence of presbyacusis in relationship to other genotypes.27 However, it does 
not only help selecting potentially interesting loci for linkage analysis or genes for 
mutation analysis, but it is also valuable for genetic and individual counseling. 
ARTA in general depict the progression and deterioration of HI and thus can be 
very useful for counseling purposes within the investigated family. It may also 
inspire to undertake fundamental experimental studies on inner ear function in 
relation to mechanisms underlying genetic HI. 
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USHER SYNDROME 
INTRODUCTION 
"Usher syndrome" covers a group of autosomal recessive inherited disorders 
characterised by sensorineural HI and visual impairment mainly due to RP. In some 
of the patients vestibular dysfunction also occurs. This syndrome is named after 
Charles Usher, a Scottish ophthalmologist who described familial retinal pigment 
disorders and noted that some of his RP patients also had HI.1 Three different clinical 
types of Usher syndrome nowadays are known. Usher syndrome type I is 
characterised by congenital, profound deafness associated with vestibular areflexia 
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and RP. Usher syndrome type II is characterised by moderate to severe sensorineural 
HI, intact vestibular responses and RP, whereas Usher syndrome type III is 
characterised by progressive HI, variable vestibular function and RP.2 
Table 1. Genetic subtypes of Usher syndrome. 
Usher type I 
Usher type II 
Usher type III 
Genotype 
USHla 
USHlb 
USHlc 
USHld 
USHle 
USHlf 
USHlg 
USH2a 
USH2b 
USH2C 
USH3 
Locus 
14q32 
l lq l3 .5 
l l p lS . l 
10q21-22 
21q 
10q21-22 
17q24-25 
lq41 
3p23-24.2 
5ql4.3-q21 3 
3q21-q25 
Gene 
-
MY07A 
USHIC 
CDH23 
-
PCDH75 
SANS 
USH2A 
-
-
USH3 
Several genotypes were found to be causing these three clinical types of Usher 
syndrome (Table 1). Currently, 7 loci have been mapped for Usher syndrome type I 
(USH1A-USH1G), 3 loci for Usher syndrome type II (USH2A-USH2C) and 1 locus for 
Usher syndrome type III (USH3).3 Five of the 7 genes involved in Usher syndrome type 
I have been cloned. Cadherin 23 (CDH23J is the gene involved in Usher syndrome 
type Id (USHld) and has been mapped to chromosome 10q21-22. This gene is also 
known to be involved in DFNB12, an autosomal recessive type of nonsyndromic HI. 
Therefore, USHld and DFNB12 are allelic disorders.4-6 The CDH23 gene is not the only 
gene involved in syndromic as well as nonsyndromic HI; other genes are: USHIC 
(USHlc/DFNB18), SLC26A4 (Pendred syndrome/DFNB4), WFS1 (Wolfram 
syndrome/DFNA6/14), COL11A2 (DFNA13/Stickler syndrome) and MY07A 
(USHlb/DFNAll/DFNB2).7-i2 
This report describes the findings of audiovestibular and ophthalmological 
examinations in 10 patients from 4 different families (3 USHld, 1 DFNB12) carrying 
CDH23 mutations and relates the encountered features to the underlying genotype. 
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PATIENTS AND METHODS 
Patients, families and the associated genotype 
In this study, 4 families were examined and their pedigrees are shown in Fig. 1. After 
the identification of pathogenic mutations in the CDH23 gene (shown in Table 2), 
these families were contacted again for additional audiovestibular and 
ophthalmological examinations. From all patients and non-affected family members 
a written informed consent was obtained. In addition, medical history was taken in 
all patients focusing on audiovestibular and visual impairment. 
Table 2. Genotype of 3 USHld families and 1 DFNB12 family 
Family 
1517 
1071 
1066 
Branch A 
Branch Β 
Mutation 1 
U50G>C (A484P) 
IVS45-9G>A 
IVS20+1OA 
D2148N 
D2148N 
Mutation 2 
1450G>C (A484P) 
unknown 
unknown 
D2148N 
D1341N 
Exon 
14 
46 
20 
47 
47,31 
Domain 
EC5 
EC19 
EC7 
EC20 
EC20, EC13 
EC: extracellular Cadherin domain 
USH1D FAMILIES 
Two sibs each were affected by Usher syndrome type I in 2 Dutch families (1066 and 
1071). In a third family (1517), originating from Flanders, Belgium, again two sibs 
were affected by Usher syndrome type I. Individual II-5 from this family did not 
participate in the study, however, her previous clinical data was retrieved with her 
permission. Mutation analysis of the CDH23 gene revealed a homozygous 1450G>C 
mutation in both affected individuals of the Belgian family 1517. This mutation not 
only leads to an amino acid substitution of proline for alanine at position 484, but 
also can be predicted to cause a splicing defect of exon 14. In family 1071, one 
heterozygous mutation in both affected individuals was identified in the CDH23 
gene: IVS45-9 G>A; this mutation affects the splice-acceptor region preceding exon 
46. So far, the second mutation has not been identified. In family 1066, a IVS20+1 
G>A mutation was identified in CDH23, whereas the second mutation in this family 
remains to be identified. The IVS20+1G>A mutation also disrupts the donor splicing 
sequence. All identified mutations are located within the extracellular Cadherin (EC) 
domains of Cadherin 23 and lead to truncation of the protein. Genetic testing in the 
USH1D families was performed by heteroduplex analysis and confirmation of the 
identified mutations by sequencing. Some exons were studied directly by 
sequencing. This way, in families 1066 and 1071, with only one identified CDH23 
mutation, more than 95% of the known coding region of CDH23 was screened. 
USHld 
DFNB12 
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Recently, these genetic findings were described by Astuto et al ^ The BDGP sphce-
site prediction program available at the Berkely Drosophila Genome Project Splice 
Site Predicition by Neural Network Web Site14 was used to predict the effect of 
splice-site mutations 
DFNB12 FAMILY 
Four patients of the fourth family (W90-004), a large consanguineous family with 
nonsyndromic autosomal recessive sensorineural HI, were shown to be affected by 
DFNB12 and 3 of them could be contacted and decided again to participate in this 
study For individual IX-17, the data retrieved from her previous clinical 
examinations dating from the seventies and eighties of the past century were used 
Mutation analysis recently showed that mutations in two different genes were 
responsible for the HI in this family 1 5 The HI in branch C of this family (Fig 1) was 
caused by a homozygous 35delG mutation in the GJB2 gene (DFNB1) In branch A, 
patients X-l and X-2 were found to have a homozygous D2148N mutation in CDH23, 
whereas both patients IX-15 and IX-17 of branch Β are compound heterozygous for 
this mutation and the D1341N mutation These two amino acid substitutions are 
located in the highly conserved calcium-binding sites of the extracellular Cadherin 
(EC) domains of Cadherin 23 
Audiometrie examinations 
Audiometrie examination consisted of standard clinical pure-tone audiometry in a 
sound-treated room Previously performed audiometrie examinations were retrieved 
to evaluate possible individual progression of HI Some of the previously recorded 
audiometrie data of family W90-004 were described by Marres et a l 1 6 Individual, 
longitudinal pure tone thresholds were analysed for progression of HI using linear 
regression analysis (binaural mean air conduction threshold on age) It was checked 
whether progression could be called significant, ι e zero outside 95% confidence 
interval for slope at 2 or more out of 6 or 7 frequencies At each frequency, the last-
visit binaural mean pure tone threshold was compared between USHld and DFNB12 
patients using a 2x2 contingency table and Fisher's exact probability test The level of 
significance used in all tests was ρ = 0 05 
Vestibular examinations 
Vestibulo-ocular examinations were performed with the patient sitting in upright 
position in a rotatory chair Visually guided eye movements were evaluated 
(saccades, optokinetic nystagmus and smooth pursuit eye movements), including 
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monitoring of the presence of any spontaneous or gaze-evoked nystagmus 
Vestibular tests were performed in the dark with eyes open The vestibulo-ocular 
reflex was evaluated using velocity steps of 90°/s in either direction with 
electronystagmography and computer analysis as previously described 1 7 The cervico-
ocular reflex was elicited only in patients showing a lacking vestibulo-ocular reflex 1 8 
Ophthalmological examinations 
Ophthalmological examinations consisted of corrected visual acuity measurements, 
slit-lamp examinations and funduscopy Visual fields were evaluated by Goldmann 
perimetry using test targets V-4, III-4 and 1-4 Test target III-4 was evaluated according 
to AMA guidelines19 Additional ophthalmological tests included electroretmography 
and electro-oculography, both performed and evaluated according to ISCEV 
standards 2 0 2 1 Colour vision was tested using the Tokyo Medical College colour vision 
test, the Standard Pseudoisochromatic plates, the Ishihara test, the New Colour test 
by Lanthony, the Light discrimination test and the Farnswoth-Munsell 100 Hue test, 
as previously described 2 2 Dark adaptation was performed with the Goldmann-
Weekers adaptometer Finally, the fundus was photographed and fluorescein 
angiography was performed to record the retinal picture 
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Figure 2 Individual last visit audiograms Circles, right ear (air conduction level), crosses, left ear 
Downward arrow, out-of scale measurement 
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RESULTS 
Audiometrie findings 
Longitudinal analysis of pure tone thresholds could be performed in 3 USHld 
patients (n = 5-12, range of age: 2-39 years), as well as in 2 DFNB12 patients (n = 4, 
range of age: 10-40 years). None of these patients showed significant progression of 
HI (data not shown). Figure 2 shows the individual last-visit audiograms of both 
patient groups. The USHld patients generally only had residual hearing at the low 
frequencies (125 - 500 Hz), whereas the DFNB12 patients showed severe to profound 
sensorineural HI with thresholds that could be measured up to and including 4 kHz 
in most cases. 
Comparison between USHld and DFNB12 patients revealed that the USHld patients 
had significantly worse hearing than the DFNB12 patients at all frequencies except 
for the highest ones (p < 0.05). Figure 3 shows the "mean audiogram" for the DFNB12 
patients (n=4) and the USHld patients (n=6). 
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Figure 3 "Mean audiograms" in both patient groups. Bar represents 
1SD. Asterisk indicates significant result of Fisher's exact probability 
test, which included out-of-scale measurements (downward arrow). 
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Vestibular findings 
All examined USHld patients started to walk independently at age > 18 months, 
except for patient III-l of family 1066 (at age 12 months). Smooth pursuit was not 
tested in the USHld patients because they had difficulty with catching up the target, 
and was found to be normal in the DFNB12 patients. USHld patient 11:3 of family 
1517 (aged 40 years) tended to show spontaneous nystagmus in the dark. Saccades 
were normal in all patients. Optokinetic nystagmus could be elicited in all USHld 
patients, except for the oldest one (II-l, family 1071) who had very poor vision. 
Optokinetic nystagmus showed sufficiently high slow-phase velocity except in 
patient II-3 of family 1066 (aged 18 years). Vestibular examinations disclosed 
vestibular areflexia in all patients and in 3 patients the cervico-ocular reflex was 
found to be enhanced, which is in line with the findings in labyrinthine-defective 
subjects previously described by Huygen et al.18 
Ophthalmological findings 
All of the examined Usher syndrome type I patients suffered from nyctalopia in 
childhood; most of them had been diagnosed to have RP in the first decade of life. As 
expected, none of the patients with DFNB12 complained about their vision. 
Table 3 shows the results of the ophthalmological examinations. None of the 3 
DFNB12 patients had evidence of malfunction of the retina. Funduscopy revealed 
remarkable findings in 2 of the 3 DFNB12 patients. In patient X-l, almost 
symmetrical small yellowish flecks with central clustering of pigment at the level of 
the retinal pigment epithelium (RPE) were seen in the posterior pole of both eyes. 
These flecks were most clearly seen in the right fovea (Fig. 4a). Patient X-2 showed 
decreased filter action of the RPE on fluorescein angiography and had increased 
reflexes and minifolds of the internal limiting membrane in the macular area. Patient 
IX-15 had no retinal abnormalities on funduscopy. 
Five USHld patients had ophthalmological findings characteristic for RP with 
attenuated vessels, bony spicules, thinning of the RPE and a waxy disk appearance. 
In patient II-2 of family 1071, a white elevated structure above the disc was seen, as 
well as a common choroidal naevus (Fig. 4b). This whitish lesion was not unlike the 
retinal changes seen in Bourneville's tuberous sclerosis.23 Patient II-3 of family 1517 
had remarkable asymmetry of eye findings. His right eye only had light perception 
and showed severe bony spicules, whereas both were less severe in 
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Table 3. Visual characteristics in 3 DFNB12 patients and 5 USHld patients. 
Patient, family 
Gender 
Age (y) 
VAS(%) RE 
LE 
VFS (%) RE 
LE 
FAS (%) 
FFS (%) 
FVS (%) 
Media RE 
LE 
EOG 
ERG 
Dark 
Adaptation 
Colour Vision 
[X-2] 
male 
29 
105 
90 
100 
100 
102 
108 
100 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
DFNB12 
[X-l] 
male 
33 
105 
105 
97 
98 
105 
104 
100 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
[IX-15] 
female 
52 
100 
100 
91 
93 
100 
93 
93 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
[11-3], 1066 
male 
26 
90 
80 
51 
50 
88 
51 
45 
minor SPC 
SPC + 
Extinguished 
Extinguished 
N.A. 
Red-green 
defect 
[II-l], 1066 
female 
33 
90 
95 
44 
36 
94 
44 
41 
vitreous body 
strings 
Normal 
Extinguished 
N.A. 
N.A. 
Normal 
U S H l d 
[11-3], 1517 
male 
40 
•p 
80 
0 
43 
64 
43 
28 
SPC ++, divergent strabism 
minor SPC, some cells in 
vitreous body 
Extinguished 
Extinguished 
No lp 
Normal 
[II-2], 1071 
female 
47 
60 
60 
31 
32 
60 
32 
19 
SPC ++, 
surgery 
SPC ++, 
surgery 
N.A. 
Extinguished 
N.A. 
N.A 
[II-1],1071 
male 
51 
No lp 
Nolp 
N.A. 
N.A. 
0 
0 
0 
minor SPC 
SPC ++, 
surgery 
N.A. 
Extinguished 
N.A. 
N.A. 
VFS: Visual Field Score; VAS. Visual Acuity Score; FAS: Functional Acuity Score; FFS: Functional Field Score; FVS: Functional Vision Score; EOG: 
electro-oculogram; ERG: electroretinogram, N.A.: not available; SPC: subcapsular posterior cataract; lp: light perception; RE: right eye; LE: left eye. 
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4.A 4.B 
Figure 4. A. Fundus photograph of the right eye of DFNB12 patient X-l, around the macula, 
depigmentations with central clustering of pigment can be seen (arrows). B.Fundus photograph of 
the right eye of USHld patient II-2 of family 1071, a white elevated spot can be seen above the waxy 
disc, bone spicules and attenuated vessels are also seen. The retinal pigment epithelium has 
vanished almost completely. 
his left eye. In all USHld patients, the electroretinogram and electro-oculogram 
were extinguished and poor best-corrected visual acuity scores were found. All 
patients had tunnel vision confirmed by Goldmann perimetry and all had 
functional vision scores below 45% (< 50% indicates severe loss of vision).19 One 
patient (II:l,family 1071) had total loss of vision. In four of the 5 Usher syndrome 
patients subcapsular posterior cataracts were seen; two of them have had cataract 
extraction for this condition, whereas the other patients may need surgery in the 
future. 
DISCUSSION 
Comparison of the audiometrie features of 6 USHld and 4 DFNB12 patients, all 
identified by at least one mutation in the CDH23 gene, revealed that the USHld 
patients had significantly more HI than the DFNB12 patients. In addition, only the 
USHld patients had vestibular areflexia and progressive RP. Two DFNB12 
patients showed slightly abnormal funduscopic findings. In patient X-l, bilateral 
abnormal flecks of the RPE were seen and in patient X-2 slight wrinkling of the 
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internal limiting membrane and a decreased filter action of the RPE were noticed, 
although neither of these features caused any functional problems. The present 
findings are in line with previous observations,6-13 which noted that amino acid 
substitutions in CDH23 cause severe to profound HI with normal vestibular 
responses and retinal function (DFNB12) and that mutations that lead to CDH23 
protein truncation cause congenital profound deafness, vestibular areflexia and 
the development of RP (USHld). 
Astuto et al. reported on mutation analysis of CDH23 in a large group of patients.13 
In a selected panel of probands with Usher syndrome type I, they identified 
CDH23 mutations in 35 of 69 probands with Usher syndrome. USH1D was found 
to be caused by nonsense, frameshift, splice-site and missense mutations. In only 3 
families, 2 missense mutations were identified and these families all had an 
atypical form, with variation in the retinal phenotype, of Usher syndrome type I. 
All other missense mutations were compound heterozygous with a truncating 
mutation of the other allele. Nonsyndromic autosomal recessive HI families were 
also examined and only amino acid substitutions were observed. Results of 
ophthalmological examinations in these patients with nonsyndromic autosomal 
recessive deafness in some cases showed asymptomatic RP-like manifestations. 
Missense mutations in the CDH23 gene, therefore, may have a subtle effect on the 
retina, which was also noted in two of the present DFNB12 patients. In addition, 
Astuto et al. also describe that USHld patients display a wide range of hearing 
loss and RP phenotypes, differing in severity, age of onset, type and the presence 
or absence of vestibular areflexia.13 The findings in the present USHld patients are 
typical for Usher syndrome type I. The second mutation in CDH23 was not 
identified in families 1066 and 1071. It may be possible that the second mutation in 
these families is a splice-site mutation in an intron or is a regulatory mutation 
which so far can not be detected by heteroduplex analysis. 
Cadherin 23 is a transmembrane protein with 27 extracellular Cadherin repeats, a 
transmembrane domain and a cytoplasmic domain. It is encoded by CDH23, which 
consists of 69 exons.5'6 Cadherins are important for cell-to-cell contact and the 
organization of the extracellular matrix. Binding of calcium ions to these proteins 
is essential for linearization, rigidification and dimerization of the Cadherin 
molecules.24-25 Mutations in Cdh23 lead to disorganization of the stereocilia of the 
hair cells in the inner ear of waltzer, the mouse model for USHld.25 The missense 
mutations found in the present DFNB12 family and in other DFNB12 families 
124 
USHER SYNDROME 
reported in literature are located in the highly conserved extracellular calcium-
binding motifs. Modelling has shown that these mutations are likely to induce a 
decrease in the capacity for calcium binding.15 As calcium provides rigidity to the 
elongated structure of Cadherin molecules it is likely that mutations in these 
calcium-binding motifs lead to a disturbance of the elongated shape of Cadherin. 
Cadherin 23 has been suggested to be a candidate molecule for forming the lateral 
links or tip links between the stereocilia.25·26 A disturbed elongated shape of 
Cadherin 23 may therefore lead to disorganisation of the stereocilia because two 
mutated Cadherin 23 molecules are not able to interact directly or with an 
additional molecule to correctly establish these links.15 This report shows that the 
HI caused by mutations in CDH23 is significantly more severe in USHld than in 
DFNB12. It therefore seems likely that the truncated protein in USHld totally 
disturbs the interaction and elongated shape of the stereocilia and thus negatively 
influences the mechano-electrical transduction in cochlear hair cells, whereas the 
disturbance in function of cochlear hair cells is less severe in the DFNB12 patients 
with reported amino acid substitutions in the conserved calcium binding motifs. 
Another pathogenic mechanism is suggested by Wilson et al., who claimed that 
Cadherin 23 may in addition be involved in ion homeostasis of the endolymph in 
the inner ear, because of expression of Cdh23 in the utriculo-saccular foramen, the 
ductus reuniens and Reissner's membrane.27 
The abnormal funduscopic findings in patient X-l of the DFNB12 family are 
atypical for RP, however, they are clearly abnormal. The small flecks may have 
been caused by previous inflammation of the RPE as described by Krill and 
Deutman,28 but this could not be substantiated in this patient. Forgacs and Bozin in 
1966 described similar flecks in 2 sisters and therefore suggested a genetic 
etiology. 29 An alternative explanation of the bilateral flecks and the decreased 
filter action of the RPE in the present two brothers could be that these two findings 
relate to accumulation of lipofuscin. Lipofuscin accumulation is known to occur in 
Stargardt's disease, age-related macular dystrophy and in some forms of RP.30 The 
protein of another Usher syndrome type I gene, MY07A, has a crucial function in 
the normal processing of ingested disk membranes in the RPE, primarily in the 
basal transport of phagosomes into the cell body where they then fuse with 
lysosomes.30 When myosin Vila is absent, the halflife of the phagosomes is 
extended and it is suggested that impaired phagosome degradation may be 
responsible for the accumulation of lipofuscin in the RPE in some forms of RP.30·31 
In the cochlea, several Usher syndrome type I proteins (USHlb, USHlc, USHld 
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and USHlg) form a functional complex that shapes the sensory hair cell bundle.32-
14
 Hypothetically, these genes may also interact in the process of ingestion of outer 
segment disk membranes and phagosome degradation in the RPE. Possibly, the 
lipofuscin accumulation seen in the present two DFNB12 patients is caused by a 
disturbance of the phagosome degradation in the RPE. 
Both DFNB12 patients with abnormal retinal findings, have a homozygous 
missense mutation (D2148N) in CDH23, whereas a normal retina was seen in the 
older patient IX-15, who was compound heterozygous for two missense mutations 
(D2148N/D1341N). Possibly, the homozygous combination of the D2148N 
mutation affects the retina more than a combination of this mutation with 
D1341N. Another possibility is that this difference is caused by the different 
position of these two mutations and subsequent relationship with the EC domains. 
Also, some previously studied USHld families, characterised as atypical, showed 
absent, delayed or atypical ophthalmological features suggestive of RP.35 It may 
therefore be useful to examine the retina of patients with nonsyndromic autosomal 
recessive HI for abnormalities, indicating the possible involvement of CDH23. 
From this study we conclude that the 2 missense mutations in CDH23, found in 4 
patients of the DFNB12 family, cause nonsyndromic sensorineural HI, which is 
accompanied by clinically silent funduscopic abnormalities in 2 of the present 
patients. More elaborate, ophthalmological studies of DFNB12 patients need to be 
performed to answer the question whether there is a true relationship between the 
mutations and the encountered funduscopic abnormalities. Inactivating splice-site 
mutations in CDH23 were found in 6 patients from 3 USHld families that lead to 
significantly more severe HI than in the DFNB12 patients and, in addition, to RP 
and vestibular areflexia. 
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USHER SYNDROME 
INTRODUCTION 
The Usher syndromes are a group of autosomal recessive inherited disorders 
characterised by RP, bilateral sensorineural HI and vestibular dysfunction in some 
cases. They are the most common cause of deaf-blindness worldwide and the 
combined prevalence is estimated to range from 3.5 to 6.2 in 100,000 persons.1·2 
The Usher syndromes show clinical as well as genetic heterogeneity. They are 
divided into 3 clinical types that differ in type and degree of hearing and 
vestibular impairment. Usher syndromes type I are characterised by profound 
congenital deafness and vestibular areflexia. Usher syndromes type II show mild 
to moderate congenital HI with intact vestibular responses, whereas Usher 
syndrome type III shows remarkable progression of HI and variable vestibular 
responses. All clinical types I, II and III develop RP later in life, from the first or 
second decade onwards. Intensive genetic research in the past ten years has led to 
the identification of 11 loci (USH1A-USH1G, USH2A-USH2C and USH3) and to 
date 7 genes responsible for Usher syndrome: MYOZ4(USHlb), LJSHïC(USHlc), 
CDH23(USHld), PCDH15(USHlf), SANS (USHlg), üSH2A(USH2a) and 
iiSH3(USH3).3 
RP leads to impaired dark adaptation, progressive visual field constriction and 
reduction in visual acuity and may eventually lead to blindness. Patients with 
Usher syndrome are also susceptible to the development of posterior subcapsular 
cataract that may severely hamper vision but is amenable to surgery. 
Several studies on visual field deterioration, visual acuity and fundoscopic 
appearance on clinically classified49 or genetically linked1011 Usher syndrome type 
I and type II patients have been performed, however, none of these studies 
categorised patients on the basis of mutation analysis. Most of these studies 
focused on detecting differences in visual system signs and symptoms between 
Usher syndrome type I and type II. The present study is similar, however, it is the 
first one that presents cross-sectional analysis of visual acuity and visual field 
deterioration related to age to compare between USHlb and USH2a patients, who 
are all identified by mutation analysis of the MY07A and USH2A gene, 
respectively. In addition, individual serial measurements are presented. To 
evaluate visual impairment we used the functional acuity score (FAS), functional 
field score (FFS) and functional vision score (FVS) as defined in the 5th edition of 
the AMA Guides for the Evaluation of Permanent Impairment.12 
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PATIENTS AND METHODS 
Patients 
The study included 19 patients from 13 different families with the clinical 
diagnosis of Usher syndrome type I and 40 patients from 28 different families with 
the clinical diagnosis of Usher syndrome type II (Tables 1-2). Patients were only 
included when the visual acuity scores and/or visual fields were evaluated at 
least once. Patient selection occurred retrospectively as well as prospectively. 
Some patients only participated in DNA analysis but not in repeat clinical 
examinations; in these cases previously retrieved examination data were used. 
Nearly all patients were examined at the Department of Ophthalmology of the 
University Medical Centre St Radboud, however, a few patients did not come to 
Nijmegen and with their permission we retrieved visual acuity and Goldmann 
perimetry examination results from elsewhere. It should be emphasised that the 
only inclusion criteria used in this study were the clinical diagnosis of Usher 
syndrome type I or II, the availability of visual function assessments as well as a 
genetic diagnosis of either USHlb or USH2a. The visual function data were 
accepted without a priori criteria, provided that they were reliably measured and 
sufficiently documented. The patients enrolled in this study were never subjected 
to whatever selection on account of their visual acuity or visual field findings. 
Clinical examinations 
After written informed consent had been obtained, clinical evaluation of most of 
the affected individuals was performed. This consisted of taking a medical history 
as well as performing audiovestibular and ophthalmological examinations. The 
audiovestibular examinations were used to establish the clinical diagnosis of 
Usher syndrome type I (severe to profound hearing loss and vestibular areflexia) 
or type II (residual high-frequency HI and intact vestibular responses). 
Ophthalmological examination consisted of at least one best-corrected visual 
acuity measurement or one Goldmann perimetry examination. The patients who 
were examined at the Ophthalmology Department of the UMC St Radboud in 
addition as a standard underwent external eye examination, slit-lamp microscopy, 
funduscopy, electro-oculography and electroretinography. The results of these 
examinations confirmed the diagnosis of RP in all affected individuals and part of 
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the examination results have been described previously w 1 1 The development of 
posterior subcapsular cataract or lens opacifications may negatively influence 
visual acuity in Usher syndrome patients Therefore, the FAS was evaluated for 
USHlb and USH2a patients with cataract or lens opacifactions and for those 
without It was also checked which of them underwent cataract extraction during 
or outside the observation period 
Molecular genetics 
Blood samples were collected from the patients for linkage and mutation analysis 
All type I patients were diagnosed to have USHlb and all type II patients were 
diagnosed to have USH2a on the basis of a pathogenic mutation of at least one 
allele within the MY07A and USH2A gene, respectively Ten different MY07A 
mutations were found m our group of USHlb patients, whereas 7 different 
USH2A mutations were identified in the USH2a patients group The distribution 
and combinations of these mutations within the families are shown in Tables 1 
and 2 To determine a possible deleterious effect of truncating mutations when 
compared to amino acid residue substitutions, the mutations were classified as 
"inactivating" (+) or "non-inactivating" (-), respectively Given a general lack of 
sufficient numbers of patients with exactly the same mutation combinations, score 
behaviour was also compared between different classes of mutation combinations, 
indicated as +/+, +/-, -/-, + / ? and -/7 
Evaluation of visual acuity and visual field deterioration 
Visual acuity was measured according to common standards by using Snellen 
charts Best-corrected measurements of both eyes were used for further 
evaluation The visual acuity measurement for each eye was converted into a 
visual acuity score (VAS) according to Weber-Fechner's law The functional acuity 
score (FAS) was determined by the equation FAS = (3 χ VASboth eves + VASicft c\c + 
VASnghteye)/512 
Visual fields were evaluated by Goldmann perimetry of both eyes and in most 
cases the isopters for the V-4, III-4 and 1-4 test targets were measured The 
Goldmann perimetric fields were quantified by plotting the III-4 isopter according 
to the description of the American Medical Association in their 5 t h edition of the 
Guides for the Evaluation of Permanent Impairment n The visual field score (VFS) 
for each eye separately and both eyes combined, was obtained by drawing 10 
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meridians in the visual field examination form; 2 in each upper quadrant (25°, 65°, 
115° and 155°) and three in each lower quadrant (195°, 225°, 255°, 285°, 315°, 345°). 
These VFSs were converted to a functional field score (FFS) using a similar 
equation as for the conversion of the VAS. Finally, the functional vision score 
(FVS) was determined by the FAS and the FFS based on the equation FVS = (FFS χ 
FASyiOO.12 
Table 1 Genotype of 19 USHlb patients examined (families Α-M), with one mutation detected, 
monoallehc (?, second mutation unknown), or with two mutations detected (homozygous, compound 
heterozygous) and classification of mutation combination in terms of inactivating versus non-
mactivating mutation Outlier pertains to cross-sectional analysis (Fig 1) 
Patient 
Al 
A2 
A3 
B4 
C5 
D6 
D7 
E8 
E9 
FIO 
G i l 
H12 
H13 
114 
J15 
K16 
L17 
L18 
M19 
Mutat ions 
R1240Q/R212C 
R1240Q/R212C 
R1240Q/R212C 
ΕΠ70Κ/' 
R1240CyR1240Q 
R1743W/R1743W 
R1743W/R1743W 
Κ212ΐνΗ212Η 
R212H/R212H 
E1170K/R1240Q 
E1170K/E1170K 
E1170K/R212H 
E1170K/R212H 
RUWQf 
L1840fs/Q1798X 
RUIOWP 
Q1798X/D120fs 
Q1798X/D120fs 
R666X/7 
Type a 
7-
-/-
-/-
-/' 
-/-
-/-
-/-
7-
7-
-/-
-/-
-/-
-/-
-/' 
+/+ 
-/' 
+/+ 
+Λ 
+ / 7 
η 
2 
1* 
2 
Cataract 
C+ 
C-" 
c-
c-
c-
c-
c-
c-
c-
c-
c + 
c-
c-
c + 
c-
c + 
c-
c ? 
c-
C o m m e n t 
Belgian 
(outlier low FFS) 
", + inactivating, - non-mactivating, 7 unknown mutation, b. Previous cataract extraction at ages 34 
and 36 years, *, hmitid field evaluation did not enable calculation of functional scores, C+, cataract, 
C-, no cataract, C 7 , unknown cataract, n, number of longitudinal measurements 
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Table 2 Genotype of 40 USH2a patients examined (families A-AB), with one mutation detected, 
monoallelic (7, second mutation unknown), or with two mutations detected (homozygous, or 
compound heterozygous mutations) and classification of mutation combmahon in terms of 
inactivating versus non-inactivating mutation Outliers pertain to cross-sectional analysis (Fig 1) 
The longitudinal data of patients commented on are marked in Fig 3 by bold connection lines 
Patient 
Al 
A2 
B3 
C4 
C5 
D6 
D7 
E8 
F9 
G10 
H l l 
H12 
113 
J14 
J15 
J16 
J17 
J18 
J19 
K20 
L21 
M22 
N23 
024 
025 
P26 
Q27 
R28 
R29 
S30 
T31 
U32 
U33 
V34 
W35 
X36 
Y37 
Z38 
AA39 
AB40 
Mutahons 
C419F/? 
C429F/? 
E767fs/C536R 
E767fs/R317R 
E767fs/R317R 
C429F/' 
C419F/? 
£767>? 
£767>' 
C419F/? 
W409X/W409X 
W409tyW409X 
E767fs/E767fs 
C419F/' 
C419F/C536R 
C419F/? 
E767fs/C536R 
C419F/C536R 
E767fi/? 
C419F/C419F 
E767fs/C419F 
C419F/? 
E767fs/E767(s 
E767fs/E767fs 
E767fs/E767fs 
ElèlfsP 
E767fsP 
C419F/W409X 
C419F/W409X 
E767/S/' 
E767^/ ' 
E767fs/E767fs 
E767fs/E767fs 
R317W 
R317R/? 
C419F/C536R 
Q748X/Q1468X 
C536R/' 
C536JV7 
E767fi/? 
Type-
-P 
-n +/-
+ / + 
+ / + 
-n 
-n + / 7 
+ / ' 
-n + / + 
+/+ 
+/+ 
-n 
-/-
-n 
*/-
-/-
ν 
-/-
V-
V7 
+/+ 
+/+ 
+ / + 
+ / 7 
+ / 7 
-/+ 
-/+ 
V7 
+ / 7 
+ / + 
+ / + 
+ / 7 
V7 
-/-
+Λ 
-/7 
V7 
+ / 7 
η 
2* 
3 
7 
5 
1 
3 
1 
5 
4 
3 
10 
1 
1 
3 
3 
1 
2 
2 
2 
1 
1 
1 
2 
1 
1 
1 
2 
4 
4 
1 
1 
1 
1 
7 
4 
2 
2 
4 
3 
1 
Cataract 
c ? 
C+ 
C+ 
C+ 
C ' 
C+ 
C-
C+ 
C+ 
C-
C-
c-
c+ 
c+ 
c-
c+ 
c+ 
c-
c-
c+ 
c+ 
c+ 
c+ 
c+ 
c+ 
C ' 
c+ 
c-
c-
c-
c-
c 
c 
c+ 
c-
c-
c-
c-
c+ 
c+ 
Comment 
Late onset (age > 40 y) of VA loss 
and possibly also of field impairment 
Poor VA relative to age and late onset (age > 
25 y) of field loss 
These 2 sibs establish a significant cluster 
characterised by relatively poor FFS and FVS 
(outlier low FAS) 
(outlier high FFS) 
Late onset (age > 40 y) of VA loss 
a
, + inactivating, - non-inactivating, 
calculation of functional scores, C+, 
longitudinal measurements, y, years 
7
 unknown mutation, *, limited field evaluation did not enable 
cataract, C-, no cataract, C 7, unknown cataract, n, number of 
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In some patients whose previous examination results had been retrieved but could 
not be updated, the data did not include both visual acuity and visual field 
measurements obtained on the same day and either of these measurements was 
lacking in some patients. When similar, consecutive measurements were available, 
the last-visit measurement was elected for cross-sectional analysis. The present 
analyses only covered the functional scores FAS, FFS and FVS defined for both 
eyes. 
Statistical analysis 
Cross-sectional data were analysed using linear regression analysis. The data 
included single-snapshot measurements and the last-visit measurements in the 
cases with longitudinal observations. Significant deterioration was concluded to 
exist if the 95% confidence interval (CI) for the slope of the regression line did not 
include zero. Individual linear regression lines pertaining to (part of) the available 
longitudinal data were derived in some suitable cases to obtain an estimate of 
(local average maximum) individual longitudinal deterioration rates and compare 
the results to those obtained in the cross-sectional analysis. Where appropriate, a 
person's individual regression line was compared to the corresponding cross-
sectional regression line that had been recalculated with exclusion of that person's 
last-visit measurement in order to avoid sharing of the latter data point. A method 
similar to analysis of covariance (ANCOVA) was used for comparing across 
regression lines to find out whether or not the lines were significantly different in 
slope and/or elevation, i.e. the ordinate of the grand mean for a cluster of plotted 
data points. The program first tested between slopes and then between elevations 
only if the slopes were not significantly different. Pooling of slopes and Y 
intercepts across different subgroups of patients (specified in Results) was 
performed where possible. Separate comparisons between slopes were performed 
using one-way analysis of variance (ANOVA) and/or Student's t test; this test 
included Welch's correction if Bartlett's test detected unequal variances. In the 
cross-sectional analysis, outliers (indicated in Tables 1 and 2 and Fig. 1 below) 
were identified by using the 95% prediction contours for the regression lines that 
were calculated initially for all available measurements. A commercial program 
was used for the statistical analyses and plots (Prism 3, GraphPad, San Diego, CA, 
USA). The level of significance used in all tests was Ρ = 0.05. 
136 
USHER SYNDROME 
RESULTS 
Methodological considerations 
During the analyses, two potential methodological problems were encountered. 
First, there was an obvious difference in age distribution between the USHlb and 
USH2a patients involved in the cross-sectional analysis, which covered only the 
last-visit and single-snapshot measurements (Fig. 1). Both patient groups showed 
a pseudonormal distribution for age with mean ages of approximately 27 and 36 
years for USHlb and USH2a, respectively. This difference was significant 
(Student's t test). For this reason, we repeated the relevant tests aimed at detecting 
possible differences in age-dependent cross-sectional scores while matching for 
age. A window (17-47 years) covering an overlapping range of ages was used that 
included the youngest USH2a patient (aged 19) and the oldest USHlb patient 
(aged 45, Fig. 1 below). The second potential problem was the possible influence of 
cataract development on visual acuity scores. Examinations showed that 4 of the 
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Figure 1. Cross-sectional analysis (last-visit and single-snapshot measurements) in USHlb (filled 
circles) and USH2a patients (open circles) illustrated in separate plots of the functional scores FAS, 
FFS and FVS (%) against age (years) The linear regression lines are included in each panel (solid, 
USHlb; dashed, USH2a). Small symbols, outliers (specified in Tables 1-2) excluded from linear 
regression analysis. The vertical hairlines mark the wmdow (17-47 years) covering an overlapping 
age range that was used for matching by age. 
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18 evaluated USHlb patients and 20 of the 35 evaluated USH2a patients had to 
some extent developed cataract. However, the difference in prevalence of cataracts 
between these two patient groups can be explained by the associated age 
distribution in both patient groups, i.e. the USH2a patients were significantly 
older. Below, the FAS is compared between patients with and without pre-existent 
cataracts within each patient group. 
Cross-sectional analysis 
Fig. 1 shows the data points used for the cross-sectional analyses in USHlb and 
USH2a patients, as well as the regression line calculated for each group. 
Significant deterioration with advancing age was found in all three types of 
functional scores in either group of patients. There was no significant difference 
between the regression lines pertaining to USHlb or USH2a in each of the three 
types of scores. The pooled values for slope were -0.7%, -1.0% and -1.5% per year 
in either patient group for the FAS, FFS and FVS, respectively. Slopes could be 
pooled across the 3 types of score and the 2 patient groups and was -1.0% per year. 
The results of all the tests comparing score behaviour between the patient groups 
were essentially similar after matching for age (Fig. 1, vertical hairlines). 
50 
Age(y) 
Figure 2. Individual longitudinal analyses (connected symbols) in USHlb patients The (solid) 
linear regression line established in the cross-sectional analysis for USHlb was copied from 
Fig. 1. 
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Cross-sectional analysis and cataract 
No significant difference in the FAS between (USHlb or USH2a) patients with 
cataracts and without cataracts appeared when comparing the corresponding 
regression lines. However, it was noted that USH2a patients with cataracts scored 
slightly worse than those without (data not shown). 
Longitudinal data 
Longitudinal data are shown in Fig. 2 (USHlb) and in Fig. 3 (USH2a). The 
individual longitudinal regression lines (not included in Figs 2-3 for reasons of 
clarity) were compared to the corresponding overall cross-sectional regression line 
(Fig. 2, solid line; Fig. 3, dashed line). This procedure involved only one or two 
USHlb patients , which did not produce a significant difference between the 
individual regression line and the corresponding cross-sectional regression line 
pertaining to all the other USHlb patients. 
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Figure 3 Individual longitudinal analyses (connected symbols) in USH2a patients The (dashed) 
regression line established in the cross-sectional analysis for USH2a was copied from Fig 1 Bold 
connection lines highlight the patients whose score behaviour deviated substantially/significantly 
from the trend shown by the cross-sectional regression line (Table 2). 
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All of the regression lines calculated for the FFS for the separate USH2a patients 
(data not shown) had a steeper slope (median -2.4%/year) than the cross-sectional 
regression line (Fig. 3, slope -0.9%/year). The finding of steeper slopes was 
significant: supposing that the chance of showing a steeper slope than the cross-
sectional regression line is ρ = 0.5, the probability of finding 7 out of 7 slopes 
having higher values can be estimated to be 0.008 in the appropriate binomial 
distribution. Similar observations indicating a discrepancy between the results of 
the longitudinal and the cross-sectional analyses could be made regarding the 
plots of the FAS or the FVS against age in USH2a (Fig. 3). Some of the longitudinal 
data suggested nonlinear development of the functional vision scores with 
advancing age. In these cases, we estimated an individual "maximum 
deterioration rate" by visually inspecting the plots and fitting a slope tangent to 
the part with the steepest descent. The highest estimates based on more than 2 
consecutive measurements per patient of the individual maximum deterioration 
rate for the FAS, i.e. about 5%/year, were found in 2-3 patients (including patient 
V34) at age 35-50 years (Fig. 3). The last 2 measurements for patient F9 indicated a 
rate as high as about 20%/year. Maximum individual deterioration rates for the 
FFS and FVS were about 3-4%/year and 4-5%/year, respectively, in some patients, 
including R28 and R29 (Fig. 3). 
Score behaviour and cataract 
Longitudinal acuity scores (FAS) could be compared relative to age between 5 
USH2a patients with and 4 without pre-existent cataracts. Focusing on linear 
regression analysis of relevant parts of these data, no significant difference 
between corresponding regression lines was found (data not shown). 
Score behaviour and genotype 
Separate cross-sectional analyses and longitudinal analyses (data not shown) were 
performed covering the separate classes of biallelic mutation combinations + / + , 
+/-, -/-, -/? and +/?, as shown for the individual patients in Tables 1 and 2. The 
analyses were repeated with exclusion of the mutation combinations -/? and +/?. 
There were no significant differences found between regression lines pertaining to 
any of the different classes of mutation combinations within the USHlb or the 
USH2a group. As regards separate biallelic mutation combinations, it can be noted 
that 2 sibs with USH2a (R28 and R29) having the C419F/W409X combination 
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established a significant cluster (Fisher's exact probability test) characterised by 
relatively poor values of the FFS and FVS (Fig. 3 and Table 2). 
DISCUSSION 
Development of visual impairment with advancing age in Usher type I and Π 
PRESENT STUDY 
The present cross-sectional analysis (Fig. 1) revealed significant deterioration of 
the FAS, FFS and FVS with advancing age without any significant difference in 
score behaviour between the USHlb and USH2a patients, no matter whether or 
not the window of overlapping ages (17-47 years) was applied. Apart from that, 
inspection of the available longitudinal data bearing on individual USH2a patients 
disclosed that some of these patients showed a far higher rate of deterioration than 
was indicated by the present cross-sectional analysis (Fig. 3). Apparent nonlinear 
score deterioration made it more appropriate to use (local) "maximal deterioration 
rates" rather than average rates for some of our USH2a patients. Part of the 
apparent discrepancy in the results of cross-sectional and longitudinal analyses 
may have been due to bias of ascertainment: patients experiencing the most severe 
deterioration are those most likely to undergo repeat examinations. However, 
even if all the patients who happened to be followed up would have had very 
similar deterioration rates, it is conceivable that substantial across-subjects 
differences in the age of onset of deterioration would have attenuated the 
deterioration rate calculated in the cross-sectional analysis, which, apart from 
single-snapshot measurements, only included last-visit measurements. 
PREVIOUS STUDIES 
Several previous studies analysed visual acuity and visual field deterioration in 
Usher syndrome type I and Usher type II patients.4 9 However, all of these studies 
only included patients that were classified on the basis of clinical findings and 
none was based on the results of linkage or mutation analysis. Most of these 
previous studies showed significantly more favourable visual acuity and visual 
field measurements in Usher syndrome type II patients than in Usher syndrome 
type I patients.4-5-7 Unfortunately, none of these studies comprised appropriate 
longitudinal analyses. In a study by Seeliger et al.8 Usher syndrome type II 
patients seemed slightly less affected than type I patients, however, without any 
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significant difference. Tsilou et al.9 also found no significant difference in visual 
acuity and visual field measurements related to age between type I and type II 
Usher syndrome patients. Some previous studies have shown a significantly 
earlier presentation of night blindness in Usher type I and a significantly earlier 
diagnosis of RP in Usher type I than in Usher type II.4-9 However, it also seems 
possible that such findings relate to the fact that USHlb patients, because of their 
profound deafness combined with vestibular areflexia, depend more on their 
vision for spatial orientation than do USH2a patients. 
Methodological considerations 
Cross-sectional studies based only on clinically classified patients may produce 
misleading results for at least two important reasons. First, the existence of major 
genetic heterogeneity, i.e. a mixture of patients with mutations in different genes, 
cannot be ruled out. Second, cross-sectional data may not reflect the true course of 
impairment with advancing age, especially if there are substantial across-subjects 
differences in the age of onset of visual impairment and/or if deterioration 
proceeds in nonlinear fashion. For both these possibilities we found some 
indications in the present USH2a patients (Fig. 3). We were unable to uncover 
substantial, significant differences between our patient groups, i.e. USHlb versus 
USH2a, possibly because of a lack of sufficient suitable data. Provided that 
sufficient numbers of fully genotyped patients are included, future studies, 
preferably covering appropriate longitudinal analyses, may demonstrate such 
differences to exist. 
Cataract 
It is known that about 50% of Usher syndrome patients will develop posterior 
subcapsular cataract in the course of their life.13 Some of them may undergo 
cataract extraction to improve visual acuity but, unfortunately, in some others this 
is no longer effective. No unusual prevalence of intraoperative or postoperative 
complications has been noted to occur in patients with RP or Usher syndrome.14 In 
the present study we found significantly less USHlb patients with cataract than 
USH2a patients, however, it should be kept in mind that the group of USH2a 
patients had a significantly higher age at their last-visit measurements than the 
USHlb patients and that the prevalence of cataracts increases with age. 
Controlling for age by using regression methods, we could not find any significant 
difference in FVS behaviour between patients with or without cataract in either 
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USHlb or USH2a. However, there was an indication of poorer scores in USH2a 
patients being associated with cataracts. Studies of larger numbers of genotyped 
patients are probably needed to settle this issue. 
Foveal lesions 
A study by Fishman et al.6 showed that foveal lesions were more prevalent in 
Usher syndrome type I than in type II. These authors took standard fundus 
photographs of their patients, which was not done on a regular basis in ours. 
Perhaps it can be stated that if our Usher syndrome type I patients had similar 
atrophic- or cystic-appearing foveal lesions as the type I patients described in that 
study they would have had clearly poorer visual acuity scores than our type II 
patients, which did not appear to be the case. However, not only the methods of 
examination differ between the studies, but also the patient selections. A major 
problem is that we do not know whether or not the Usher type I and II patients 
described by Fishman et al.6 show linkage to the same respective loci as ours. 
Method to evaluate visual impairment in retinitis pigmentosa 
In literature, several ways of analysing visual field size and visual acuity in 
patients with RP have been used. In the present study, we followed the 5th edition 
of the Guides to the Evaluation of Permanent Impairment, described by the 
American Medical Association.12 To analyse visual field loss, the Esterman grid, or 
paper and pencil method as described in the Methods section, can be used and 
both methods lead to similar scores of visual field loss. The advantage of using 
such methods is that both the decrease in visual field size and visual acuity in a 
given patient can be integrated into a score of visual impairment, i.e. the FVS (%). 
The latter score divides the patients into certain classes of impairment, with their 
related abilities in performing daily living tasks. Patients with a FVS of < 50% may 
no longer sufficiently benefit from vision enhancement techniques, such as large 
print, better illumination and better contrast, but may need to shift to vision 
substitution techniques comprising talking books and Braille.12 In the present 
study the USHlb and USH2a patients had FVSs below 50% from about 30 to 40 
years of age (Figs 1-3) and should be informed about such possibilities. 
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Genotype-phenotype correlation 
Specific combinations of biallelic mutations found in our patients generally did 
not allow for appropriate statistical testing between the associated score 
behaviours because of a lack of sufficient numbers of observations. A possible 
exception was the finding of relatively poor FFS and FVS in 2 sibs with USH2a 
(R28 and R29, Fig. 3) with the mutation combination C419F/W409X (Table 2). 
Although, in principle, the functional vision scores of these sibs represent 
stochastically independent measurements, one cannot exclude the possibility that 
the similarity in their apparently deviant score behaviour related to the inherent 
high degree of genotypic similarity. Similar suprafamilial functional vision score 
findings in patients with the C419F/W409X mutation combination are therefore 
needed to establish conclusive evidence. Apart from considering specific mutation 
combinations, the patients were also classified by genotype according to specific 
types of biallelic combinations in order to increase the number of observations per 
separate category. Combinations of inactivating and non-inactivating mutations 
were being considered, because studies in other disorders have shown that 
inactivating mutations sometimes cause a more severe phenotype in autosomal 
recessively inherited disorders.15 We failed to detect any significant difference in 
functional vision score development with advancing age between the different 
classes of genotypes causing USHlb or USH2a. Again, this may have been due to 
the relatively low numbers of patients studied. It seems worthwhile to extend the 
present study, undertake similar studies at other centres, or perhaps embark on a 
multi-centre study. This is especially so because molecular genetic knowledge and 
technology are developing rapidly and complete genotyping of Usher syndrome 
patients is coming within reach. The patients and their families are also becoming 
increasingly aware of the new possibilities and opportunities and are developing a 
growing interest in findings bearing on an individualised prognosis. Detailed 
clinical studies of phenotype in relation to detailed knowledge of the underlying 
genotype are necessary to satisfy their and our curiosity. 
Conclusions 
The findings of this study and previous studies seem to be of at least some general 
value for the counselling and rehabilitation of patients with Usher syndrome and 
their families. Finetuning of the analyses seems possible in the long run on the 
basis of the results to be obtained from more elaborate longitudinal studies of 
phenotype features in fully genotyped patients. 
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USHER SYNDROME 
INTRODUCTION 
In 1858 Albrecht von Graefe was the first to describe the combination of bilateral 
sensorineural HI and tapetoretinal degeneration.1 This combination was later 
named after Charles Usher, an ophthalmologist who described several families 
with hereditary retinal pigment disorders and HI in the Bowman lecture of 1935.2 
Julia Bell was the first to emphasise differences in HI between affected 
individuals.3 Davenport and Omenn introduced a clinical classification for the 
Usher syndrome in 1977.4 After several modifications, three different types of 
Usher syndrome are characterised on the basis of their audiovestibular phenotype. 
Usher syndrome type I shows severe to profound congenital HI and vestibular 
areflexia. Usher syndrome type II shows congenital HI that is mild to moderate 
with intact vestibular responses. Type III of the Usher syndrome is mainly seen in 
Finland and has progressive hearing loss without precisely defined vestibular 
responses. Typically, the essential difference in symptoms between Usher 
syndrome type I and II can be characterised by stating that type I patients assess 
themselves as deaf individuals becoming blind, whereas type II individuals regard 
themselves as blind persons with a hearing problem.5 
Classification is now mainly based on genetic subtyping. To date, eleven different 
loci and six different genes, of which three (CDH23, PCDHIB and USH3) only 
recently were described, are known to cause the Usher syndromes (Table I). In 
1990 the first locus for Usher syndrome type II was mapped to chromosome lq6, 
which was followed eight years later by the detection of the gene (L7SH2A) 
responsible for Usher syndrome type IIa.7 
The first detailed reports on pure tone threshold, speech recognition score and 
vestibular analysis data in Usher syndrome type II patients without knowledge of 
the correlated genotype was given by Myers et al.8 and Kumar et al.9. Previous 
reports by our group described part of the present patients to evaluate progression 
of HI in longitudinal10 and cross-sectional11 analyses. However, this was done 
without the present genotype identification based on more elaborate mutation 
analysis. 
The present report describes features of HI in Dutch Usher syndrome patients 
with one or two mutations in the USH2A gene. Cross-sectional analysis was 
performed on raw (uncorrected) and presbyacusis-corrected pure tone audiometry 
data, as well as on speech recognition scores. 
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Table 1 Genetic subtypes of Usher syndrome and their chromosomal localization, gene and 
important reference(s) 
Usher subtype 
Usher la 
Usher lb 
Usher Ic 
Usher Id 
Usher le 
Usher If 
Usher Ig 
Usher Ha 
Usher lib 
Usher He 
Usher III 
Chromosome 
14q32 
l l q l 3 5 
l l p l S l 
10q21-q22 
21q 
10q21 1 
17q24-q25 
lq41 
3p23-24 2 
5ql4 3-213 
3q21-25 
Gene 
USHER TYPE I 
-
ΜΎ07Α 
USH1C 
CDH23 
-
PCDHÎ5 
USHER TYPE II 
USH2A 
-
USHER TYPE III 
USH3 
Reference - year 
Kaplan et al * -1992 
Weil et al3 0-1995 
Verpy et al 11/ 
Bitner-Glindzicz et al12 - 2000 
Bork et al21, Bolz et al " - 2001 
Chaib et al ^ -1997 
Ahmed et al " , Alagramam et al ^ -
2001 
Mustapha et al v - 2002 
E u d y e t a l 7 - 1 9 9 8 
Hmam et al ^ -1999 
Pieke-Dahl et al ^ - 2000 
Joensuu et al *' - 2001 
PATIENTS AND METHODS 
In this study, audiometrie data of 36 Usher syndrome patients with one or two 
mutations in the USH2A gene were examined. These patients, 17 men and 19 
women, had a mean age of 38 years (range 14-57 year). Eleven Dutch families only 
had one affected individual. Ten other Dutch families had more than one person 
affected with Usher syndrome. All were diagnosed to have Usher Ha on the basis 
of a pathogenic mutation of at least one allele within the ÌÌSH2A gene. Three 
different mutations (E767FS, C419F and W409X) were found to be responsible for 
Usher syndrome in these 36 patients. In 21 patients the USH2A gene was mutated 
in only one allele (group A). Of these 21 patients, there are 14 affected sibs from 6 
families and 7 isolates. Allele segregation around the USH2A locus confirms our 
presumed USH2a diagnosis in aforementioned sibships. In 15 patients, 
homozygous or compound heterozygous mutations were identified (group B). 
After informed consent, clinical examination of affected individuals was 
performed consisting of medical history taking, audiovestibular and 
ophthalmological examinations. Vestibular testing was performed as previously 
described by Marres et al.12 Ophthalmological examination included external eye 
examination, corrected visual acuity measurements, Goldmann perimetry, slit-
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lamp microscopy, ophthalmoscopy, electro-oculography and electroretinography. 
The results of the ophthalmological examinations confirmed the presence of 
tapetoretinal degeneration and some were described previously.13 All patients 
were clinically diagnosed to have Usher syndrome type II on the basis of their 
vestibular responses. 
The audiometrie profile of these patients was evaluated at various ages. Pure tone 
(air and bone conduction) thresholds for the different sound frequencies (0.25 - 8 
kHz) and speech recognition scores were assessed according to ISO norms.1415 
Bone conduction levels were evaluated only to exclude conductive hearing loss. 
Statistical analyses were performed on the total group of patients as well as the 
subgroups A and B. 
Last-visit pure tone audiometry threshold data (binaural mean of air conduction) 
were used for cross-sectional linear regression analysis (threshold on age) using 
Prism 3.02 software (GraphPad, San Diego, CA, USA). Progression was designated 
significant when a significant positive slope (P < 0.025) was determined. A 
significantly high prevalence of this finding among the frequencies tested (p<0.05 
in the corresponding binomial distribution) was considered to be conclusive 
evidence of progression. Individual threshold data were corrected for 
presbyacusis by subtracting the (sex- and age-related) median (P50) presbyacusis 
threshold as indicated by the ISO 7029 norm.16 Progression of threshold data 
beyond presbyacusis was evaluated in a similar way. ARTA were derived on the 
basis of the results of the cross-sectional regression analysis of the raw 
(uncorrected) threshold data. 
Individual (mean of monaural) maximum phoneme recognition scores (%Correct) 
from last-visit performance-intensity plots were submitted to cross-sectional 
regression analysis in 30 patients. A similar analysis was also applied to 
performance-impairment data (maximum phoneme score plotted against average 
pure tone thresholds at 1, 2 and 4 kHz (PTAi4 kHz)), as well as for performance-age 
data (maximum phoneme score plotted against age). The 90%Correct score (X90) 
was called onset age with age as the X coordinate and onset level with PTAn RH^  
being the X coordinate. The slope in the performance-age plot was called 
deterioration rate and the slope in the performance-intensity plot was called 
deterioration gradient. Nonlinear regression analysis was applied using the 
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alternative equation for the regression line, Y = slope(X-X9o) + 90, to obtain the 
95% confidence interval (95% CI) for X90. 
To compare slopes and intercepts across the different sound frequencies, as well as 
between subgroups A and B, analysis of covariance (ANCOVA) was used. 
Intercepts and slopes were pooled, where this appeared to be permitted. 
RESULTS 
All 36 patients generally showed a down-sloping pure tone audiogram. The cross-
sectional analysis of the pure tone threshold data of all patients (circles) is 
illustrated by Figure 1. Significant progression of HI (bold regression lines) was 
detected. Comparison between slopes (ANCOVA) did not detect a significant 
difference (F=0.65, DFn=5, DFd=402, P=0.66). The pooled slope or Annual 
Threshold Deterioration (ATD) was 0.5 dB/year. Intercepts were significantly 
different (ANCOVA, F=102.6, DFn=5, DFd=407, P<0.0001). After correction for 
presbyacusis (asterisks), HI only showed significant progression at 0.25-0.5 kHz 
(dotted and bold dashed lines). The ATD for presbyacusis-corrected data could 
not be pooled across frequencies (F=2.82, DFn=5, DFd=402, P=0.016); it decreased 
gradually from 0.6 dB/year at 0.25 kHz to virtually zero at 4-8 kHz (there was no 
point in comparing the intercepts for this reason). 
Group A (heterozygous USH2A mutations) and group Β (homozygous or 
compound heterozygous USH2A mutations) showed no significant difference in 
threshold related to age (separate group data not shown). There was no 
substantial difference in threshold related to age detected between patients with 
different mutations or combinations of mutations (separate data not shown). 
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Figure 1 Cross-sectional analysis of binaural mean air conduction threshold (dB HL, circles) in 
36 Dutch USH2a patients Regression lines are included and bold when significant progression 
was detected. Dotted and dashed lines represent presbyacusis-corrected data (asterisks). 
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.25 .5 1 2 4 8 kHz 
Frequency 
Figure 2 Age Related Typical Audiograms (ARTA) Age is given in italics 
ARTA for the patient group as a whole are shown in Figure 2. The pooled 
audiogram slope was about -9 dB per octave. 
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Figure 3 Cross-sectional analysis of mean monaural phoneme recognition score (%Correct at 
maximum performance) related to age (year) and PTAi-i kHz (dB HL) for 30 Usher Ha patients. 
Linear regression lines (bold continuous lines) are depicted Dotted lines and bold figures 
relate to the 90%Correct score (X90). 
Figure 3 shows the plots for speech performance in relation to age and the level of 
HI. The performance-age plot (left panel) shows an onset age of 38 year (95% CI: 
29-46 year) and a deterioration rate of 0.4 %/year (95% CI: 0.1-0.7 %/year). The 
performance-impairment plot (right panel) shows an onset level of 69 dB HL (95% 
CI: 64-74 dB HL) and a deterioration gradient of 0.6 %/dB HL (95% CI: 0.4-0.8 
%/dB HL. There was no significant difference in speech recognition score 
behavior between the subgroups A and Β (data not shown). 
DISCUSSION 
All patients, diagnosed with USH2a based on one or two mutations in USH2A, 
showed HI with a downsloping audiogram configuration with a mean threshold 
slope of -9 dB per octave that was mildly progressive by about 0.5 dB per year. 
After correction for mean presbyacusis, significant progression only persisted at 
0.25-0.5 kHz. No tangible difference was found in threshold related to age 
between group A (single mutation in ÌÌSH2A) and group Β (homozygous or 
compound heterozygous mutations in USH2A). Speech recognition scores for 
these patients were virtually normal up until the fourth decade of life and 
continued to be relatively good at a more advanced age in the face of the level of 
impairment developed. 
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In a longitudinal regression analysis performed on pure tone audiograms of 23 
USH2a patients diagnosed on the basis of linkage analysis, van Aarem et al.10 
found cases with stable as well as progressive hearing loss. Wagenaar et al.11 
performed cross-sectional regression analysis of pure tone audiograms of 27 
USH2a patients. Eleven of these patients were found to have the relatively 
frequent 2299delG (formerly designated 2314delG) USH2A mutation, the 
remaining sixteen had been linked to the USH2A locus. They found progressive 
HI of 0.7 dB/year on average for 0.25-4 kHz that could not be explained by 
presbyacusis alone. They also concluded that USH2a could be distinguished from 
USHlb at age < 40 year by the thresholds at the low frequencies (0.25-1 kHz) (11). 
The present study focused on families who are known to have a pathogenic 
mutation in at least one allele of the USH2A gene. Up to now, in some of the 
families included in our previous studies10·11, no mutations in LÌSH2A were found, 
despite positive LOD scores. A search for the common 2299delG mutation was 
first conducted on our Usher syndrome type II patients. The entire USH2A gene in 
patients without this specific mutation was sequenced to detect other possible 
pathogenic mutations. 
The most common mutation in USH2A is the 2299delG (E767FS) mutation. 
Recently, a common origin of this widespread geographic mutation was suggested 
by Dreyer et al.17 Usherin (USH2A) is known to code for several domains. It 
contains one laminin type VI domain, ten laminin-like epidermal growth factor 
(EGF) domains and four fibronectin type III domains.18 W409X is a nonsense 
mutation and C419F a missense mutation located in the laminin type VI domain. 
E767FS is a nonsense mutation found in the laminin-like EGF domain. The exact 
function and role of usherin in the cochlea and retina is still unknown. In the 
present study we could not detect any difference in hearing features between 
patients carrying either of the three detected mutations. This may be due to the 
limited number of cases in this study. It is also possible that an appropriate 
longitudinal study uncovers tangible differences in progression between different 
patients, as apparently was the case in a previous study10, that go undetected in a 
cross-sectional study. Of the three patients who showed significant progression in 
that study, only one [patient F l l in ref. 10] was included in the present study; a 
homozygous W409X mutation was found in this patient. 
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Some of the genes responsible for the Usher syndromes also harbour mutations 
that cause recessive or dominant forms of sensorineural HI. MY07A, the gene 
responsible for USHlb, also harbours mutations that cause DFNA11 and 
DFNB2.19'20 Mutations in CDH23 (USHld) are also responsible for DFNB12.21 At 
this moment no recessive or dominant forms of nonsyndromic HI have been 
ascribed to USH2A, however, a missense mutation (Cys759Phe) seems to cause a 
recessive form of RP without hearing loss, as described by Rivolta et al.22 These 
examples show that syndromic and non-syndromic forms of HI and pigmentary 
retinopathy may be caused by different mutations in one gene. 
Detailed pure tone threshold and speech recognition score data have been 
previously reported by others in Usher type II patients without knowledge of the 
genotype.8-9 We performed linear regression analysis of these data using the 
present methods and found results that were fairly similar to those obtained in our 
USH2a patients as depicted in Figure 1 (previously published data not included). 
However, one possible difference with the present results was that the Usher type 
II threshold data8-9 did not show any significant progression, except for the 8 kHz 
frequency. This may have been caused by the generally larger amount of scatter 
that appeared to be present in their Usher type II threshold data8-9, which may or 
may not have been related to (unknown) heterogeneity in genotype in the 
previously established Usher type II group. 
Table 2 Results of cross-sectional analysis of speech recognition scores related to age or level of 
hearing impairment for the present group of USH2a patients and previously described groups of 
patients having DFNA223, DFNA52 4 or DFNA91 1 
SPEECH RECOGNITION SCORES RELATED TO 
Age (year) ΡΤΑ,-ωι,(αΒ HL) 
Onset age Deterioration rate Onset level (dB Deterioration gradient 
(year) (%/year) HL) (%/dB HL) 
USH2a/USH2A 38 0 4 69 0 6 
DFNA2/KCNQ42·1 34 0 3 65 0 5 
DFNAS/DFNAS24 16 0 7 41 0 4 
DFNA9/COCH2 3 43 1_8 45 1 2 
Table II shows the present results compared to those obtained in speech 
recognition studies conducted in additional autosomal dominant non-syndromic 
types of HI with fairly similar audiometrie characteristics: DFNA223, DFNA524 and 
DFNA923. The speech recognition score data published in previous reports on 
Usher type II patients8-9 were also re-analysed with the present methods. The 
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deterioration rate and gradient were fairly similar to those obtained in our Usher 
IIa patients. However, onset age in the previously reported Usher type II 
patients8·9 may have been younger and onset level may have been lower compared 
to our patients. Given their age and level of pure tone thresholds, our USH2a 
patients had fairly similar speech recognition scores to those of DFNA2/KCNQ4 
patients, as described by Bom et al.23 Initially, KCNQ4 was thought to be expressed 
predominantly in the outer hair cells of the cochlea.25 However, recent findings in 
the rat suggest that expression follows gradients and is strongest in the inner hair 
cells of the lower turn and the outer hair cells of the upper turn of the cochlea.26 
Because DFNA2/KCNQ4 is associated with primary dysfunction of the lower 
turns of the cochlea, this probably is related to a lack of K+ channels in inner hair 
cells. Outer hair cells are supposed to operate as "cochlear preamplifiers" that are 
involved in cochlear fine-tuning mechanisms.27 Bom et al. therefore suggested the 
possibility that relative sparing of outer hair cell function relates to relatively good 
speech recognition in DFNA2/KCNQ4.23 Because DFNA2 resembles USH2a not 
only in pure tone audiometry but also in speech behavior, a similar effect can be 
suggested to occur in USH2a. Suggestions to the same extent have been made for 
DFNA5/DFNA524, in sharp contrast with DFNA9/COCH, where the relatively 
poor speech recognition is thought to be caused by widespread pathologic 
intracochlear alterations.23·28 Up to now, no specific cochlear locations or functions 
have been identified for usherin that might support or refute the present 
hypothesis of primary involvement of outer hair cells, especially in the lower 
cochlear turns. 
From the present study can be concluded that Usher syndrome patients with one 
or two mutations in the USH2A gene have moderate to severe sensorineural HI 
with a downsloping audiogram-pattern that is mildly progressive at about 0.5 dB 
HL per year. 
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USHER SYNDROME 
INTRODUCTION 
Usher syndrome in general 
The general prevalence of Usher syndrome is estimated to be 3.5-6.2 per 100,000.' 
Worldwide it is the most common cause of deaf-blindness accounting for more 
than 50% of the deaf-blind population2 and for 3-6% of the congenitaliy deaf 
population.3 Characteristic features are sensorineural HI, retinitis pigmentosa 
(RP), or pigmentary retinopathy and, in some cases, vestibular dysfunction. 
Table 1. Genetic subtypes of Usher syndromes 
Subtype 
USHla 
USHlb 
USHlc 
USHld 
USHle 
USHlf 
USHlg 
USH2a 
USH2b 
USH2C 
USH3 
Chromosome 
14q32 
l lq l3 .5 
l l p lS . l 
10q21-22 
21q 
10q21.1 
17q24-25 
lq41 
3p23-24.2 
5ql4.3-21.3 
3q21-25 
USHER TYPE I 
USHER TYPE II 
USHER TYPE III 
Gene 
MY07A 
USHÌC 
CDH23 
PCDH75 
SANS 
USHIA 
USH3 
Prevalence 
2% 
60% 
5% 
20% 
Rare 
10% 
Rare 
80% 
Rare 
15% 
Rare 
The Usher syndrome has been classified into three different types on the basis of 
audiovestibular findings.4 Usher syndrome type I is characterised by profound HI 
and vestibular areflexia. Usher type II by moderate to severe HI and intact 
vestibular function, and Usher type III by progressive HI and generally intact 
vestibular function. Genetic classification occurs by genotype on the basis of the 
identification of the chromosomal loci and the responsible genes; the first part of 
the name of each genetic subtype (USH1, USH2 or USH3) reflects the clinical 
classification (Table 1). At this moment at least 11 loci are known to be involved in 
Usher syndrome and 7 genes have been identified (Table I).5 The most prevalent 
genetic subtypes of Usher syndrome are Usher syndrome type lb (USHlb) and 
Usher syndrome type IIa (USH2a), accounting for approximately 60% and 80% of 
Usher type I and Usher type II cases, respectively. 
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Usher syndrome type Πα 
In 1990 USH2A was linked to chromosome lq41.6 The identification of the USH2A 
gene was reported by Eudy et al. (1998).7 Still little is known about the function of 
usherin, the USH2A protein transcript. It is a basement membrane protein, which 
is expressed in the capillary and structural basement membranes of the human 
and murine retina and in the murine inner ear from birth into adulthood. It is 
believed to be critical for normal development and tissue homeostasis in the inner 
ear and retina.8 
USH2a patients are characterised by moderate to severe downsloping 
sensorineural HI, with mild progression by about 0.5 dB per year.9-10 Visual 
deterioration has been evaluated in several studies on Usher type I and II 
patients.1 1 1 5 In USHlb and USH2a patients, RP leads to a progressive decrease in 
visual acuity (VA) and visual field size with advancing age.16 
Aim of present study 
Although, by definition, patients with Usher syndrome type II have intact 
vestibular responses,4 it was noticed during ongoing Usher studies that Usher 
type II patients seldom appeared to have fully normal vestibulo-ocular reflex 
(VOR) parameters. We wondered whether any systematic changes in VOR 
parameter values could be found in the Usher type II patients, who later became 
identified as USH2a patients. If so, it might be possible to establish a relationship 
between changes in the VOR, optokinetic nystagmus (OKN) or optokinetic after 
nystagmus (OKAN) responses and deteriorating visual functions. 
METHODS 
Patients 
This study comprised 29 Dutch USH2a patients that underwent vestibulo-ocular 
examination with electronystagmography and computer analysis. After informed 
consent had been obtained, clinical examination of affected individuals was 
performed consisting of medical history taking and audiovestibular and 
ophthalmological examinations. Ophthalmological examinations consisted in most 
patients of a complete eye examination (corrected VA measurements, Goldmann 
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perimetry, slit-lamp ophthalmoscopy, electro-oculography and electroretino-
graphy). The results of these examinations confirmed the diagnosis of RP in all 
affected individuals. In addition, the patients were diagnosed to have Usher 
syndrome type II on the basis of vestibular responses and specific audiometrie 
features. Twenty patients came from 9 multi-affected families, whereas 9 patients 
were the only affected individuals in their family. 
Molecular genetics 
Blood samples were collected from all patients and their non-affected relatives for 
linkage and mutation analysis. All Usher syndrome type II patients included in 
this study were diagnosed to have USH2a on the basis of a pathogenic mutation in 
at least one allele within the USH2A gene. Five different mutations (R317R, 
W409X, C419F, C536R, and E767fs) were identified. In 11 patients an ÜSH2A 
mutation was found in only one allele and in 18 patients homozygous (n=7) or 
compound heterozygous (n=ll) mutations were identified. The truncating 
mutations where classified as inactivating mutations (i) and the amino acid 
residue substitutions were classified as non-inactivating (ni) mutations. Given a 
general lack of sufficient numbers of patients with similar mutations, the analyses 
mainly compared different classes of mutations, indicated as: i/i, i/ni, ni/ni, i/? 
and ni/?. 
VA and visual field evaluation 
To evaluate visual impairment, the functional acuity score (FAS), the functional 
field score (FFS) and the functional vision score (FVS) were used from the AMA 
Guides 5th ed.17 VA was measured according to common standards by using 
Snellen charts in 23 of the 29 patients. Best-corrected measurements of each eye 
separately and both eyes combined were used to derive the FAS. The visual field 
measurements were performed by Goldmann perimetry of both eyes and included 
isopter evaluation at the V-4 target in most cases and in a number of cases the III-4 
and 1-4 targets. The Goldmann perimetric fields were quantified for each eye 
separately and both eyes combined by plotting the III-4 isopter, which was 
measured in 16 of the 29 patients that were analysed, and thus the FFS was 
derived. It is important to realise that the FVS is a score combining both the VA 
and visual field scores, i.e. FVS = (FAS*FFS)/100, and that both the FAS and FFS 
are defined for binocular vision.17 
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Oculo-vestibular testing 
The patient was seated in upright position in a rotatory chair at 1.20 m in front of a 
hemicylindric screen. Electronystagmography was employed with computer 
analysis of the nystagmus slow phase velocity (SPV). As the corneoretinal 
potential is strongly reduced in many of these patients, it proved to be important 
that sufficient amplification was applied with appropriate filtering to avoid noise 
and artefacts. On the other hand, as dark adaption is lacking in these patients, the 
corneoretinal potential was remarkably stable. Horizontal angular eye positions 
were calibrated before each test, using bright red LEDs under direct visual control 
of an observer. In the patients with very poor VA, calibration was aided by using 
tactile enforcement: the observer took the patient's index finger and guided it to 
the intended position to touch the correct LED. Because in such a situation blind 
or nearly blind patients often tend to show initial overshooting of the target, the 
eye position record was read off when the observer noticed that the patient's eyes 
were on target. It was examined whether spontaneous nystagmus was present in 
the light or in complete darkness with eyes open. The latter condition was also 
used in vestibular tests. Lateral eye positions were screened for gaze-evoked 
nystagmus in the light. 
Binocular bidirectional OKN responses were elicited at 40o/s and 60o/s constant 
velocity stimulation by moving shadows (n = 24, 7.5° wide at 7.5° separation) 
projected onto the screen. Only a relatively short stimulus duration with an 
equivalent analysis interval of 10 s or less was used with abrupt velocity steps and 
direction transitions in order to mainly address the cortical OKN system ("direct 
OKN pathway", see Ilg 1997 or Leigh and Zee 1999 for review)18-19. Monocular 
bidirectional OKN was elicited in 6 patients using 40°/s constant velocity 
stimulation with similar velocity steps at short intervals as used for eliciting 
binocular OKN. The OKN response level was characterised by the mean SPV of a 
representative steady-state part of the response profile. Smooth pursuit was not 
formally tested as it proved to be difficult for many of the patients with small 
visual fields to capture the visual target and it was anticipated that poor VA might 
account for additional visual tracking problems in many of them. OKAN was 
elicited (in 7 patients) by whole-body rotation at 50c/s in two directions. Loading 
was performed by constant rotation at this velocity in full light for one minute to 
address the subcortical OKN system with its "velocity storage mechanism" (for 
review, see Ilg 1997 or Leigh and Zee 1999)18'19, after which rotation continued at 
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the same velocity, the lights were switched off (experimental time zero) and 
OKAN was recorded. Computer analysis of OKAN responses was performed in 5 
patients. The first few seconds of the nystagmic response in darkness were 
discarded, but the estimated initial velocity (VOKAN) still pertained to SPV 
extrapolated to experimental time zero. VOKAN and the dominant OKAN time 
constant (TOKAN) were calculated by regression analysis from the SPV profile 
during decay after loading, similar to velocity-step responses.20 In addition, 
cumulative (slow-phase) eye displacement during OKAN (CEDOKAN) was 
measured from the chart recording using a paper and pencil method to also 
include the 2 patients whose OKAN response was not analysed by computer. The 
geometric mean of VOKAN, TOKAN and CEDOKAN for the two nystagmus directions 
was derived (see reason below) from each patient's response for further analysis. 
The across-subjects median and range were determined. The monocular OKN 
responses were only qualitatively evaluated to check whether they were 
approximately similar in level and bidirectional symmetry to the binocular OKN 
responses. 
Previously established normal values for OKN responses were used that had been 
obtained from 99 subjects. They had normal vision and normal, quantitatively 
évaluable OKN responses, were not taking any drugs that might have influenced 
their responses, had intact vestibular responses and ages that were 
homogeneously distributed across a broad range (14 - 72 years, mean 41.3 years). 
The mean response level at 40°/s stimulation was 37.6 c / s and did not show a 
significant correlation with age. The mean response level at 60 0 / s stimulation was 
50.5 0 / s , however, the latter showed a significant correlation with age (r = 0.346, Ρ 
= 0.0005) with a downward slope of -0.15 0/s per year. The 95% prediction 
interval for the regression lines was derived to determine which of the OKN 
responses in the Usher syndrome patients were within normal limits (Figure 5). 
The OKN responses obtained from the USH2a patients were also compared to the 
responses separately obtained from a group of patients having a fairly similar type 
of progressive visual impairment but no functional VOR. For this purpose we 
used the data obtained with exactly the same method and conditions from 33 
Usher type I patients with confirmed vestibular areflexia, 23 of whom had been 
genotyped (18 USHlb and 5 USHld). Part of these data have been previously 
reported.21 
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The VOR was evaluated using velocity step tests of 90°/s and binaural caloric tests 
with water irrigation. The velocity step response parameters analysed were those 
previously established.20 Their 90% confidence interval (CI) had been established 
by Theunissen et al. (1986)22: initial velocity (V), time constant (T) and 
Gesamtamplitude (G = VT, equivalent to cumulative eye position, see Huygen and 
Nicolasen 1985)20. The 90% CI was adapted for using the mean value calculated for 
each response parameter for the right-beating and the left-beating nystagmus 
responses, see Table 2 below. It should be noted that the parameters V, Τ and G all 
have lognormal distributions22 and that for this reason the geometric mean was 
calculated. Significant directional preponderance (DP), i.e. beyond the 95% CI, was 
defined as a relative (percentual) difference (i.e. absolute value) in a given velocity 
step parameter (V, Τ or G) between the two nystagmus directions of > 28% for V, 
> 25% for Τ and > 22% for G.22 
Caloric responses 
The caloric test was performed with the patient in a recumbent position, the head 
elevated by 30° from the earth horizontal, with the stimulus conditions and 
analysis as previously described.23 Bithermal (30 and 44CC) water irrigation (150 
ml in 20 seconds) was employed. The response parameter was the mean SPV of 
the postcaloric response at culmination. Bilateral caloric weakness was concluded 
to exist if the level of all single responses from either ear (at culmination) was < 
7°/s. Unilateral caloric weakness was concluded to exist if either there was no 
response at all or hardly any response from one side, or when the side difference, 
i.e. the percentual difference in response level between both sides as defined for 4 
irrigations, was > 20% (assumed normal limit). Caloric DP was not evaluated, 
because only a relatively small proportion of the patients had binaural bithermal 
caloric irrigations. The (arithmetic) mean binaural caloric response level was used 
for further analysis. 
Statistical analyses 
Plots were prepared and statistical analyses and tests performed with a 
commercial program (Prism 3, GraphPad, San Diego, CA, USA). Linear regression 
analysis was used to detect significant correlation coefficients (Pearson's r). Partial 
correlation coefficients were calculated where possible, within the same data set, 
to find out whether any spurious correlations could be identified. Comparisons 
between regression lines were performed using a type of analysis similar to 
168 
USHER SYNDROME 
analysis of covariance (ANCOVA). Nonlinear regression analysis was only used to 
arbitrarily fit a dose-response curve with variable slope to the OKN response 
levels plotted against age. Binomial distribution statistics were used to test 
whether the proportion of (a combination) of significantly high or low response 
parameter values was high enough to indicate a significant finding (i.e. tail 
probability, Ρ < 0.05 in the corresponding binomial distribution). The level of 
significance generally used in the tests was Ρ = 0.05. 
RESULTS 
Binocular OKN findings 
The bidirectional mean OKN response levels at ages below 45 years were normal 
(Figure 1, see also Figure 5A below) compared with the normal OKN responses 
obtained from routine vestibular examinations (Methods). Above that age a 
substantial decline in OKN response was found. OKN responses could not be 
elicited in 2 patients with very poor vision. Relative to their age (51 and 53 years), 
their poor OKN responses may have been in line with the general deterioration of 
these responses at a more advanced age, as is shown in Figure 1. Most of the 
patients with very poor OKN responses did not have formal functional vision 
scores (as indicated by special symbols in Figure 1), however, crude VA and/or 
field measurements (data not shown) were available from previous examinations. 
A significant negative correlation between OKN response level and age was found 
(Figure 1). As will be elaborated below, the correlation between the OKN response 
level at 60°/s and age (i.e. at age < 50 years) vanished when partialing out Τ (Table 
3). 
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Figure 1 Plots of individual response parameter values (small circles) against age Small circle combined 
with a cross represents patient with probable peripheral vestibular impairment (unilateral or bilateral 
caloric weakness) Regression lines are shown m bold for significant correlations Curves in top panels 
were arbitrarily fitted (Methods) Small circle marked by a dot inside indicates patient with an incomplete 
set of functional vision scores, small circle marked by a larger concentnc circle indicates patients without 
any functional vision score evaluation Dashed curves in 3 bottom panels indicate trends derived from 
individual longitudinal analyses by Pennmgs et a l 1 6 
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Monocular OKN and OKAN findings 
Monocular OKN showed the same response level as binocular OKN and was 
bidirectionally symmetric. OKAN was easily elicited from each patient that was 
tested. The median VOKAN was 270/s (range 18-390/s), the median TOKAN 17 s 
(range 3-35 s) and the median CEDOKAN 375° (range 65-650°). 
VOR and functional vision score findings 
One patient showed VOR responses that were not reliable enough for 
quantification in either nystagmus direction. In the other patients, DP measures 
for V, Τ and G were only evaluated if no unilateral caloric weakness was found 
(Table 2), however, caloric tests were not always bithermal and not obtained in all 
patients. 
Table 2. Statistics for (binaural mean values of) VOR-related parameters. Bold values, significantly 
high proportion of finding according to binomial distribution statistics. 
Velocity-step 
Parameter V 
95% CI 33-58°/s 
Shighvalue(N=28»or26 b ) 9 
Normal value 13 
S low value 6 
[5 of 24]' 
Unilateral weakness (see text) (N=27) 
Bilateral weakness (see text) 
S DP (N=25J) 1 
response 
Τ 
13-23 s 
8 
18 
2 
[2 of 24p 
5 
G 
545-1000° 
12 
10 
6 
[5 of 24p 
7 
Cold caloric 
response level 
12-377 s 
0 
16 
10 
2 
1 
a
, velocity step test ; b, caloric test;c, excluding unilateral and bilateral weakness and cases without 
caloric test; d / excluding unilateral weakness and cases without caloric test; CI, confidence interval; 
DP, directional preponderance; G, Gesamtamplitude (cumulative eye displacement), N, total number 
of quantifiable responses; S, significant (P < 0.05), T, time constant of VOR; V, initial velocity 
VOR responses were found in all patients, but they were fully normal in only 1 of 
the 26 patients in whom both velocity step and caloric responses could be 
evaluated. Table 2 shows that significantly high values of the parameters V, Τ and 
G occurred significantly more often than could have been expected on the basis of 
chance alone. This also applied to significantly low values, except for T, even if 
cases with probable peripheral vestibular impairment were excluded. Caloric test 
results also showed significantly low values in significant proportion, although 
neither unilateral nor bilateral pathological caloric weakness was a significant 
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finding. Significant directional preponderance values were found in significant 
proportion for the velocity step parameters Τ and G (Table 2). 
Figure 1 shows a significant decrease not only in OKN response level but also in 
the FAS, the FFS and the FVS, as well as a significant increase in Τ and caloric 
response level with advancing age. It was remarkable that in a separate study on 
progressive visual impairment in USH2a patients, part of whom also participated 
in the present study,16 the results of individual longitudinal analyses indicated a 
higher rate of deterioration of the functional vision scores, especially the FAS, than 
did the results of the concomitant or the present cross-sectional analysis. Also, the 
visual impairment study covered higher ages of the patients than the present one. 
It is therefore important to invoke the trends (dashed curves in bottom panels of 
Figure 1) derived from the longitudinal analyses performed in that study for the 
sake of comparison (Discussion). 
Linear regression analysis seemed to be appropriate as a first step towards 
(partial) correlation analysis in the case of every parameter covered by the panels 
in Figure 1, except when OKN response levels were involved. These response 
levels showed a fairly linear relationship to age with only minor decay at ages < 50 
years, but an apparently much more rapid decay at higher ages, constituting a 
nonlinear relationship. This relationship, together with a bias in missing values, 
i.e. the fact that especially the older patients tended to have an incomplete set of 
functional vision scores or no such scores at all evaluated, prohibited 
straightforward (partial) correlation analysis. The relationship between OKN and 
age was further explored by distinguishing 4 (sub)categories of patients (Figure 2). 
Category 1, all data whatsoever included, no matter whether or not functional 
vision scores had been assessed (n = 28-29 for oculo-vestibular responses, small 
circles in Figure 1); category 2, complete data set (n = 13-14, except for caloric 
response; umarked small circles in Figure 1); category 3 , not all functional vision 
scores measured (n = 13-14, symbols marked with dot inside in Figure 1); category 
4, no functional vision score at all evaluated (n = 4-5, symbols marked with large 
circle in Figure 1). The regression lines (labeled 1-4) corresponding to these 
categories are included in Figure 2. The slope of the regression line becomes 
steeper when going from category 2 (patients with all key parameters measured) 
through 3 (not all of the visual parameters evaluated) to 4 (no visual parameters 
evaluated). ANCOVA was performed where appropriate, i.e. only when 
comparing between the mutually exclusive categories 2 and 3, or 2 and 4, to find 
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out whether there were significant differences between regression lines. Indeed, 
there was a significant difference found between the regression lines for categories 
2 and 4 (Figure 2A). The (significant) differences in slope largely disappeared 
when patients older than 50 years of age were excluded (Figure 2B), in line with 
the observation that the diminished OKN responses were associated with 
advanced age. There was also an association with poor visual function (data not 
shown), as was already mentioned above. 
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Figure 2a,b Same as top panels in Figure 1, now with different symbols (symbol keys in 
bottom left panel pertaining to categories of patients and regression lines labeled 1-4, 
including all patients (A), or including only the patients below 50 years of age (B). Category 
1, all patients (n = 28-29 for oculo-vestibular responses); category 2, patients with a complete 
data set (n = 13-14, except for caloric response), category 3, not all functional vision scores 
evaluated (n = 13-14); category 4, no functional vision score at all evaluated (n = 4-5). The 
expression 2,4 S indicates that regression lines 2 and 4 were significantly different 
(Methods). 
Invoking partial correlations for further analysis is only valid within the context of 
a complete set of data. We therefore decided to perform such an analysis only 
within either category 1 for the vestibulo-ocular response parameters, or within 
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category 2 with a complete set of data comprising VOR parameters and functional 
vision scores. Given the above described nonlinearity pertaining to the OKN 
response levels at age > 50 years, we also decided to perform (partial) correlation 
analyses within category 1 involving age, OKN response levels and Τ only for ages 
of < 50 years, without invoking functional vision scores (Table 3). 
Table 3. Effect of partialing out any of the parameters indicated (columns) on significant 
correlations (rows) involving OKN60*, Τ and age in category 1 patients (presence or absence of 
functional vision scores ignored) aged < 50 years. 
Significant Controll ing for: 
Correlat ion Age OKN60 Τ 
OKN60xAge vanishes 
OKN60xT vanishes 
TxAge persists 
*, OKN60 denotes OKN response level at 60o/s stimulation 
Intercorrelations between response parameters 
Some significant correlations between response parameters (data not shown) were 
obviously trivial. These included the correlation between the OKN response levels 
at 40 and 60°/s stimulation, the correlation between the caloric response level and 
the gain-related VOR parameters V and G, as well as the correlation between 
either V or Τ and G (data not shown). As the OKN response level at 40o/s 
stimulation behaved fairly similarly to the one at 60o/s stimulation, only the latter 
was included in further (e.g. partial correlation) analyses. Similarly, the 
parameters G and caloric response level were no longer considered next to T. 
Of major importance to the present study are the relationships between either the 
OKN or VOR response parameters on the one hand and the visual parameters on 
the other hand (Figures 3-4). In the plots in Figures 3 and 4 T, the FAS, the FFS and 
the FVS replace age (Figures 1-2) as independent variable. 
Figure 3A shows that the OKN response level at 60o/s seemed to correlate 
significantly with T, no matter whether the 3 patients with clearly outlying poor 
response levels were included (solid bold regression line) or excluded (bold 
dashed regression line). The OKN response level at 40o/s only showed a 
significant correlation with Τ if the 3 patients with the poorest responses were 
excluded (dashed bold regression line). As indicated in Figure 3A, none of the 
latter patients had a formal evaluation of any of the functional vision scores; they 
therefore belonged to the above defined category 3 and 4 patients. 
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OKN response level (40°/s) 
A 
Β 
OKN response level (60°/s) 
OKN response levçl (407s) 
2,3 ns 
2,4 S 
4 
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T(s) 
Figure 3 a^c. Same as two top panels in Figure 1, with Τ replacing age as "independent" 
(X) variable for all data (A), with different symbols and regression lines (B, C) for the 
categories of patients 1-4 (Figure 2) for all data (B), and for the patients below 50 years of 
age (C). A: The solid regression line pertains to all data points including outlying values 
(response level < 20°/s); the dashed regression line pertains to the data points excluding 
these values. Symbols marked similar to Figure 1. Β and C: details similar to Figure 2 A, B. 
ns, not significant; S, significant. 
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Exploring the relationship between OKN response level and Τ further, it appeared 
(similar to Figure 2A) that the regression lines showed increasing negative slopes 
from category 2 through 3 to 4, again with significant differences between the 
regression lines pertaining to the categories 2 and 4 (Figure 3B). The differences 
between the categories largely disappeared when including only patients aged 
below 50 years (Figure 3C). It thus showed that also the analysis of the correlation 
between OKN response level and Τ could be best performed within category 1 at 
ages of < 50 years. The significant correlation between OKN response level and Τ 
vanished when controlling for age (Table 3). 
Table 4 Effect of partialing out any of the parameters indicated (columns) on significant 
correlations (rows) involving T, age (mean 32, range 20-49 years), the FAS, FFS and FVS in category 
2 patients (all functional vision scores evaluated) 
Significant Control l ing for. 
Correlat ion X^i FAS FFS FVS 
TxAge persists persists persists 
TxFAS vanishes vanishes na 
TxFFS vanishes vanishes na 
TxFVS vanishes Na na 
na, not applicable because of the arithmetic relationship between the FVS and both the FAS and the 
FFS (Methods) 
Figure 4 shows OKN response level and Τ plotted against the FAS (A), the FFS (B), 
or the FVS (C). The OKN response levels did not show any significant correlation 
with any of these scores (Figure 4). However, it should be kept in mind that the 
category of patients involved, i.e. category 2 comprising the patients who had all 
relevant measurements (n = 15), constituted a selection of the patients by age. The 
older ones with diminished OKN response levels (Figure 1) generally had no 
complete set of functional vision scores evaluated. For this reason, it seems likely 
that the correlation between OKN response levels and functional vision scores was 
biased: correlations involving OKN response levels have therefore been omitted 
from Table 4. 
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OKN response level ( 4 0 » OKN response level (4078) OKN response level (4117s) 
FAS(%) FFS (%) FVS(%) 
Figure 4 a,b,c. First two rows of panels similar to top panels in Figure 1, bottom panels 
similar to the panel for Τ in Figure 1, now with the FAS (A), the FFS (B) or the FVS (C) 
instead of age as independent variables. 
There was a significant positive correlation between Τ and age (Figure 1) that 
persisted when controlling for the OKN response level at 60°/s stimulation (Table 
3), the FAS, FFS or FVS (Table 4). The significant negative correlation between Τ 
and either the FAS, the FFS or the FVS (Figure 4) vanished when partialing out 
age. The correlation between Τ and the FAS (Figure 4A) vanished when 
controlling for the FFS and the same applies to the correlation between Τ and the 
FFS (Figure 4B) when controlling for the FAS (Table 4). 
It should be emphasised that correlations involving the parameter Τ appear in 
both Table 3 and 4 in two different settings, i.e. bearing on category 1 patients 
aged < 50 (Table 3) or category 2 patients who had all key parameter values 
assessed (Table 4). As already explained in relation to Figures 1 and 3, it had been 
checked that the correlation coefficients involving Τ related to compatible features 
of the regression analyses in both categories. 
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Findings related to specific mutations or the type of mutations 
A systematic analysis was performed along the same lines as described above to 
see whether any of the findings were related to certain types of mutations There 
were no substantial differences found (data not shown) between the responses of 
patients with inactivating or non-inactivating mutation combinations, or between 
any subgroups of patients with any specific mutation(s) 
DISCUSSION 
Recapitulation of findings 
From the first patients with Usher type II we examined - more than 15 years ago -
onwards, we were impressed by the variability in VOR findings According to the 
clinical definition of Usher type II, the VOR was intact, but the patients seldom 
showed normal responses Any abnormal value, high or low, seemed possible for 
the VOR parameters to occur and we could not discern any system in the 
variations observed for many years Below it will be attempted in separate 
sections to find possible explanations for the observed parameter changes, some of 
which seemed to be associated with visual function deterioration 
As anticipated, the binocular OKN responses deteriorated with increasing age and 
the same applies to the functional vision scores, ι e the FAS, FFS and FVS (Figure 
1) There was no finding to suggest a relationship between the decrease in OKN 
response levels and the decrease in either of the functional vision scores (Figure 4) 
However, as elaborated above, the limited number of patients (n = 15) who had 
both OKN response levels and functional vision scores evaluated did not cover a 
representative age range or an appropriate range of OKN response levels Despite 
the different age ranges, there was no apparent discrepancy detected in VOR 
parameter values between the category (2) of patients with all relevant 
measurements (n = 15) and the whole group of patients (category 1, η = 28 or 29) 
It therefore seemed justified to study correlations involving Τ within the two 
different patient categories 1 and 2 (Tables 3-4) There was a surprising increase in 
Τ value found with increasing age (Figure 1) and decreasing functional vision 
scores (Fig 4), it also appeared that the OKN response level decreased with 
increasing Τ value (Figure 3) Monocular OKN and OKAN responses are 
recapitulated below 
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VOR parameter values 
The present analyses demonstrated that abnormal high or low values of (some of) 
the VOR parameters V, Τ and G occurred more often than could have been 
anticipated on the basis of chance alone (Table 2). Some of our patients were 
spectacle wearers, most of them being myopes, but they were not allowed to use 
their glasses during calibrating and testing. We checked the effect of applying the 
appropriate corrections for VOR gain, which comprise a binocular combination of 
the precise spherical and cylindrical refraction corrections of the patient's glasses, 
such as has been previously outlined by Cannon et al. (1985).24 Correction 
produced only minor changes in gain estimates that did not affect the 
classification of the response parameter values according to significantly low or 
high values shown in Table 2. 
We have no conclusive explanation for the finding that significantly low values of 
the response parameters V or G and the caloric response level, or the significant 
DP detected for the parameters Τ and G, occurred in significant proportions (Table 
2). Low values of V, Τ or G may be related to peripheral labyrinthine 
impairment.20 For this reason, we highlighted the data points representing the 
patients who showed unilateral or bilateral caloric weakness in some of the 
figures, but it seemed that the number of such cases did not suffice to explain the 
high proportion of low response parameter values (note c to Table 2). It can be 
suggested that the high proportion of low caloric response levels (Table 2) would 
indicate a tendency towards poor peripheral vestibular function, even in cases 
where the criteria for diagnosing pathological unilateral or bilateral caloric 
weakness were not met. 
Part of the high Τ values might be explained by the tendency of Τ to increase with 
increasing age and increasing visual impairment (Figures 1 and 4). The same 
tendencies were shown to some degree by the parameter G (shown in Figure 1 in 
relation to age, other data not shown). Although the parameter V showed a slight 
tendency to decrease with advancing age (Figure 1), it also showed at least some 
tendency to increase with increasing visual impairment as covered by the FAS and 
the FFS (data not shown). So it seems possible that all 3 VOR parameters had some 
tendency to increase their value in association with increasing visual impairment. 
The clearest tendency, however, was shown by the VOR time constant T. 
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OKN response level, age and Τ 
The OKN response level decreased with advancing age (Figure 1) and increasing 
value of Τ (Figure 3). The correlations between OKN response level and age or Τ 
may have been spurious ones because they vanished when controlling for Τ and 
age, respectively (Table 3). However, it should be kept in mind that the limitation 
of age < 50 years excluded most, if not all, of the relevant decrease in OKN levels 
associated with visual impairment. Therefore, even if a significant correlation 
between OKN response level and age or Τ had been found to persist after 
partialisation, this would not have produced any relevant information regarding 
the age and impairment ranges of interest. Nevertheless, it was obvious that OKN 
response levels deteriorated dramatically at age > 50 years (Figure 1). Looking for 
a possibly concomitant trend in functional vision scores, we considered the trends 
obtained from longitudinal analyses in the study by Pennings et al. (2004)16 that 
are also depicted in Figure 1 (bottom panels, dashed curves). Only the FAS 
showed a similar type of nonlineari ty, i.e. a clear transition to a more rapid 
deterioration from about the age of 40 years onwards. Thus, the decline in OKN 
response level lagged behind the major decline in the FAS (Figure 1). A steady 
decline in the FFS and FVS is seen all over the age range of 30-50 years. It can be 
also conceived that gradually increasing visual impairment would appreciably 
affect OKN response levels only once a critical level of impairment has been 
attained that pertains to a critically low value of the retinal slip gain. Such a 
bottleneck might be reflected by an apparent transition in the graphic relationship 
between OKN response level and age. The latter might be even more tangible if 
during the gradually increasing visual impairment some regulatory or 
homeostatic mechanism would be active to maintain a normal OKN level for as 
long as possible. Comparison between the OKN response levels measured in our 
USH2a patients and the normal limits obtained at our laboratory (Methods) clearly 
showed that at ages below 45 years all patients had normal OKN response levels 
(Figure 5A). It should be emphasised that they were still having these normal 
OKN response levels whilst they were already developing a considerable degree 
of visual impairment (Figure 1). 
Given the notion that mainly the cortical OKN system must have been involved, it 
is opportune to invoke the mechanism of optokinetic training25 as a possible 
explanation. Previous studies have shown that OKN training not only enhances 
OKN response levels but also the VOR.2627 We speculate that OKN enhancement 
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in the USH2a patients resulted in seemingly normal OKN response levels despite 
the already declining optokinetic system, and that concomitant enhancement of an 
intact VOR has lead to apparent vestibular hyperreactivity 
It is also possible that the intriguing phenomenon of cortical filling-in is involved 
Valmaggia and Gottlob (2002)28 described 3 patients with age-related macular 
degeneration with a large (15-18° diameter) central scotoma caused by an occult 
subfoveolar neovascularization While looking at the OKN stimuli, the patients 
either did not see the stimulus and produced minimal OKN, or filled in the 
scotoma and perceived the stripes, which then elicited OKN with a normal gain 
Voluntary switching between the two conditions was possible At a repeat 
examination 1 year later, the patients continuously perceived the OKN stimulus 
and produced OKN during the entire test Similarly, in a previous study, all 
patients, whatever the size of their scotoma, constantly perceived the OKN 
stimulus and exhibited OKN 2 9 Such features may be explained by long-term 
cortical adaptation In these patients, filling-in of their central scotoma must have 
taken place starting from more peripheral parts of the retina One wonders as to 
whether a similar type of filling-in phenomenon of peripheral scotomas can occur 
that originates from the more central part of the retina If that is the case, 
especially patients with advanced RP might experience its action 
(Other) correlations involving the VOR time constant 
The VOR time constant Τ further showed correlations with age (Figure 1), the FAS 
(Figure 4A), FFS (Figure4B) and FVS (Figure 4C) All of the latter 3 correlations 
vanished when controlling for age The correlation between Τ and age persisted 
when controlling for any of the functional vision scores (Table 4) or the OKN 
response level (Table 3) and therefore seems unlikely to have been secondary to 
visual impairment or changes in OKN responses When controlling for any one of 
the 2 variables FAS or FFS, the correlation between Τ and the remaining variable 
vanished (Table 4) It therefore seems reasonable to assume that the 3 variables T, 
FAS and FFS were in some way associated, although the correlations between Τ 
and the functional vision scores may have been spurious ones, because they 
vanished when controlling for age (Table 4) The constellation of these findings 
favours an interpretation in terms of an increase in Τ secondary to the 
deterioration of visual function with advancing age However, again, there were 
insufficient data bearing on parameter behaviour at age > 50 years (Figure 1) 
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Monocular OKN and OKAN 
No substantial difference in response characteristics between bidirectional, 
binocular OKN and monocular OKN responses was found. In particular, we could 
not find any temporo-nasal asymmetry. This finding, which is similar to a 
previous finding reported in patients with RP by Heide et al.30, favours the notion 
that mainly the cortical OKN system was involved in the present OKN responses, 
that were elicited with velocity-step stimuli with only a short duration of constant 
velocity. 
We compared our OKAN responses to those reported by Simons and Büttner31 for 
normal subjects that were obtained with fairly similar stimulus equipment and 
conditions as used in our patients. It appeared that the initial OKAN velocities in 
our USH2A patients matched well with those specified for their normal subjects of 
similar ages. This contrasts with the findings obtained by Heide et al.30 from their 
RP patients (aged 23-56 years with a remaining central visual field with a 
horizontal diameter in the range of 18-50°). It seems relevant that the latter authors 
did not apply whole-body rotation, which is a very effective stimulus for eliciting 
OKAN, probably more effective than motion of only the visual surround, as was 
applied by them. It is also possible that some of their RP patients had Usher type I 
with vestibular areflexia (vestibular examination was not mentioned), a condition 
in which OKAN cannot be elicited (see Leigh and Zee 1999 for review).19 OKAN 
responses depend on the subcortical OKN system (indirect OKN pathway) with 
its velocity storage mechanism. Given the present results, it is clear that the 
subcortical OKN system in our patients was intact. Our patients in whom OKAN 
had been assessed had ages in the range of 23^49 years and a monocular central 
visual field diameter (Goldmann perimetry with III-4 isopter) of between 18 and 
88° (the FFS was in the range of 36-82). Because none of them showed clearly 
diminished OKN responses (their binocular OKN response levels were in the 
range of 40-56°/s at 60°/s stimulation), the possibility remains that USH2a 
patients with diminished OKN responses also have diminished OKAN responses. 
Nevertheless, if that would be the case, it would not explain our finding of 
diminished OKN responses, because these were elicited in a way that hardly 
addressed the subcortical OKN system. 
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Effect of VA or visual field size on OKN response level 
Obviously, OKN responses are impossible without sufficient VA, but what is 
sufficient? Monocular OKN cannot be elicited from the affected eye in children 
with congenital monocular cataracts, however, OKN is intact postsurgery (for 
example, Ben Ezra and Paez32). It has been argued before that VA has only a minor 
influence on OKN gain when the fundamental spatial frequency can be still 
resolved.,3 Heide et al.10 described that VA in their RP patients varied between 
0.04 and 0.8 and was thus sufficient to resolve the low spatial frequency of 0.067 
cycles/deg. This corresponds to stripes that subtend and are separated by a 
horizontal visual angle of 7.5°, which is identical to our OKN stimulus. VA in the 
best eye of our patients was in the range of 0.05-1, except for the 2 patients from 
whom no OKN could be elicited, who had VA 0.0033 or light perception only. 
According to the calibration values presented by Weder and Wiegand34, OKN is 
just elicitable from a patient with VA 0.05 if he or she is looking from a distance of 
3.75-4.00 m at a pattern of moving light dots projected on a screen at 1 cm 
diameter and separation. The corresponding visual angle of the stimulus (1 cycle 
corresponds to 2 cm at 375-400 cm distance) is about 0.3°. The maximum viewing 
distance for VA < 0.001 is 0.25-0.75 m, which implies that the stimulus (1 cycle of 2 
cm) should subtend a visual angle of at least 1.5° to 4.6°, i.e. still sufficient to 
resolve the stimulus we used (1 cycle subtending a visual angle of 15°). 
This does not inform us about the gain of the OKN response to a given 
suprathreshold stimulus. It is possible that some of our patients at a more 
advanced age had insufficient VA for optimal resolution of the stimulus, which 
resulted in a poor OKN response. However, this does not exclude the possibility 
that their poor OKN response (also) reflected their concomitantly reduced visual 
field size. 
Functional significance of VOR enhancement 
It can be easily demonstrated that both a high VOR gain and a long VOR time 
constant, which is associated with a small phase lead (with reference to ideal 
compensation) at higher frequencies, lead to a reduction of retinal slip, i.e. reduce 
the retinal slip position (or gaze) error and retinal slip (or gaze) velocity associated 
with the VOR. However, it seems more relevant to consider retinal slip under the 
condition of combined visual and VOR stimulation, such as, for example, is 
brought about by natural head movements. Das et al.35 and Lee et al.36 studied the 
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so called visually enhanced VOR (WOR) and found considerable enhancement of 
the W O R gain, with only minor phase errors, during rotation in the range of 
natural head movements under normal viewing conditions. The combination of a 
high W O R gain and a small phase error produced retinal slip velocities of below 
60/s. These studies involved interaction between the VOR and the smooth pursuit 
or the visual fixation system, however, essentially similar enhancement has been 
found in previous studies combining the VOR and OKN.37"10 Psychophysical 
studies have shown that retinal image motion exceeding about 5-6°/ s is associated 
with declining VA.41-42 It can therefore be suggested that a reduction in (dynamic) 
VA in normal subjects elicits the type of W O R enhancement that was 
demonstrated by the above mentioned visual-vestibular interaction studies. We 
speculate that the pre-existent, permanent reduction in (static) VA in our USH2a 
patients likewise has elicited permanent VOR enhancement. If we suppose that 
patients with such a type of visual impairment can tolerate more retinal slip than 
is usual, this may be an advantage because their enhanced VOR, which can be 
characterised as vestibular hyperreactivity, might otherwise render them 
especially susceptible to motion sickness. In addition, it has been shown that 
restricting the field of view reduces the magnitude of optokinetically elicited 
motion sickness.43-44 
Given the specific finding of OKN enhancement during VOR stimulation as 
reported by Koenig et al.38 and Böhmer and Pfaltz26, it also seems possible that in 
our patients the enhanced VOR helped to maintain OKN at a functional level 
during natural head movements for as long as possible whilst the visual field was 
being reduced and therefore retinal slip gain must have been declining. As 
described in Methods, we took the opportunity to compare the OKN response 
levels in our USH2a patients to the response levels obtained from Usher type I 
patients, who have a fairly similar type of progressive visual impairment but lack 
the VOR. The OKN response levels obtained from the Usher type I patients were 
normal (Figure 5B) and very similar to those obtained from the USH2a patients 
(Figure 5A). There was no apparent difference in the type of decline of the OKN 
response level observed at a more advanced age between the two types of 
patients. The only apparent difference was that the decline seemed to occur at a 
slightly lower age in the Usher type I patients (Figure 5B). Admittedly, the 
numbers of data points bearing on patients (USH2a or Usher type I) of relevant 
ages, was too small to obtain reliable estimates of the age at which the OKN 
response level started to decline. However, a certain tendency for a slightly earlier 
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start of visual impairment in at least the genotyped USHlb patients compared to 
the USH2a patients was noted to occur m a separate study 1 6 This is in line with 
some of the previously reported findings pertaining to comparisons between 
clinically diagnosed Usher type I and II patients 1 1 1 3 
(°/s> OKN response level (40°/s) (•'s> OKN response level (60°/s) 
(°/s> OKN response level (40°/s) 
Β 
<°/s> OKN response level (60°/s) 
30 40 50 60 
Age (year) 
Figure 5 a,b Same OKN data for USH2A as shown in top panels of Fig 1, compared 
with (B) (unpublished) OKN data of 33 Usher type I patients, 23 of whom had been 
genotyped (18 USH1B and 5 USH1D) Small symbol, outlying value Straight line with 
pair of dotted lines represents regression line with 95% hyperbolic prediction interval 
derived from 99 normal subjects (unpublished data, data points not shown) 
Anyway, the comparison between the two types of Usher syndrome illustrated by 
Figure 5 clearly demonstrates that having a functional VOR was not a necessary 
prerequisite for the USH2a patients to be able to maintain a functional OKN 
response level The mere fact that a similar mamtenance could also be achieved by 
(Usher type I) patients who have a fairly similar type of progressive visual 
impairment but no VOR or a functional subcortical OKN system, confirms that it 
must be the cortical OKN system and associated cortical mechanisms, more 
specifically mechanisms that involve learning or training, that play a major role in 
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maintaining normal OKN response levels for as long as possible. In this context it 
seems pertinent that a central (parafoveal) part of the retina, which is particularly 
linked to the cortical OKN system (see Leigh and Zee 1999 for review)19 keeps 
functioning, at least partially, in these patients for as long as they are still having a 
functional level of VA. It seems possible that cortical mechanisms that help tuning 
the OKN system (and the VOR system?) can afford a lower level of VA than the 
cortical mechanisms requiring visual fixation and recognition. 
Patients with advanced RP are known to have mobility problems45 and poor 
mobility behaviour (see also Turano et al.46 or Li et al.47 with their references). It is 
possible that reduced mobility, especially with diminished head movements, has 
caused a secondary VOR enhancement to develop. We have previously suggested 
this to be the case in patients with idiopathic spasmodic torticollis,48 as well as in 
patients with muscular dystrophy,49-50 a significant proportion of whom showed 
an increased VOR gain. 
Turano et al.46 also demonstrated that patients with advanced RP have an 
increased tendency to look downwards when they walk, which showed a 
significant negative correlation with their horizontal field extent. Depending on 
whether the head is inclined in downward direction, or only the eyes are deviated 
downwards, this might influence the VOR gain. In the primary head position, the 
horizontal semicircular canals have a forward elevation of about 30°. Downward 
inclination of the head by 30° would place these canals in an earth-horizontal 
plane, which would increase the stimulus proper by about 15%, i.e. 
100%/cosine(30o). If instead the head would be kept in primary position and only 
the eyes would deviate downwards, the VOR gain could be decreased, because it 
is attenuated by a factor equal to the cosine of the angle between the optical axis 
and the plane of head rotation .51 If any such change in VOR gain would have been 
retained during our VOR assessment, it would have only marginally influenced 
the statistics of significant proportions of some of the significantly high or low 
VOR parameter values presented in Table 2, thus without affecting the 
conclusions. 
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USHER SYNDROME 
INTRODUCTION 
Usher syndrome (OMIM #276900) is an autosomal recessive syndrome that is 
characterised by sensorineural HI, RP and in some cases vestibular dysfunction. 
The prevalence of Usher syndrome in Northern Europe is estimated to range from 
3.5 to 6.2 per 100,000 inhabitants and the syndrome accounts for about 50% of 
deaf-blindness cases.1·2 Three clinical types are distinguished on the basis of 
audiovestibular features. Usher syndrome type I (USH1) is characterised by 
congenital, profound deafness, RP and vestibular areflexia. In Usher syndrome 
type II (USH2) the HI is moderate to severe with downsloping pure-tone 
audiograms; there is RP and an intact vestibular response. Usher syndrome type 
III (USH3) is characterised by fast progressive HI, RP and variation in vestibular 
responses between patients.3 Initially, it was assumed that USH1 was more 
prevalent than USH2, however, a large-scale study of Usher syndrome patients 
from Germany showed that USH2 probably accounts for twice as many cases as 
USH1.2 
Several genetic subtypes have been identified for the 3 clinical types of Usher 
syndrome. To date, eleven loci (USH1A-USH1G, USH2A-USH2C, USH3) are 
known and the corresponding genes have been identified for seven of these 
(USH1B/MY07A, USHIC/USHIC, USH1D/CDH23, USH1F/PCDHÎ5, 
U S H 1 G / S A N S , U S H 2 A / USH2A, U S H 3 A / ( iSH3A) . 4 *«* references thcran
 S o (ar> USH2A 
is the only gene identified for IJSHl.^ USH2A (OMIM *276901) encodes usherin, 
which consists of 1546 amino acids and has an estimated molecular weight of 170-
180 kDa.5'6 At the N-terminal end of the protein there is a signal peptide, which is 
followed by a thrombospondin domain, a laminin N-terminal domain type VI, 10 
laminin-type epidermal growth factor-like domains and 4 fibronectin type III 
domains.5-6 Usherin is a basement membrane protein in the mouse and human 
cochlea and the retina, and is also expressed in many other tissues.7-8 By in situ 
hybridisation USH2A transcripts were shown to be present only in the perinuclear 
cytoplasm of the photoreceptor cells in the outer nuclear layer in humans, mice 
and rats.9 However, with antibodies against usherin the protein could not be 
detected in this layer but in the lens capsule and the Bruch's layer between the 
RPE and the choroid, which is very rich in basement membranes.78 So far, the 
function of usherin in the cochlea and the retina is unknown. 
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It is estimated that mutations in USH2A account for the majority of USH2 cases.5 
To date, 32 mutations in USH2A have been described for Usher syndrome type Ha 
(USH2a) in a review by Ahmed et al.4 Different types of mutations are found in 
the entire coding region of the gene. The most prevalent mutation in USH2A is the 
c.2299delG (p.Glu767fs) mutation. Besides as USH2, mutations in the USH2A gene 
can manifest as atypical Usher syndrome10 or as nonsyndromic recessive RP.1112 
Remarkably, two individuals were reported to be homozygous for the c.2276G>T 
(p.Cys759Phe) mutation without any signs of RP or HI.12 
This report presents the results of ÜSH2A mutation analysis in 70 Dutch families 
that were clinically classified as USH2. Combining these 70 families with 9 
previously reported Dutch families, enables us to estimate the prevalence of 
LZSH2A mutations as the cause of USH2 in the Netherlands. Also, knowing the 
causative mutations greatly facilitates DNA-diagnostics and genetic counseling. 
MATERIAL AND METHODS 
Patients 
Seventy Dutch families with 89 USH2 patients were evaluated in this study. Fifty-
six patients were isolated cases and in 14 multicase families there were 33 patients. 
All patients were diagnosed to have USH2 based on the combination of moderate 
to severe high-frequency sensorineural HI, RP and intact vestibular responses. All 
participating family members signed an informed consent form and the study was 
approved by the local ethics committee. Results of audiometrie, ophthalmic and 
vestibular examinations in a number of the patients have been described 
previously.13-17'unPubllshed result5 Affected family members of 21 families did not 
participate in our clinical studies but were clinically examined elsewhere and 
referred to our hospital for DNA diagnostics of the USH2A gene. Nine of the 
present 70 families were included in the genetic studies by Weston et al.6 and by 
Dreyer et al.18 So far, only one heterozygous mutation (p.Glu767fs in 6 families 
and p.Cys419Phe in 3 families) was identified in these families and therefore they 
were included in the present study in an attempt to identify the second mutation. 
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Mutation analysis ofUSHIA 
Genomic DNA was extracted from blood samples according to Miller et al.19 
Oligonucleotide primers used for PCR amplification were previously described by 
Weston et al.6 A forward (5'-TGTAAAACGACGGCCAGT-3') and reverse (5'-
CAGGAAACAGCTATGACC-3') M13-tag were added to the described primers. 
Exons were amplified by PCR, using the PTC200 thermo cycler (MJ Research, Inc.) 
and standard conditions. The products were purified with the StrataPrep PCR 
purification Kit (Stratagene). For sequencing, the tags were used as primers. 
Sequence analysis was performed with the ABI PRISM Big Dye Terminator Cycle 
Sequencing V2.0 Kit and the reactions were analysed with the ABI PRISM 3700 
DNA analyzer (Applied Biosystems). Sequence analysis was performed in one 
patient per family. In 49 of the 70 families all 21 exons of the USH2A gene 
(GenBank NM 007123, version: 3) were sequenced. In the remaining 21 families 
heteroduplex analysis, WAVE/DHPLC, Amplification-Refractory Mutation 
System (ARMS) assay or sequence analysis of a number of exons of the USH2A 
gene were performed as previously described.6 After the detection of two mutant 
alleles the remaining exons were not analysed in these 21 families. 
The presence of the putative splice site mutation c.949C>A (p.Arg317Arg) was 
tested in 184 control DNA samples by Acil digestion and the prediction of the 
splice site efficiency was performed by using the splice site prediction program 
NNSPLICE 0.9 version from the Berkely Drosophila Genome Project website 
accessible on the World Wide Web (http://www.fruitfly.org/seq tools/splice.htmQ. 
An ARMS assay was performed to test for the presence of the nucleotide 
substitution of a cytosine for an adenine at position 2252 (c.2252C>A), causing 
p.Ser841Tyr with the following primers, a common forward primer (5'-
CAGTGTGACACCTGCAGAGA-3'), a mutant reverse primer (5'-
GCAAGGCAGACAGAGGAAGT-3') and a wildtype reverse primer (5'-
GCAAGGCAGACAGAGGAAGG-3'). Two mutations introduced a stop codon 
and were not tested in control samples. 
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RESULTS 
USH2A mutation analysis 
In 40 of the 70 USH2 families at least one USH2A mutation was identified, one 
mutation in 27 families and two mutations in 13 families. Ten different mutations 
were found (Table 1). Six previously described mutations were found in more than 
one patient, c.l042A>C (p.Asn346His), c.l227G>A (p.Trp409X), c.l256G>T 
(p.Cys419Phe), c.l606T>C (p.Cys536Arg), c.2137G>C (p.Gly713Arg) and 
c.2299delG (p.Glu767fs). The p.Glu767fs mutation is the most frequent mutation in 
the present study and identified in 18 alleles in 16 families. In 13 families the 
p.Cys419Phe mutation was detected in 14 alleles and we identified 3 families with 
the p.Trp409X mutation in 3 alleles. The p.Cys536Arg mutation, previously 
reported in 1 Danish family,20 was identified in 6 alleles of 6 Dutch families and 
the p.Asn346His mutation was seen in 3 alleles in 3 families. The latter mutation 
was previously described in a Danish, American, Swedish and Norwegian 
family.6-20 The p.Gly713Arg was identified in 2 alleles and was previously 
identified in a Danish family.20 The c.923-924insGCCA (p.His308fs) mutation was 
identified in one allele of one family. This mutation, referred to as c.921-
922insCAGC, was described previously in 2 alleles in 2 American families.6 Leroy 
et al.21 identified in one allele a p.His308fs mutation, which was described as c.921-
922insGAGC. 
Three novel mutations were identified in this study. In exon 6, the substitution of 
an adenine for a cytosine at nucleotide position 949 (c.949C>A) is predicted to lead 
to a new splice site. The donor splice site probability of the sequence increases 
from 0.13 to 0.85 due to this nucleotide substitution. The nucleotide change does 
not cause an amino acid substitution (p.Arg317Arg). The mutation was found in 
four different families; in 3 families heterozygously with an unknown mutation in 
the second allele and in 1 family in combination with the p.Glu767fs mutation. It 
was not seen in 184 control samples. Two novel mutations were detected in one 
patient. Both cause the substitution of a stop cod on for a codon for glutamine, 
p.Gln748X (c.2242C>T) and p.Glnl468X (c.4405C>T) located in exon 13 and in 
exon 21, respectively (Table 1). 
One novel single nucleotide polymorphism (SNP) was detected in 1 patient, the 
substitution of an adenine for a cytosine at nucleotide position 2252 in exon 13 
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(C.22520A) leads to the amino acid substitution p.Ser841Tyr. This nucleotide 
change was found in 2 of 93 control samples. 
USH2a prevalence 
The frequencies of the identified mutations in the Dutch USH2a population are 
shown in Table 1. The genotype of 9 additional Dutch families from the Nijmegen 
Usher syndrome studies have been reported previously by Weston et al.6 and 
Dreyer et al.18 In these families both USHZA mutations were identified. Of these 9 
families, 5 were homozygous for the p.Glu767fs mutation and 1 was homozygous 
for the p.Trp409X mutation. The three remaining families were compound 
heterozygous for the p.Cys419Phe and the p.Glu767fs mutation, the p.Cys419Phe 
and the p.Trp409X mutation and the p.Glu767fs and the p.Trp409X mutation. 
Including these families to be able to determine the prevalence of USH2a in the 
Dutch Usher syndrome type II population, results in 79 families with a clinical 
diagnosis of Usher syndrome type II. 
Table 1. Mutations identified in the Dutch USH2a population 
Nucleotide change 
c.923-924 ins GCCA 
C.9490A 
C.1036A>C 
c 1227G>A 
c 1256G>T 
c 1606T>C 
c 2137G>C 
C.22420T 
c.2299delG 
C.4405OT 
Unknown 
Amino acid 
change 
p.His308fs 
p.Arg317Arg 
p.Asn346His 
p.Trp409X 
p.Cys419Phe 
p.Cys536Arg 
p.Gly713Arg 
p.Gln748X 
p.Glu767fs 
p.Glnl468X 
Type of 
mutation 
Nonsense 
Splice-site 
Missense 
Nonsense 
Missense 
Missense 
Missense 
Nonsense 
Nonsense 
Nonsense 
Exon 
6 
6 
6 
7 
7 
9 
12 
13 
13 
21 
Domain 
Laminin type VI domain 
Laminin type VI domain 
Laminin type VI domain 
Laminin type VI domain 
Laminin type VI domain 
1st laminin EGF-hke domain 
4th laminin like domain 
5th laminin EGF-like domain 
5th laminin EGF-like domain 
Carboxy tail region 
Relative 
frequency 
0 
0 01 (0.01) 
0.05 (0.04) 
0 04 (0.03) 
0 04 (0.07) 
0 18 (016) 
0 08 (0 06) 
0 03 (0 02) 
0.01 (0.01) 
0.23 (0.31) 
0.01 (0.01) 
0 35 (0.29) 
Newly identified USH2A mutations are presented in bold. Patients with one mutated USH2A allele 
were assumed to be of the USH2a subtype The relative frequency of the mutations is that of 
USH2A alleles in the present study (total number of 80 alleles, including the 9 families with 
heterozygous mutation previously published6·111) " The relative frequency between brackets 
includes the genotype of 9 Dutch families previously published in the studies by Weston et a l 6 and 
Dreyer et al.18 (total number of 98 alleles). 
In 49 of the 79 examined USH2 families (62%), pathogenic mutations in the 
USHZA gene were identified. In 28% (22/79) of the families mutations in both 
alleles could be detected and in 34% (27/79) a mutation was found in only one 
allele. In 30 families (38%) no mutations in the USHZA gene were discovered. 
Thus, 45% (71/158) of the mutated alleles in all USH2 families were identified. 
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When we assume that all the USH2 patients with one mutated USH2A allele are 
true USH2a patients that have a second so far unidentified USH2A mutation, it is 
possible to deduce the estimated prevalence of USH2a in the Dutch USH2 
population. When a is the fraction of detected USH2A mutations and b the fraction 
of undetected LÎSH2A mutations, the fraction of the families with two detected 
mutations is a2, that with one mutation is 2ab and with two undetected mutations 
is b2. Using the ratio between the families with two known mutations and one 
known mutation together with the two equations a2 +2ab+b2 =1 and a+b=l, one 
can calculate a and b and thus the total number of USH2a families among the 
studied families. The calculated number of USH2a families was 57 and thus the 
number of USH2a families in which we did not detect a mutation is 8. This means 
that the estimated prevalence of USH2a in the studied Dutch USH2 population is 
72% (57/79) and that 28% of the mutated USH2 patients is due to mutations in one 
or more different genes. 
Haplotype analysis. 
For the frequently occurring p.Glu767fs mutation it is already known that it 
represents an ancestral founder mutation.18 To determine whether this is also true 
for the most frequent mutations in the present patient group, SNPs in the USH2A 
gene were analysed. In 49 of the 70 families all 21 exons of the USH2A gene were 
sequenced and 10 SNPs could be scored (Table 2). Six of these SNPs were 
previously described in the study on the haplotypes associated with the 
p.Glu767fs mutation.18 In the present study 4 novel SNPs were added. One of 
these 4 SNPs is located in noncoding sequences (c.l644+34A>C) and 3 are in 
coding sequences (c.l931A>T, c.3945T>C, c.4371G>A). Although the DNA of the 
parents of the patients was not available or the USH2A gene was not completely 
sequenced, on the basis of homozygosity we could deduce the haplotype 
associated with 3 of the frequent mutations, p.Arg317Arg, p.Cys419Phe and 
p.Cys536Arg (Table 2). The haplotypes associated with the p.Arg317Arg and 
p.Cys536Arg mutations are the same as that already known to be associated with 
the p.Glu767fs mutation.18 The p.Cys419Phe mutation segregates with a different 
haplotype (derived from 8 families). There were no multiplex families with only 
one USH2A mutation, in which the haplotype of the other affecteds could be 
evaluated. Analysis of two markers flanking the ÎJSH2A gene (D1S2827 and 
D1S490) revealed no mutation-associated alleles. 
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Table 2 Haplotypes associated with frequently encountered USH2A mutations 
SNP nucleotide variation Exon pArg317Arg ρ Cys419Phe ρ Cys536Arg pGlu767fs 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
c 373A>G 
c 5 0 4 O A 
c 1 4 1 9 0 T 
c 1644+34A>C 
c 1931A>T 
c 3157+35A>G 
c 3812-80T 
c 3945T>C 
c 4371G>A 
c 4457A>G 
2 
3 
8 
9 
11 
15 
18 
18 
20 
21 
A 
G 
C 
A 
A 
A 
Τ 
Τ 
G 
A 
G 
A 
C 
A 
Τ 
G 
Τ 
Τ 
G 
G 
A 
G 
C 
A 
A 
A 
Τ 
Τ 
G 
A 
A 
G 
C 
A 
A 
A 
Τ 
Τ 
G 
A 
The ρ Glu767fs core haplotype was previously described by Dreyer et al ι 8 
DISCUSSION 
This report describes the results of mutation analysis of the L7SÌ-Ì2A gene in 70 
Dutch USH2 families Ten different mutations were identified, 3 of which are 
novel (p Arg317Arg, ρ Gln748X and ρ Glnl468X) In 62% of these 70 families and 
in 9 previously published Dutch families, an USH2A mutation in at least one allele 
was identified Several other studies 6 2 0 2 1 2 2 have performed mutation analysis of 
the USH2A gene and prevalence data are shown in Table 3 for comparison The 
percentage of families with an USH2A mutation among the selected USH2 families 
is varying from 42-87% As can be expected, the present study and the studies by 
Weston et a l 6 and Dreyer et a l 2 0 that used sequence analysis with or without 
prescreening, report the highest percentages (62%, 67% and 87%, respectively) of 
families with USH2a The percentage of detected mutated iiSH2A alleles by 
Dreyer et a l 2 0 is high, which is mainly due to the high percentage of ρ Glu767fs 
alleles 
In the Dutch USH2 population 62% of the USH2 patients were shown to have at 
least 1 mutation in the USH2A gene In fact, we can estimate that 72% of the USH2 
population in fact has USH2a This percentage is similar to that mentioned in the 
study by Weston et a l 6 (74%) who studied families from various origins The 
linkage-based estimation of 90% USH2a among Dutch USH2 families by Pieke-
Dahl et a l 2 3 seems to be an overeshmate 
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In the present study, the p.Glu767fs mutation has a prevalence of 23% of the 
present ÌÌSH2A alleles, including correction for the previously described Dutch 
families, this percentage is 31% (Table 3). In other studies, this percentage varies 
from 32-44% in patients from European countries or the United States.618·21-22 Also 
the p.Cys419Phe mutation is frequently found, in 16% of the alleles in the Dutch 
population of USH2 patients. These results have consequences for DNA-
diagnostics. When testing for the p.Glu767fs and the p.Cys419Phe mutations only, 
already 47% of the mutated alleles can be detected. Also, only 3 of the 10 
mutations known in the Dutch population are private mutations. Thus, it is 
possible to find 68% of the USH2A mutations that are detectable by sequencing of 
the coding region and the exon-intron boundaries, by testing for the mutations 
that occurred more than once. These mutations are clustered in only 5 exons. 
Besides the already known haplotype associated with the p.Glu767fs mutation, we 
were able to deduce an associated haplotype for the p.Arg317Arg, p.Cys419Phe 
and the p.Cys536Arg mutations, which suggests an ancestral relationship. The 
p.Cys536Arg and p.Arg317Arg mutations have the same haplotype as the 
p.Glu767fs mutation. However, it has to be kept in mind that this haplotype has a 
relative frequency of 0.60.18 The p.Cys419Phe mutation is identified in 16 alleles in 
15 families (19%) and has another core haplotype. Together with the p.Trp409X 
and the p.Arg317Arg mutation, which are identified in 6 and 4 families, 
respectively, the p.Cys419Phe mutation is so far only described in patients from 
the Netherlands. These mutations might therefore be Dutch founder mutations. 
However, haplotype analysis of the p.Trp409X mutation was not possible, because 
in 4 families only a few exons of the IJSH2A gene were sequenced. For statistical 
significance of the association of these mutations with a specific haplotype more 
patients have to be analysed and/or DNA of parents or other family members has 
to become available. The SNP haplotypes were also evaluated in patients with one 
mutated USH2A allele assuming that the deduced haplotypes are indeed always 
associated with the frequently occurring mutations. This analysis shows that the 
common haplotype associated with the p.Glu767fs mutation is also frequently 
associated with the unknown mutation (data not shown). In addition, there are a 
number of other haplotypes seen in patients with an unknown mutation, three of 
which occur more than once. Therefore, we can conclude that there are not only 
one or two frequent, unknown mutations. 
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Table 3 Prevalence of USH2a in Usher syndrome type II families and prevalence of the ρ Glu767fs mutation, as presented in several studies 
Reference 
Used techniques 
USH2a,a
m
/N,an, 
1 allele mut/Nram 
2 alleles mut/Nfam 
mut/Na 
ρ Glu767fs/Na 
ρ Glu767fs/USH2aa 
Eudy et al ' 
Sequencing 
23/96 (0 24) 
14/96 (0 15) 
9/96 (0 09) 
32/192(017) 
29/192 (0 15) 
29/46 (0 63) 
Liu et al "> 
ρ au767ß 
screening 
12/23(052) 
8/23(0 35) 
4/23(017) 
16/46(0 35) 
16/46(0 35) 
16/16(1 00) 
Beneyto 
et al » 
ρ Glu767ß 
screening 
15/59 (0 25) 
11/59(019) 
4/59 (0 06) 
19/118(0 16) 
19/118(016) 
19/19(1 00) 
Leroy et al21 
Heteroduplex 
15/36 (0 42) 
12/36 (0 34) 
3/36 (0 08) 
18/72 (0 25) 
11/72(015) 
11/30(0 37) 
Najera et al22 
SSCP 
23/59(0 39) 
15/59 (0 26) 
6/59 (0 10) 
27A18(0 23) 
19/118(016) 
19/46(0 41) 
Weston et 
a l 6 
Sequencing0 
38/57 (0 67) 
18/57 (0 32) 
20/57 (0 35) 
58/114 (0 51) 
31/192 (016) 
31/76(0 41) 
Drey er et 
al2 0 
Sequencing0 
27/31 (0 87) 
9/31 (0 29) 
18/31 (0 58) 
45/62 (0 73) 
24/62 (0 39) 
24/54 (0 44) 
Dutch 
population 
Sequencing0 
49/79 (0.62) 
27/79 (0.34) 
22/79 (0.28) 
71/158 (0.45) 
30/158 (0.19) 
30/98 (0.31) 
Eudy et a l 5 evaluated only 18% of the ORF and identified 3 mutations These studies1024 evaluated only the presence of the pGlu767fs mutation0 
Prescreening with other techniques In italics, percentages that are related to studies that did not evaluate the entire USH2A gene In bold, the results of 
the present study and the 9 previously published Dutch USH2a families6W USH2afam, number of USH2a families, Nfam number of examined families, 
Na number of examined alleles, USH2aa, USH2A alleles 
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In three related studies, the audiometrie, ophthalmic and vestibular features of 36, 
40 and 29 USH2a patients, respectively, were analysed to detect possible 
genotype-phenotype correlations.:16':17'unPubl,shed «suits Extension of the audiometrie 
analysis described in Pennings et al.16 with 13 USH2a patients also did not reveal 
significant differences in audiometrie performance between between groups of 
patients with truncating or inactivating ÜSH2A mutations and groups with non-
inactivating IÌSH2A mutations. Since the designation non-inactivating for 
missense mutations cannot be stated definitely until more is known about usherin 
function and the number of patients per mutation was rather low in the analysis, 
we cannot exclude that genotype-phenotype correlations might be present for 
USH2a patients but we expect that the phenotypic differences between groups are 
minor. So far, only the p.Cys759Phe mutation in the ÌÌSH2A gene was shown to be 
almost exclusively associated with a specific phenotype namely non-syndromic 
RP. Only one USH2a patient is described with this mutation and the mutation in 
the second allele remained undetected.20 Also, there are two individuals 
homozygous for the p.Cys759Phe mutation who are non-symptomatic.12 Not only 
the p.Cys759Phe mutation exhibits large phenotypic variation but also the 
p.Glu767fs and the p.Arg334Trp mutations. Patients with the p.Glu767fs mutation 
can suffer from typical USH2 (homozygous and heterozygous), atypical USH with 
progressive hearing loss and variable vestibular dysfunction and RP (homozygous 
or heterozygous), RP with mild hearing loss or RP only (heterozygous).10-11 The 
p.Arg334Trp mutation when homozygously present either causes USH2 or 
atypical USH.25 These phenotypic differences together with interfamilial and 
intrafamilial differences in USH2 suggest that both genetic and environmental 
factors influence the phenotypic consequences of USH2A mutations. 
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USHER SYNDROME 
INTRODUCTION 
The Usher syndromes, named after Charles Usher, a British ophthalmologist from 
the beginning of the previous century, comprise a number of related autosomal 
recessive hereditary diseases that affect hearing, vision and in some cases, 
vestibular function. HI is congenital and of sensorineural origin. Vision is 
impaired by pigmentary retinopathy or retinitis pigmentosa (RP) and is 
characterised by childhood or adolescent onset and severe constriction of visual 
fields that ultimately leads to tunnel vision. 
Clinically, the Usher syndromes are classified into three different types.1 Usher 
syndrome type I is characterised by congenital, profound sensorineural HI with 
abnormal speech development, vestibular areflexia and RP. Usher syndrome type 
II shows moderate to severe congenital high-frequency HI, intact vestibular 
responses and RP. Usher syndrome type III involves postlingual, progressive 
sensorineural HI, variable vestibular responses and RP.2 These three clinical types 
of Usher syndrome are genetically heterogeneous and currently eleven loci 
(USH1A-USH1G, USH2A-USH2C, USH3) and six genes (USHlb-MYOZA, USHlc-
USH1C, USHld-CDH23, USHlf-PCDH25, USH2a-L/SH2A, USH3-LÎSH3) have 
been identified.3 
Owing to the observation of a high prevalence of progressive HI in the Finnish 
population of Usher syndrome patients, research into Usher syndrome type III has 
mainly been conducted in Finland. It resulted in several clinical2'4-7 and genetic811 
reports on Usher syndrome type III. Recently, the LfSH3 gene has been identified 
with three pathogenic mutations.8 Later, the genomic structure of the USH3 gene 
was revised and new mutations were identified.12-13 In view of these findings, we 
have recently performed linkage and mutation analyses on the LÎSH3 gene of 
several families with Usher syndrome. These analyses identified the first Usher 
syndrome type III family from the Netherlands with a new L7SH3 mutation. 
Phenotype and genotype characteristics of the two patients in this family are 
described below. 
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Figure 1. Pedigree of a Dutch family with a homozygous 149-152delCAGG + insTGTCCAAT 
mutation in USH3 Squares indicate men, circles indicate women. Filled symbols indicate 
affected individuals Dashed symbols indicate deceased individuals. 
PATIENTS AND METHODS 
Nearly a decade ago, two Usher syndrome patients from a Dutch family (family 
1525) agreed to participate in the Nijmegen Usher syndrome studies. In 2002, 
Patient IV:1 was a young woman aged 21 years, who was first seen at our 
outpatient clinic at age < 3 years. Patient 111:3 was a man aged 44 years, who was 
first seen at the age of 23 years. Blood samples were taken from these patients and 
their relatives and sent to the Center for the Study and Treatment of Usher 
syndrome in Omaha (Nebraska, USA) for linkage and mutation analyses. On the 
basis of the clinical findings described below, it was first decided to test the 
affected persons' blood samples for mutations in the MY07A gene responsible for 
USH1B. As no disease-causing mutations were identified in MY07A, it was 
decided to test the USH3 gene for pathogenic mutations as well. 
After informed consent had been obtained, the two patients underwent clinical 
examination according to our study protocol. This consisted of medical history 
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and audiovestibular and ophthalmological examinations. Audiometrie 
examination included standard pure-tone audiometry in a sound-treated room. 
Individual longitudinal pure-tone threshold data were analysed for progression of 
HI using linear regression analysis (threshold on age); out-of-scale thresholds and 
thresholds that could be attributed to vibro-tactile stimulation were excluded. 
Progression was considered to be significant when a significantly positive slope (P 
< 0.025) was detected for the threshold data at a sufficiently high number of 
different sound frequencies (P < 0.05 in the appropriate binomial distribution). 
Vestibular testing consisted of electronystagmography using a rotatory chair with 
computer analysis and caloric tests, as described previously.14 Saccadic, 
optokinetic and vestibular nystagmus responses were evaluated. The cervico-
ocular reflex was tested in the case of lack of a vestibular response.15 
Ophthalmological examination included corrected visual acuity measurements, 
slit-lamp microscopy and ophthalmoscopy. The fundus of patient 111:3 was 
photographed. Goldmann perimetry, using test targets V-4, III-4,1-4,1-3,1-2 and I-
1, was performed to evaluate visual fields. Visual fields were compared to the 
patterns of progressive visual field impairment described by Grover et al.16 
Electro-oculographic and electroretinographic examinations were performed as 
described previously.17·18 
RESULTS 
Genetics 
The two patients were initially diagnosed as having Usher syndrome type I on the 
basis of severe hearing loss and the inadequate speech of individual IV:1 and the 
vestibular areflexia of individual 111:3. Recently, mutation analysis of the USH3 
gene has been performed and revealed a homozygous deletion of four bases 
(CAGG) coupled with the insertion of 8 bases (TGTCCAAT) at position 149, 
leading to a frameshift in codon 50 with the creation of a stop at codon 61 in both 
patients (using the revised gene structure1213). This mutation is expected to totally 
disrupt the production of the USH3 protein. The distribution of mutations within 
this family is shown in Figure 1. Despite the homozygous mutations, 
consanguinity does not apply to this family. 
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Audiometry 
In individual IV:1, HI was first noticed at the age of 8 months. The first pure-tone 
audiogram, obtained at the age of 3 years, showed a mean threshold of 105 dB HL 
at 1, 2 and 4 kHz. At present, she is suffering from severe to profound HI and has 
the typical "speech of the deaf". Patient 111:3 has remarkably well-developed 
speech for his profound HI. His mother stated that his hearing started to 
deteriorate from the age of 4-5 years onwards. Therefore, we conclude that this 
individual had no (or only limited) prelingual HI. However, no threshold 
evaluations were available relating to prelingual age. Longitudinal analysis of 
pure-tone thresholds showed severe to profound hearing loss in both affected 
individuals. No significant progression in HI could be detected in patient IV:1 
over a follow-up period of 11 years (age 3 - 1 4 years) or in patient 111:3 over a 
follow-up period of 14 years (age 23 - 37 years) (Figure 2). Figure 3 shows the 
mean pure tone audiograms of the two patients. 
Vestibulo-ocular responses 
Individual 111:3 started walking at 13 months, which strongly suggests intact 
vestibular function at that age. However, examination at the age of 37 years 
revealed vestibular areflexia with typical cervico-ocular reflex enhancement.15 
There are no indications of a history of infectious disease or treatment with 
ototoxic drugs. Individual IV:1 started walking at the age of 14 months and had 
normal vestibular responses when examined at 13 years. Saccades and optokinetic 
nystagmus responses were normal in both patients and neither of them showed 
spontaneous or gaze-evoked nystagmus. 
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Figure 3. Mean pure-tone audiograms of patients IV:1 (mean age 8.6 years) and 111:3 (mean 
age 30.7 years). Attached arrows indicate higher-than-depicted threshold because of 
excluded out-of-scale values 
FIGURE 4a FIGURE 4b 
Figure 4. Funduscopic images of the right eye of patient 111:3 showing retinitis pigmentosa sine 
pigmento. Figure 4.a depicts the centre and figure 4.b the nasal periphery of the right eye 
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Table 1. Ophthalmological examination results of patients IV:1 and 111:3 
IV:1 111:3 
Age (yrs) 
Corrected visual acuity 
Media 
Goldmann perimetry 
EOG (Arden ratio) 
ERG 
Dark adaptation 
Fund u scopy 
14 
OD 0.5 ; OS 0 4 
ODS normal 
Field phenotype 2 
OD: 0.93 
OS: 0.76 
ODS extinguished 
Not performed 
retinitis punctata albescens 
33 
OD: 0.5 , OS: 0.6 
ODS normal 
Field phenotype 4 
OD: 0 98 
OS· 1.12 
ODS extinguished 
Subnormal 
retinitis pigmentosa sine pigmento 
OD oculo dextra, right eye; OS: oculo sinistra, left eye; ODS: both eyes 
Ophthalmological examinations 
Table 1 lists the ophthalmological examination results for individual IV:1 at the 
age of 14 years and for individual 111:3 at the age of 33 years. The best-corrected 
visual acuity measured in patient IV:1 (OD:0.5; 05:0.4) was slightly poorer than 
that in patient 111:3 (OD:0.5; OS:0.6). Both patients had a clear lens without any 
signs of cataract formation. Funduscopy in individual IV:1 showed RP with 
symmetrical, sparse bone spicules in all quadrants and small yellowish-white 
spots in the retinal pigment epithelium: retinitis punctata albescens (RPA). 
Funduscopy of patient 111:3 revealed RP without any bone spicules: retinitis 
pigmentosa sine pigmento (RPSP) as can be seen in Figure 4. Goldmann perimetry 
confirmed constriction of the visual fields, which was more severe in individual 
111:3 than in individual IV:1. At the age of 37 years, patient 111:3 showed a small 
temporal island in the left eye for the isopter at test target V-4. At the age of 13 
years, individual IV:1 showed nasal restriction and a temporal ring scotoma for 
the isopter at test target III-4. Neither patient was able to see test target 1-1. 
Therefore, patient IV:1 was judged to have field phenotype 2 while individual 111:3 
was judged to have field phenotype 4, as defined by Grover et al.16 The EOG 
Arden ratio (Lp/Dt ratio) was < 1.80, which indicates functional impairment of the 
retinal pigment epithelium. Both patients had an extinguished ERG that also 
confirmed RP. 
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DISCUSSION 
Genetics 
Although Usher syndrome type III is believed to be rare (2-4% of all Usher 
patients), it constitutes a general proportion of 40% of all Usher patients in 
Finland.5 Recently, Joensuu et al.8 have identified the ÌÌSH3 gene and three 
causative mutations. Y100X (Finma|or) is a nonsense mutation identified as the 
Finnish founder mutation in 52 Finnish families. M44K (Finmmor), a substitution of 
lysine for methionine, was encountered in two Finnish families. The c.231-
233delATT, a 3 bp deletion resulting in the substitution of one methionine for 
isoleucine and leucine at codons 77 and 78, was identified in a consanguineous 
Italian family previously linked to USH3.19 Fields et al. recently described the 
revised genomic structure of the USH3 gene and four new disease-causing 
mutations.12 Adato et al.13 described similar findings with an USH3A transcript of 
232 amino acids, however, they predicted this protein (designated clarin-1) to have 
four transmembrane domains instead of the three domains suggested by Fields et 
al.12 Adato et al. also suggested that USH3A possibly plays a role in sensory 
synapses and is expressed in mouse sensory hair cells.13 The present Dutch family 
has an additional mutation in ÜSH3 that was homozygously present in both 
subjects: 149-152deICAGG + insTGTCCAAT. 
Audiometry 
Usher syndrome type III is generally characterised by progression of sensorineural 
HI. However, no progression could be detected in either of the present two 
patients over a follow-up of over 10 years. In the Finnish patients, progression was 
found to be severe, although there was wide variation in progression and onset 
age between patients.2-4 Pakarinen et al.2 reported on 42 Usher syndrome patients, 
linked to the USH3 locus. From their Tables 1-2, listing the first and last pure-tone 
threshold (at 0.5-4 kHz), we calculated individual progression in thresholds of 0-4 
dB/year. In their Fig. 2, these authors showed serial audiograms of 3 patients. In 
two cases (Figs 2b and 2c), average progression was 2-4 dB/year at all frequencies. 
In one case (Fig. 2a) average progression was 1-6 dB/year at 0.125-1 kHz and 8-13 
dB/year at 2-8 kHz. Comparing the present data to those reported by Pakarinen et 
al.2, it would seem that our patient IV:1 had profound HI at a relatively young age. 
This patient may have had severe or profound congenital HI or have experienced 
early, severe progression. In either case, HI prohibited normal speech and 
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language development. Remarkably, Pakarinen et al.2 (1995, p. 147) reported that 
"Speech expression was either normal or slightly deviant, but in almost all cases 
good enough for communication." Consequently, Usher type III may be clinically 
misdiagnosed as Usher type I when there is early, severe HI to the degree shown 
by individual IV:1. On the other hand, Usher syndrome type III may resemble 
Usher type II when the onset of progression is relatively late and the rate of 
progression is not clearly different from that reported in USH2A patients.20 All the 
Finnish Usher type III patients were selected on the basis of clinical findings. 
However, the present two Dutch cases demonstrate that the phenotype related to 
mutations in the USH3 gene may be atypical for Usher type III and can mimic 
those of other clinical types of Usher syndrome. 
Vestibular function 
Although vestibular function is often said to be variable in Usher syndrome type 
III, there is hardly any evidence of this. The first instrumental evaluation was 
performed on four affected members of one family.6 Caloric responses were 
present in three out of the four patients. The fourth patient had spontaneous 
nystagmus compatible with periodic alternating nystagmus. Therefore it can be 
questioned whether meaningful evaluation of vestibular responses was actually 
feasible in this patient. Pakarinen et al. performed vestibular examination on 17 
patients linked to the USH3 locus. The results were normal in 9 subjects, whereas 8 
patients showed "decreased" function. One of these patients apparently had 
vestibular areflexia.2 Gasparini et al.19 mentioned that vestibular function was 
normal in their four Italian Usher type III patients, without giving any details of 
methods and findings. The available evidence suggests that although vestibular 
function may be decreased, complete vestibular areflexia is certainly not typical of 
Usher type III. This does not exclude the possibility of incidental findings of 
vestibular areflexia due to an intercurrent cause, such as infectious disease or 
treatment with ototoxic drugs. Otterstedde et al. has recently introduced a new 
clinical subtype of Usher syndrome type I that consists of profoundly deaf patients 
with normal vestibular function.21 However, their data were only based on clinical 
findings and no attention was paid to the underlying genotype. In view of the 
present findings in individual IV:1, we believe that profoundly hearing impaired 
individuals with normal vestibular responses should be tested for L7SH3 
mutations. 
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Oph thalmological findings 
Progression of visual deterioration in Usher syndrome type III occurs before the 
age of 40 years and is continuous up to that age.7 Visual fields are generally still 
normal at a mean age of 16 years, but they contain a ring scotoma at a mean age of 
22 years that breaks at a mean age of 27 years. Around the age of 30 years, tunnel 
vision will have developed, while at the age of 37 years, visual acuity will have 
dropped to below 0.05 (severely impaired).7 The present patient 111:3 had tunnel 
vision without any peripheral islands at the age of 34 years, which is in line with 
previous findings. Remarkably, patient IV:1 had a breaking ring scotoma for test 
target V-4 at the age of 14 years, which seems relatively young. 
The present two patients showed remarkable fundoscopic features: IV:1 had RPA, 
whereas 111:3 had RPSP. RPA and RPSP are both manifestations of RP. These 
findings probably do not specifically relate to the USH3 genotype; fundus findings 
of the Finnish patients were typical of pigmentary retinopathy.2 Remarkably, we 
could only find two previous reports connecting RPA to HI. Van Aarem et al.22 
described RPA in a 45-year-old USH2A patient [HI 7] who has recently turned out 
to have a C419F mutation in the USH2A gene, whereas the remaining mutation on 
the other allele remains to be identified. Her sister [H16] is also affected and has 
the same mutation, but she does not have RPA. Botelho et al.23 described the 
combination of RPA and congenital HI in two siblings aged 7 and 11 years. Usher 
syndrome was considered, but there was no clinical diagnosis and the genotype 
was undetermined. To our knowledge, there are no references in Medline on the 
combination of RPSP and HI. 
CONCLUSION 
The genotype and phenotype of two Dutch Usher syndrome patients showed that 
individual IV:1 had profound sensorineural HI already at prelingual age, normal 
vestibular responses and RPA, while individual 111:3 had profound sensorineural 
HI with remarkably well-developed speech, RPSP and vestibular areflexia. These 
findings suggest that Usher syndrome type III might be misdiagnosed as either 
Usher type I or II. This study also showed that fundoscopic forms of pigmentary 
retinopathy (RPA and RPSP) can occur in Usher's syndrome. 
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WOLFRAM SYNDROME 
INTRODUCTION 
Wolfram syndrome is an autosomal recessively inherited syndrome that was first 
described by Wolfram and Wagener in 1938. ^  It is a progressive 
neurodegenerative syndrome that is characterised by the features diabetes 
insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD). Wolfram 
syndrome is rare with an estimated general prevalence of 1:770,000 and a carrier 
frequency of 1:354.2 Minimal diagnostic criteria are juvenile-onset diabetes 
mellitus and optic atrophy both mainly manifesting in the first decade of life. 
Sixty-two percent of the patients develop central (hypothalamic) diabetes 
insipidus (in 73%) and "deafness" (hearing impairment) in the second decade of 
life. Renal tract abnormalities (58%) present in the third decade, followed by 
neurological complications (62%), such as cerebellar ataxia and/or myoclonus in 
the fourth decade. Other complications include gastro-intestinal dysmotility (24%) 
and primary gonadal atrophy. Psychiatric disorders, such as depression, psychosis 
or organic brain syndrome, as well as impulsive and physical aggression are also 
common (60%) in these patients.2 Behavioural abnormalities are usually related to 
widespread neuropathological changes in the brain of Wolfram syndrome 
patients.3 These patients have a median age at death of 30 years, which usually 
results from central respiratory failure with brainstem atrophy, infectious disease, 
or suicide.2 
Genetic studies have identified WFS1, located on chromosome 4pl6.3 as the gene 
involved in Wolfram syndrome.4-5 WFS1 codes for wolframin, a transmembrane 
protein that consists of 890 amino acids. Although its role and exact function in the 
cell still have to be unravelled, wolframin shows predominant subcellular 
localization in the endoplasmic reticulum.6 
Recently, mutations in WFS2 have been found not only to be responsible for the 
autosomal recessive Wolfram syndrome, but also for an autosomal dominant form 
of non-syndromic sensorineural HI designated DFNA6/14.7<8 Wolfram syndrome 
is characterised by high-frequency sensorineural HI, in contrast to DFNA6/14 
which is characterised by low-frequency sensorineural HI.9·10 HI in DFNA6/14 can 
be either progressive or non-progressive.10 Mutation analysis of WFS2 in families 
with DFNA6/14 revealed that the identified pathogenic mutations in this disorder 
all are small non-inactivating (missense) mutations, whereas most of the 
pathogenic mutations in Wolfram syndrome patients are inactivating mutations.11 
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A recent review by Cryns et al. demonstrated that currently 80 different WFS1 
mutations have been identified in Wolfram syndrome and DFNA6/14. These 
authors propose that homozygous or compound heterozygous missense mutation 
carriers show a relatively mild Wolfram syndrome phenotype, when compared to 
carriers of two inactivating WFS1 mutations.12 
Two major reviews on HI in Wolfram syndrome were based on clinically 
diagnosed Wolfram syndrome.913 It was decided to examine hearing ability in 
Wolfram syndrome patients with identified WFS1 mutations.14 A study of a large 
consanguineous family with four Wolfram syndrome patients, showed a 
significantly increased risk of hearing loss and diabetes mellitus, independently, in 
heterozygous carriers of WFS1 mutations.15 Another report described a 
consanguinous family with two patients with a homozygous R629W mutation in 
WFS1 and one sib who is heterozygous for this mutation.16 The heterozygous 
carrier has congenital sensorineural HI, of which the authors doubt whether it is 
associated with the WFS2 mutation. It was decided not only to examine the 
patients with Wolfram syndrome, but also their family members with the purpose 
to include audiometrie findings in related heterozygous carriers of WFSÏ 
mutations in the present report. The relatives were screened for low-frequency 
sensorineural HI, as has been described for DFNA6/14 in many publications.1017"19 
This report summarises the results of these examinations in seven families with 
Wolfram syndrome, identified by WFS1 mutations. 
PATIENTS AND METHODS 
Subjects 
In this study, 33 members of seven families (WF1-WF6 and WF10) with Wolfram 
syndrome were examined, including 11 affected and 22 unaffected individuals. 
Figure 1 shows the pedigrees of these families and the individuals examined. 
Eleven patients from seven families were diagnosed to have Wolfram syndrome 
on the basis of clinical findings (at least diabetes mellitus and optic atrophy) and 
the identification of at least one mutation in WFSL After written informed consent 
had been obtained, medical history was taken in all 33 examined individuals and 
focused on features of Wolfram syndrome. 
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Figure 1 Pedigrees of seven families with Wolfram syndrome (WF1-WF6, WFIO). 
squares, male; circles, female; filled symbols indicate affected individuals; dashed symbols 
indicate deceased individuals; NE, not evaluated. 
Genetic details on mutation analyses of the families WF1-WF6 have been 
described elsewhere.14 Mutation analysis of the unaffected relatives identified 17 
carriers of heterozygous mutations in WFSI and 4 non-carriers. In 6 of the 7 
families both disease-causing mutations in WFS2 were identified, whereas only 
one mutated allele was found in family WF2, however, intronic and regulatory 
regions were not examined in this family; mutations in these regions cannot be 
excluded and neither can mutations in a gene other than WFS1. Two families (WFI 
and WF3) reported consanguinity and mutation analysis identified homozygous 
mutations in WFS1 (WFI: 460+1OA, WF3: Y508-L512del). In family WF2 only one 
mutation in WFS1 was identified: Y528fsX542. Two compound heterozygous 
mutations in WFS1 were identified for individual 11:1 from family WF4: Y508-
L512del and V412fsX440. In family WF5 two missense mutations were identified 
in WFSÏ: D211N and P607R. These two missense mutations do not result in 
inactivation of the WFS1 gene, which is the case in the identified mutations in all 
other families. In family WF6 the homozygous V509fsX517 mutation was 
identified in patient 11:1. In family WFIO, compound heterozygous mutations in 
WFSÏ (Q667X and V142fsX251) were identified, which are known to be pathogenic 
in other families previously described.20-21 
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Audiovestibular evaluation 
All 33 examined individuals underwent otoscopy and standard audiometrie 
examination consisting of pure tone audiometry according to International 
Standards Organization (ISO) standards, which included air and bone conduction 
thresholds for the octave frequencies 0.25 - 8 kHz. Bone conduction levels were 
evaluated to exclude conductive hearing loss. When HI was detected, speech 
audiometry was performed by presenting a standard monosyllabic Dutch word 
list at either ear and analyzed as previously described.21 Two patients from family 
WF3 (11:5 and 11:6) underwent Brainstem Evoked Response Audiometry (BERA) 
following normal standards and six patients (WF3, 11:5 and 11:6; WF6, 11:1; WF2, 
11:2; WF10, 11:2 and 11:3) underwent vestibular examination with a rotatory chair 
and electronystagmography as previously described.23 
Statistical analyses 
Last-visit pure tone threshold data (binaural mean air conduction threshold) were 
used for cross-sectional linear regression analysis (threshold on age). Progression 
at a given sound frequency was designated significant when a significant positive 
slope (P < 0.025, Student's t test) was found. Significant progression of HI was 
concluded to exist if significant positive slopes were found in a significantly high 
relative frequency of the measured sound frequencies (P < 0.05) according to the 
appropriate binomial distribution. 
Linear regression analysis of longitudinal individual threshold-on-age data 
(binaural air conduction level) was applied to analyse individual progression of 
HI (Figure 4). The slope was called annual threshold deterioration (ATD) and 
expressed in dB/ year. 
Analysis of covariance (ANCOVA) was performed to compare between slopes 
and intercepts of the regression lines pertaining to individual threshold 
measurements as per frequency. Where a pooled regression line could not be 
derived following this procedure, a trend line was visually fitted (Figure 4). The 
"fit" of the trend line was performed using two criteria: (1), about equal numbers 
of patients, whether followed up or measured only once, had to have thresholds 
better or worse than predicted by this line; (2), about equal numbers of the 
patients followed had to show progression higher or lower than indicated by the 
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trend line. It should be noted that the Y intercept was varied in steps of 10 dB. The 
parameters of the trend lines (slope and Y intercept) were used for constructing 
ARTA, depicted in Figure 5. For each patient concerned, it was checked whether 
the thresholds predicted for a given age conforming to the ARTA data fitted well 
to the observed threshold data (Figure 2, marginal ages indicated). 
Student's t test was used to compare mean pure tone thresholds at a given 
frequency between relevant pairs of subgroups (e.g. males vs. females); this test 
included Welch's correction if Bartlett's test detected unequal variances. The level 
of significance used was Ρ = 0.05 (Figure 3A). The same test was used to check 
whether or not any significant difference in threshold could be explained by a 
difference in age between the subgroups involved (Figure 3B). 
Cross-sectional binaural mean speech recognition scores were plotted against age 
and binaural mean PTAi,2,4 kHz level. Nonlinear regression analysis was used to fit 
nonlinear dose-response curves with variable slope as previously reported.22 The 
90%Correct score (X90) was designated onset age for X=age and onset level for 
X=PTAi,2,4 kHz (pure tone average at 1, 2 and 4 kHz). The slope was called 
deterioration rate in the performance-age plot and deterioration gradient in the 
performance-impairment plot. To simplify the results, "local average" slope (i.e. 
on a linear scale) for X>X9o was obtained by fitting a straight line as previously 
reported, using a nonlinear method to estimate X90 with 95% confidence intervals 
(95% CI) (Figure 6).24 
RESULTS 
The onset age and clinical features of the Wolfram syndrome patients are shown 
in Table 1 and some of these have been described previously.14-25 Figure 2 shows 
the audiometrie data (single and serial observations) obtained for all patients with 
Wolfram syndrome and their non-affected heterozygous relatives (carriers) with 
one WFSI mutation, arranged by family. Only one of the heterozygous carriers of 
WFSÏ mutations (WF3, 1:2) showed HI; since long she suffered from chronic 
suppurative otitis media and had developed bilateral maximal conductive hearing 
losses (Figure 2). Occlusion of the ear canals by the earmolds of conventional ear 
conduction hearing aids caused persisting otorrhoea, therefore a bone-anchored 
hearing aid (BAHA) was applied with success. None of the other examined 
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individuals showed an air-bone gap and all other carriers had normal hearing for 
their age. A remarkable difference between the degree of HI in male and female 
sibs was noticed within the families WF1, WF3 and WF10. Patients 11:1 and 11:4 
from family WF5 had normal hearing for their age and two non-inactivating 
missense mutations in WFS1 and therefore were excluded from the analysis. They 
only had mild features of Wolfram syndrome and developed diabetes mellitus at 
young age, but optic atrophy not before age 26-28 years. (Table 1) So far, they 
showed no additional features of Wolfram syndrome. 
The results of the cross-sectional analysis were analysed following the exclusion of 
the male patients, as well as the two female patients (WF5, 11:1 and 11:4) with 
normal hearing. No significant progression of HI at increasing age was found 
(data not shown). The possibility cannot be excluded that the lack of significance 
related to the small number (n=5) of the cases. The pooled ATD was 3.8 dB/year. 
Student's t test comparing the mean binaural threshold data for the female group 
(n=5) and the male group (n=4) of Wolfram syndrome patients demonstrated 
significantly more HI, predominantly in the mid-frequency range, in the female 
patients with Wolfram syndrome (Figure 3A). 
This difference is unlikely to have been caused by a difference in age between the 
two evaluated patient groups (Figure 3B). Longitudinal and single snapshot 
threshold data of all female patients are depicted in Figure 4. In Table 2 the serial 
data of the longitudinal analysis in six patients are described. Five of these 
patients were found to have significant progression of HI, whereas this was not 
the case in individual 11:2 from family WF1, who probably experienced 
progression of HI before the first measurement (Table 2, Figure 2). The dashed 
trend lines in Figure 4 visualise the ATD (dB/year) per frequency for all patients. 
The Y intercept and the slope of the trend line (Figure 4) were used to construct 
the ART A, which showed remarkable progression of mid- and high-frequency HI 
leading to severe to profound HI within the first decades of life (Figure 5). The 
dotted lines in Figure 2 indicate the predicted threshold for female Wolfram 
syndrome patients (based on the ARTA of Figure 5) at the specified age. The 
slopes of the trend lines for the low frequencies (0.25 and 0.5 kHz) were in the 
range of 1.5-2.0 dB HL/year, whereas the slopes for mid- and high-frequencies 
were in the range of 4.0-4.5 dB HL/year. 
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Table 1 Clinical findings and onset age m 11 patients with Wolfram syndrome 
Family 
patient 
WF1 
112 
113 
WF2 
112 
WF3 
115 
116 
WF4 
I I I 
WF5 
I I I 
114 
WF6 
I I I 
WF10 
112 
113 
Age 
(y) 
28 
22 
20 
32 
30 
35 
47 
42 
28 
25 
23 
Sex 
F 
M 
F 
M 
F 
F 
F 
F 
M 
M 
F 
Cons 
yes 
yes 
no 
yes 
yes 
no 
no 
no 
no 
no 
no 
DM 
3 
3 
5 
1 
4 
4 
10 
12 
4 
2 
8 
Onset 
OA 
22 
11 
6 
10 
13 
8 
28 
26 
12 
8 
9 
tAge 
D 
7 
13 
11 
9 
12 
9 
45 
NA 
25 
24 
10 
DI 
18 
19 
11 
6 
NA 
4 5 
NA 
NA 
11 
8 
16 
Renal tract 
abnormalities 
(onset age) 
yes (7) 
no 
yes (11) 
yes (20) 
yes (13) 
no 
no 
no 
yes (17) 
no 
no 
Neurologic abnormalities 
(onset age) 
none 
Seizures 
Cerebellar atrophy, bilateral extensor 
Peripheral 
responses 
Anosmia 
none 
Peripheral neuropathy * 
none 
none 
none 
plantar 
1 neuropathy \ Anosmia (8), Dysphagia (21) 
none 
Additional complications 
(onset age) 
Paranoid depression 
Depression 
none 
Pulmonal stenosis (18), 
Primary gonadal atrophy 
None 
Irritable bowel syndrome 
none 
Hypothyroidism, 
Hypertension 
Scoliosis, 
Primary gonadal atrophy 
Primary gonadal atrophy 
Depression (16) 
cons, consanguinity, D, deafness, DI, diabetes insipidus, DM, diabetes mellitus, F, female. M, male, OA, optic atrophy, NA, not applicable, y, years, +, 
secondary to diabetes mellitus (Table is modified from Van den Ouweland et al, 2002)14 
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Figure 2 Individual, m some cases serial, (binaural mean) pure-tone audiograms from affected 
(patient) males (m) and females (f) and non-affected WFSl mutation-carrying individuals (earner). 
A selection of serial audiograms was made if necessary for clarity. Dotted lines indicate estimated 
pure-tone thresholds at the age(s) of examination as indicated, relating to women with Wolfram 
syndrome and inactivating WFSl mutations. Crosses in individual 1:2 from family WF3 indicate 
binaural mean bone conduction thresholds. Age (in years) of examinations are depicted at the right 
of the audiograms. 
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Frequency (kHz) 
Figure 3 Comparison of binaural mean pure-tone thresholds per frequency (A) between four 
male patients (squares) and five female patients (circles, patients II 1 and II 4 from WF5 
excluded) with Wolfram syndrome Ρ values are depicted in italics and bold figures indicate 
significance Comparison of age between both groups is also depicted (B) 
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regression lines are included; bold lines mark significant progression. Snapshots (filled circle) of two 
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Age (year) in italics 
Table 2 Annual Threshold Deterioration (in dB HL/year) by frequency in six patients with 
Wolfram syndrome 
Patient 
WF1,112 
WF3,115 
WF3, II 6 
WF4, II1 
WFIO, II 2 
WF10, II 3 
0 25 kHz 
04 
06 
14 
-0 4 
21 
12 
0 5 kHz 
08 
15 
12 
02 
16 
39 
1kHz 
01 
30 
20 
16 
02 
54 
2 kHz 
03 
10 
26 
25 
38 
50 
4 kHz 
04 
11 
3 5 
31 
40 
41 
8 kHz 
-
45 
33 
30 
18 
33 
Bold figures indicate significant progression, male patients m italics 
Speech recognition scores are depicted in Fig 6. After exclusion because of 
outlying values of individuals 11:1 and 11:4 from family WF5 in the performance 
versus age plot there was significant deterioration in speech recognition score with 
increasing age (Figure 6A). The speech recognition score also deteriorated 
significantly with increasing PTAi,2,4 kHz (Figure 6B). The onset age was 21 year 
(95% CI: 19-24 year) and the onset level was 78 dB HL (95% CI: 64-96 dB HL). The 
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deterioration rate (Figure 6A) was 4.0 % per year (95% CI: 2.6-5.3 %/year) and the 
deterioration gradient (Figure 6B) was 1.4 % per dB HL (95% CI: 0.2-2.9 %/dB 
HL). 
100 
o 
υ 
30 40 
Age (yrs) PTA,,2,4kHl(dBHL) 
Figure 6 Cross-sectional analysis of speech recognihon score relative to (A) age (year) and (B) PTAi 2^  kHz (dB 
HL) in 11 Wolfram syndrome patients. Regression lines apply to female patients only. Scores for the 
individuals II1 and 114 from family WF5 are shown as well, they were fully normal and therefore represent 
outlying values (small symbols) in the performance-age plot (A). The scores for the male patients (squares) 
demonstrate almost non-impeded speech recognition 
Vestibular function was evaluated in six patients. In all but one patient (WF10, 
11:3) optokinetic nystagmus responses could not be elicited because of substantial 
visual impairment. Four of the six individuals had normal vestibulo-ocular 
function. One individual had a hyperactive vestibulo-ocular reflex with 
asymmetry. One individual (WF6, 11:1) had vestibular areflexia and an enhanced 
cervico-ocular reflex. BERA was performed in both patients from family WF3 and 
showed no evidence of retrocochlear pathology. 
DISCUSSION 
The present audiovestibular study of families with Wolfram syndrome is the first 
one based on the identification of mutations in the WFS2 gene. This study 
examined 11 patients with Wolfram syndrome from seven families. Patients 
generally showed progressive mid- and high-frequency sensorineural HI. Two 
patients (WF5; 11:1 and 11:4) showed exceptionally well preserved hearing for their 
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age. Their data are presented but were excluded from the analyses on the basis of 
their genotype (more details below). Within the families WF1, WF3 and WF10 a 
remarkable difference in HI between the male and female sibs was noticed (Figure 
2). Further comparison of the degree of HI between male (n=4) and female (n=5) 
patients with Wolfram syndrome caused by inactivating WFS1 mutations revealed 
that the female patients showed significantly more HI than the male patients 
especially in the mid-frequency range (Figure 3). Analyses of speech recognition 
scores of the female patients (n=5) revealed early onset at a relatively high level of 
HI; recognition scores deteriorated fairly rapidly with advancing age and an onset 
level of 78 dB HL (Figure 6). BERA, performed in two patients, showed no 
evidence of retrocochlear pathology, similar to previously reported findings.13 
Two patients from family WF5 with virtually normal hearing were excluded from 
the analyses because they had remarkably mild symptoms and signs of Wolfram 
syndrome, anyway, at a relatively high age (43 and 48 years) associated with two 
missense mutations in WFS1 (D211N and P607R). They were the only patients 
having two missense mutations in our patient group; all other identified PVFS2 
mutations lead to the inactivation of the entire gene. Probably, the combination of 
two missense mutations or these two specific mutations in WFS1 result in full-
length wolframin formation with poor functionality that leads to a milder 
phenotype of the Wolfram syndrome, as was already suggested by Cryns et al.12 
Young et al.8 reported that a homozygote from a DFNA6/14 family had type I 
diabetes mellitus at age 3 years. There was no evidence of optic atrophy at age 25 
years. This individual also had mild sensorineural HI of 20-30 dB HL at 500 and 
4000 Hz. When his symptoms are compared to the observations in individuals 11:1 
and 11:4 from the present family WF5, it can be suggested that he might develop 
optic atrophy in the next five to ten years. 
In this study, 17 heterozygous carriers of WFSÎ mutations were examined for HI 
similar to that found for DFNA6/14. None of the mutation-carrying relatives 
showed low-frequency sensorineural HI (Figure 2). A previous study15 showed 
that heterozygous carriers of WFSÎ mutations from one large consanguineous 
family had a significantly increased risk of HI, however, these data were not 
confirmed in our study of the present Wolfram syndrome families. Low-frequency 
sensorineural HI in DFNA6/14 is mainly caused by small non-inactivating 
missense mutations particularly located in the intracellular domains of 
wolframin.11 To date, only two missense mutations (K193Q and K634T) have been 
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described to cause DFNA6/14 and not to be located in the C-terminal domain of 
the transcript.11-26 The presently identified D211N missense mutation in family 
WF5 is, like K193Q, located in the N-terminal domain of the protein, however, it is 
not associated with low-frequency HI in the heterozygous carrier 1:1 of this family. 
Further genetic research is needed to explain the differences between Wolfram 
syndrome and DFNA6/14 and the function of wolframin. 
An intriguing finding in the present study was that among the patients with 
inactivating WFS1 mutations the affected women showed significantly more HI 
than the affected men (Figure 3). This was also evident from sibwise comparisons 
in families WF1, WF3 and WF10 (Figure 2). The predicted thresholds (based on the 
examination results of 5 female patients) relative to age are shown as dotted lines 
for all Wolfram syndrome patients in Figure 2.· All 4 male patients showed better 
hearing relative to their age than would be predicted if they werefemale patients 
(Figure 2, dotted lines applying to indicated ages). The two excluded female 
patients (WF5,11:1 and 11:4) showed normal hearing for their age, much better than 
predicted. Only female patient WF2, 11:2 had better hearing than would be 
expected for her age. On the basis of our examinations we suggest that her hearing 
might deteriorate progressively in the next coming years. In a separate evaluation 
of the literature (data and references not shown;n=20 families, 26 male and 24 
female patients) no substantial difference in onset age of diabetes mellitus, 
diabetes insipidus, optic atrophy as well as deafness between male and female sibs 
from one family could be found. 
We speculate that the apparent sex-related difference in HI between female and 
male Wolfram syndrome patients in the present study might be explained by the 
involvement of sex hormones. Several studies have shown that estrogen is 
important for inner ear homeostasis. In Turner syndrome patients (XO), a 
progressive dip in the mid- frequencies in combination with early-onset age-
related high-frequency sensorineural HI is detected. Progression has been 
documented in 61 % of the Turner syndrome patients aged over 35 years, whereas 
a quarter of them requires hearing aids.27 These patients do not produce estrogen 
and have ovarian dysfunction. Another study has shown that estrogen not only 
has a nuclear regulating function but also acutely inhibits ion transport by isolated 
stria vascularis. Estrogen decreases the secretion of K+ by the inhibition of 
potassium channels through a nongenomic action mechanism that leads to 
inhibition of ion transport.28 Several studies already emphasised the importance of 
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nongenomic actions of estrogen in the body. It is believed to play a role in 
neuroprotection of the brain,29 the release of insulin from the pancreatic 
Langerhans islets,30 and may also be involved in psychiatric diseases like 
Alzheimer's disease and schizophrenia.'11 These findings are in support of a 
hypothesis that nongenomic actions of estrogen are involved in the 
pathophysiology of Wolfram syndrome. We believe that wolframin plays a crucial 
role in the rapid intracellular responses of estrogen. Nongenomic actions of 
estrogen result in an intracellular Ca2+ increase, that mediates several intracellular 
messenger actions. A Ca2+ activated ATPase pump is located in the membrane of 
the endoplasmic reticulum and seems to be involved in this process as well. 
Possibly, the nongenomic effect of estrogen on this pump results from an 
interaction with the wolframin transmembrane protein that is also located in the 
membrane of the endoplasmic reticulum. However, the exact role of wolframin in 
the target organs and inner ear has to be unravelled before any such hypothesis 
can be confirmed or rejected. 
The performance-age plot of the analysed speech recognition scores showed that 
Wolfram syndrome has an early onset deterioration (21 years) and a fairly high 
deterioration rate (4.0 %/year, Figure 6A). The described deterioration rate is 
comparable to that reported for presbyacusis, although presbyacusis is 
characterised by later onset at about age 75 years."52 The performance-impairment 
plot (Figure 6B) shows that Wolfram syndrome patients have remarkably well 
preserved speech recognition for the degree of HI, as long as they have not yet 
developed profound deafness. The onset level (95% score) in Wolfram syndrome 
patients was 78 dB HL, whereas previously reported onset levels were 46 dB HL 
for DFNA9 and 65 dB HL for DFNA2 patients. Although speech recognition 
started to deteriorate in Wolfram syndrome patients at a substantially higher level 
of HI than in DFNA9, the deterioration gradient in Wolfram syndrome showed 
more similarity to DFNA9 rather than DFNA2 (Wolfram, 1.4%/dB; DFNA9, 1.2 
%/dB; DFNA2, 0.5 %/dB).32 
To date only a few studies have examined vestibular function in Wolfram 
syndrome patients.913 Although Wolfram syndrome is a progressive 
neurodegenerative disorder that also includes polyneuropathy, only limited data 
are available regarding the involvement of the vestibulocochlear nerve. The 
present study adds data on six patients who underwent electronystagmography. 
In one patient vestibular areflexia was detected. Previous case reports (n=8) have 
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described findings of vestibular hyporeflexia.913 Vestibular areflexia, however, has 
not been reported previously and may be an atypical finding in patient 11:1 from 
family WF6. In another 8 patients normal vestibular function has been described 
prevously.913 These findings seem comparable to the present study and therefore 
we conclude that there is no firm evidence of vestibular dysfunction in Wolfram 
syndrome patients. 
The present audiovestibular study of families with Wolfram syndrome is the first 
study based on mutation analysis of WFS1. It concludes that in patients with 
inactivating mutations progression of HI mainly occurred in the mid- and high-
frequency range. Female patients with Wolfram syndrome showed substantially 
more HI than male patients, including their sibs with the same mutation and 
genetic background. We speculate that this difference can be explained by the 
involvement of wolframin in nongenomic actions of estrogen resulting in 
intracellular Ca2* increase and thus influencing inner ear homeostasis. Speech 
recognition scores showed a similar degree of age-related deterioration as in 
presbyacusis, however with a much earlier onset of HI. The type of deterioration 
of speech recognition in Wolfram syndrome patients showed some characteristics 
with the types found in DFNA2 and DFNA9 patients. 
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DFNA6/14 
INTRODUCTION 
Thirty-four years ago, the Vanderbilt University Hereditary Deafness Study group 
reported on a large family with remarkable low-frequency sensorineural HI with 
an autosomal dominant pattern of inheritance.1 Konigsmark et al. described 
several years later three more families harbouring a dominant low-frequency HI 
trait.2 All families generally displayed an upward-sloping audiogram pattern. 
Nowadays, however, characterisation of nonsyndromic forms of hereditary HI 
tends to be more based on genetic characteristics than on clinical findings. The 
different loci for nonsyndromic autosomal dominant forms of HI are designated 
DFNA (DFN for deafness and A for autosomal dominant) and numbered in 
chronological order of discovery. Today 40 loci are known to cause autosomal 
dominant nonsyndromic HI.3 Only two of them, DFNA1 and DFNA6/14, are 
characterised by predominant low-frequency HI. 
Recently, it became apparent that the WFS1 gene harbours heterozygous 
mutations in DFNA6 as well as DFNA14 and that DFNA6 and DFNA14 represent 
the same locus further designated as DFNA6/14.4 Homozygous mutations in the 
WFS1 gene account for the autosomal recessive Wolfram syndrome.5·6 To date, 
three families with a heterozygous mutation in the WFSl gene have been clinically 
described: USA1 (L829P mutation4), Dutch F (T699M4) and Dutch II8 (A716T4). All 
showed mild progression of HI, however, in only one family (Dutch II) this was 
beyond presbyacusis.9 Brodwolf et al.10 recently introduced a German DFNA6/14 
family harbouring a low-mid frequency HI, based on linkage. Young et al. 11 
recently described a Newfoundland kindred harbouring the same WFS2 mutation 
(A716T) as detected in family Dutch II. 
This report describes the type of HI in two additional Dutch DFNA6/14 families 
(Dutch III and Dutch IV) that harbour two different mutations in the WFS1 gene, 
G674E and G674V respectively. 
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Figure 1. Pedigrees of the families Dutch III and Dutch IV. Square, man; circle, woman; dashed symbol, 
deceased; crossed symbol, Duchenne-type muscular dystrophy; filled symbol, low-frequency hearing 
impairment 
244 
DFNA6/14 
PATIENTS AND METHODS 
In two Dutch families, Dutch III and Dutch IV (Figurel) the WFS1 gene was 
analysed for mutations, because both families disclosed typical low-frequency 
tone audiograms. Four affected individuals from family Dutch III have a G674V 
mutation and in eight affected individuals from family Dutch IV the G674E 
mutation was found.12 From the pedigree it was concluded that the deceased 
individual 111:2 from family Dutch IV harboured the same mutation as the other 
affected persons in this family. 
In this study we establish the audiometrie profile and speech recognition 
performance in DFNA6/14 at various ages. Medical history was taken, especially 
focusing on acquired and syndromic conditions. Otoscopy was performed and 
previous audiologic data were retrieved, including data of one deceased 
individual (111:2 of family Dutch IV). Pure tone (binaural mean of air and bone 
conduction) threshold (octave frequencies 0.25-8 kHz) and speech recognition 
scores (mean of monaural maximum phoneme scores) were assessed in a sound 
treated room according to the norms defined by the International Organization for 
Standardization (ISO).1314 In one case (111:3 of family Dutch IV) the data of one ear 
(left) were excluded because of previous ear surgery. 
Cross-sectional linear regression analysis (threshold on age) was performed on 
last-visit data using the Prism 3.02 program (GraphPad, San Diego, CA, USA). 
Progression (slope) was evaluated in relation to presbyacusis. Progression was 
called significant when a significant positive slope (P < 0.025) was detected for the 
raw threshold data at a sufficiently high number of different sound frequencies (P 
< 0.05 in the appropriate binomial distribution). The significance of progression 
was also evaluated for threshold data including individual (age- and sex-related) 
correction for median (P50) presbyacusis according to the ISO 7029 norm.15 
ARTA were derived from the results of the cross-sectional regression analysis (raw 
data). Individual longitudinal regression analysis, also including correction for 
presbyacusis, was performed in three cases (111:1, IV:1 and IV:2 of family Dutch 
III). 
Cross-sectional regression analysis of speech audiometry data involved maximum 
phoneme recognition scores (%Correct) derived from individual performance-
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intensity plots. Regression analysis was performed for performance-age plots 
(score on age), as well as performance-impairment plots (score on average of pure 
tone thresholds at 0.5,1 and 2 kHz, i.e. PTA()5-2 kHz. Speech recognition scores were 
fitted by a linear regression line. The X coordinate relating to the 90%Correct score 
(X90) was called onset age for X = age and onset level for X = PTAo 5-2 kHz. The 95% 
confidence interval for X90 was obtained by performing nonlinear regression 
analysis using the alternative equation for the linear regression line, Y = slope(X-
X90) + 90. Student's t test (including Welch's correction if Bartlett's test detected 
unequal variances) was used to test on differences in X90 between the families. 
Slope was called deterioration rate for X = age and deterioration gradient for X = 
PTAo 5-2 kHz. 
Analysis of covariance (ANCOVA) was used to compare slopes and intercepts 
between different regression lines pertaining to either different frequencies within 
a given family or pertaining to the families at a given frequency. Slopes and 
intercepts were pooled if that was allowed for. 
Vestibulo-ocular responses were evaluated in two cases (IV:2 and IV:5 from family 
Dutch IV) using electronystagmography with computer analysis. Saccadic, smooth 
pursuit, optokinetic and vestibular nystagmus responses were evaluated. 
Vestibular stimulation comprised rotatory and caloric tests. Details and normal 
values have been previously described.14 
RESULTS 
Four individuals from family Dutch III and nine individuals from family Dutch IV 
showed low-frequency HI. Family Dutch IV also harbours a Duchenne-type 
muscular dystrophy trait: three affected boys (Figure 1, crossed symbols) died at 
young age without any HI by history. 
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Figure 2. Cross-sectional analysis of binaural mean air conduction threshold (dB HL) for family 
Dutch IV (open symbols) related to the patient's age (year) Regression lines are included, dotted 
lines relate to age-corrected threshold (small asterisks) Bold lines indicate significant 
progression Threshold data for family Dutch III are also included (dots and small crosshair 
symbols), however, without the corresponding regression lines. 
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Cross-sectional analysis (threshold on age) was performed in both families. The 
main results are shown in Figure 2. The family Dutch III (dots) did not reveal 
substantially different scattering of threshold data points compared to family 
Dutch IV (circles). Both families showed significant progression (bold lines in 
Figure 2, pertaining only to family Dutch IV). Family Dutch IV revealed no 
significant difference in progression between the frequencies (raw data, pooled 
ATD 1.0 dB/year). There was no significant difference in progression (raw data) 
between the families as tested for each separate frequency. However, following 
correction for presbyacusis, family Dutch IV (small asterisks) still showed 
significant progression, whereas this was not the case for family Dutch III (small 
crosshair symbols). 
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Figure 3. ARTA for five different DFNA6/14 (A present, Β previously reported1-7·8) families 
arranged according to the WFS1 mutation.·1'12 Age (year) in italics. 
ARTA for these two families displayed an ascending audiometrie configuration 
from low-frequency thresholds (fairly flat at 0.25-1 kHz) of about 40-70 dB in 
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family Dutch III and 40-90 dB in family Dutch IV (Figure 3a). The flat threshold 
configuration included 2 kHz in family Dutch III. In the younger individuals, the 
thresholds at 4-8 kHz were generally close to normal, especially in family Dutch 
IV. 
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Figure 4 Longitudinal analyses (raw threshold data) for separate frequencies (0 25-8 kHz) in the 
individuals III 1, IV 1 and IV 2 from family Dutch III Bold lines indicate significant progression 
In three cases (111:1, IV:1 and IV:2 of family Dutch III) longitudinal regression 
analysis of pure tone audiograms could be performed. Significant progression was 
detected in all of them (Figure 4) and was also resistant to correction for 
presbyacusis. ARTA derived for these longitudinal analyses (plots not shown) 
appeared to be fairly similar to those obtained for the cross-sectional analysis 
(Figure 3a). 
Figure 5 covers the analyses pertaining to speech recognition scores (performance-
age plot left, performance-impairment plot right) for the families Dutch III (dots) 
and Dutch IV (circles). The regression lines in the left panel show a fairly slow 
decrease in score with increasing age. Onset age for family Dutch III was 25 year 
(95% confidence interval 16-34 year); the deterioration rate was 0.8 %/year (95% 
confidence interval 0.5-1.1 %/year). The parameter values for family Dutch IV 
were fairly similar: onset age 28 year (95% CI 18-38 year) and deterioration rate 0.5 
%/year (95% CI 0.1-0.9%/year). A significant difference in performance between 
the families was only found in relation to the level of impairment (Figure 5, right). 
In family Dutch III (dashed line), the deterioration gradient was almost 2%/dB 
with a 95% confidence interval of 1.4-2.6%/dB. In family Dutch IV (continuous 
line), it was 0.45%/dB with a 95% CI of 0.3-0.6%/dB. There was no significant 
difference in onset level between both families (Dutch III, 58 dB HL with 95% CI 
55-61 dB and Dutch IV, 51 dB with 95% CI 42-60 dB). 
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Figure 5 Cross-sectional analysis of mean phoneme monaural (right and left) recognition score 
(%Correct) related to age (in year, left panel) and (binaural mean) PTAo5 2 kiiz (in dB HL, right panel) 
for family Dutch III (filled symbols) and family Dutch IV (open symbols) Linear regression lines are 
shown with a Roman figure indicating the family Dotted lines and bold figures relate to the 
90%Correct score 
None of the patients reported any consistent vestibular symptoms and the two 
individuals examined, showed normal ocular motor and vestibular responses. 
DISCUSSION 
The Dutch III (longitudinal analyses) and Dutch IV (cross-sectional analyses) 
families showed similar progression that persisted after correction for 
presbyacusis. On evaluation of speech recognition scores, the performance-
impairment plots were significantly different between the 2 kindreds, while the 
performance-age plots were fairly similar. 
Although nonsyndromic autosomal dominant HI is a heterogeneous condition, 
the subgroup of loci predominantly affecting the lower frequencies is 
homogeneous to some extent. DFNA1 was the first locus identified with a 
nonsyndromic autosomal dominant HI trait. It is located on chromosome 5q31 and 
is characterised as a progressive low-frequency type of HI.17·18 Lynch et al.19 
identified the responsible mutation in the DIAPH1 gene in a large Costa Rican 
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family. To our knowledge, no other families showing linkage to the DFNA1 locus 
have been described. 
Lesperance et al.20 identified a second locus for dominant low-frequency HI 
(DFNA6) on chromosome 4pl6.3 in the American family in whom the 
corresponding phenotype had been outlined by the Vanderbilt University 
Hereditary Deafness Study Group.1 Predominant involvement of the frequencies 
0.25-1 kHz was found. Recently, the raw data published in that report were re-
analysed in a cross-sectional analysis and no significant progression beyond 
presbyacusis was found.8 
In the Dutch I family. Van Camp et al.21 discovered a third locus (DFNA14) 
associated with low-frequency sensorineural HI on chromosome 4pl6.3, close to 
the DFNA6 locus but without an apparent overlap. Kunst et al.7 described the 
audiometrie presentation in this Dutch I family and demonstrated progression of 
HI but not beyond that attributable to presbyacusis. 
The Dutch II family was linked to a larger chromosomal region comprising both 
DFNA6 and DFNA14. Progression was mild but significant, and ranged from 0.5 
dB/year at 0.25 kHz to 1.3 dB/year at 8 kHz. Significant progression persisted 
after correction for presbyacusis.9 Recently Brodwolf et al.10 described an 
additional family linked to DFNA6/14 showing a non-progressive low-frequency 
HI. Young et al.11 have reported another low-frequency HI trait, designated 
DFNA38, in a Newfoundland family harbouring the same mutation (A716T) in the 
PVFSÏ gene as was found in the Dutch II family. 
ARTA for the clinically described families are depicted in Figure 3; they 
demonstrate 2 types, with (G674V and A716T) and without (T699M and L829P) 
progression beyond presbyacusis at low frequencies (0.25-1 kHz). The G674E 
mutation (Dutch III) seems to have caused a progression that is intermediate 
between these 2 extremes. Cross-sectional analysis of this family did not indicate 
progression after presbyacusis correction, but this may have been because of a lack 
of sufficient number of observations. However, longitudinal analysis in 3 
individuals from this family, involving more observations, demonstrated 
progression beyond presbyacusis. 
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Speech recognition scores have also been evaluated for some individuals of the 
Dutch II family.9 The scores for younger individuals (< 32 years) were within the 
90% tol00% range, which is in line with the mean onset ages of 25 and 28 years 
found for the Dutch III and IV families, respectively. The mean onset levels for 
these 2 families ranged from 50 to 60 dB HL. There was no substantial difference 
in pure-tone audiogram findings between the Dutch HI and IV families, although 
the 2 kHz threshold appeared to be more affected in the Dutch III family (i.e. in 
line with a flat threshold at 0.25-2 kHz). Speech performance scores relative to age 
were not substantially different. However, a significant difference in speech 
performance relative to the level of HI was detected. This difference may have 
been related to the worse pure-tone threshold found at 2 kHz in the Dutch III 
family. 
The point mutations in these 2 families cause a missense mutation of the same 
amino acid, G674. This glycine is substituted by glutamic acid in the Dutch III 
family and by valine in the Dutch IV family. The phenotype relating to the A716T 
mutation4 was similar to that in these families. 
Recently, it was demonstrated in 7 families that heterozygous mutations in the 
WFSI gene are responsible for traits linked to DFNA6/14.4 In the original family 
demonstrating DFNA6, a key recombinant that excluded the DFNA14 candidate 
region had actually been based on a phenocopy. This led to an incorrect 
localisation of DFNA6, while in fact DFNA6 and DFNA14 represent a single locus. 
The WFSÎ gene encodes the protein wolframin and is homozygously mutated in 
the Wolfram or DIDMOAD (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy 
and Deafness) syndrome. The minimum features required for the diagnosis are 
type I diabetes mellitus and optic atrophy. However, diabetes insipidus (described 
in 54-58% of cases) and "deafness" (described in 51-62%) are also common 
features of this syndrome.22 This autosomal recessive syndrome seems to be 
associated with a high-frequency HI rather than the low-frequency impairment 
found in the present families.23'24 This rare syndrome has a prevalence of 1 in 
770,000 in the United Kingdom.25 Wolframin, encoded by WFSI, is a 
transmembrane protein.5·6 It has been localised to the endoplasmic reticulum (ER) 
and probably plays a role in membrane trafficking, protein processing and 
regulation of ER calcium homeostasis.26 However, its exact location and role in the 
cochlea remain obscure. Electrophysiologic, magnetic resonance imaging and 
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neuropathologic studies2729 of this syndrome have shown general progressive 
degeneration of the central and peripheral nervous systems, including the 
vestibulocochlear nerve. Ohata et al.30 described an increased risk of HI and 
diabetes mellitus in heterozygous carriers. Unfortunately, no frequencies were 
specified and HI was defined as an overall threshold greater than 20 dB HL. 
Young et al.11 described an individual in the Newfoundland family who was a 
homozygous carrier and who had diabetes mellitus at young age and other clinical 
features reminiscent of Wolfram syndrome. However, this individual was not 
affected by optic atrophy. Therefore, it seems possible that carriers of the Wolfram 
syndrome show low-frequency HI similar to that found in DFNA6/14. 
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GENERAL DISCUSSION 

GENERAL DISCUSSION 
Hereditary deafblindness is a rare combination of two sensory handicaps that 
affect daily-life activities. Usher syndrome and Wolfram syndrome are the main 
deafblindness syndromes examined in this study. About 50% of the deafblind 
patients suffer from Usher syndrome, whereas Wolfram syndrome is rare with a 
broad spectrum of additional symptoms. Since several years, it is known that 
different mutations in the same gene may cause syndromic as well as 
nonsyndromic HI. Usher syndrome type Id and DFNB12 are, for example, both 
caused by mutations in the CDH23 gene. Another example is that recessive 
mutations in WFS2 may be causing Wolfram syndrome, whereas dominant 
mutations in this gene may cause DFNA6/14, a nonsyndromic type of low-
frequency HI whose phenotype is described in Chapter 5. The genes, which are 
involved in hereditary deafblindness, encode proteins with a specific function in 
the eye and ear. After the identification of the gene and its nucleotide and amino 
acid sequence, it may be possible to specify predictions about certain domains of 
the protein and about the function of the protein in the eye and ear. Expression 
studies and functional studies of these proteins can reveal important details about 
the function of the protein. It is, however, important to realise that without 
performing family studies and genotype-phenotype correlation studies, the 
identification of genes is much more difficult. In this chapter the main results of 
the studies covered by this thesis are discussed and recommendations are made 
for future research. 
CHARACTERISATION OF PROGRESSIVE TYPES OF HEARING 
IMPAIRMENT 
In Chapter 2 it is shown that it is possible to characterise progressive types of 
autosomal dominantly inherited nonsyndromic HI traits. On the basis of cross-
sectional and/or longitudinal regression analyses of pure-tone thresholds plotted 
against age, ARTA can be derived. ARTA show the progression of HI in an 
audiogram-like format and cover, where possible, decade steps in age. The TFA is 
a second tool that can be used for statistical testing between the different HI traits. 
The developed and described tools are useful for the evaluation of HI in newly 
identified families with hereditary HI. After analysing the pure-tone thresholds of 
affected family members, ARTA and a TFA can be derived and compared to 
normal values for TFA, obtained from families with a known genotype. As the 
number of examined and genotyped families will increase, the normal values for 
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TFA will become more and more specific. The molecular geneticists can thus be 
advised, on the basis of the ARTA and TFA, to perform mutation analysis of 
specific genes prior to costly genome scans or other types of expensive time-
consuming research. In addition, when pure tone audiograms of several affected 
family members are available, it is possible to perform a specific mutation analysis 
in DNA from the proband that is guided by the audiometrie analysis. This way, 
family studies can be performed in a cost-effective way and become less time-
consuming. It is therefore recommended always to perform such a type of analysis 
prior to gene identification studies. 
The ARTA are also valuable for genetic and individual counselling. Although 
intrafamiliar differences can be found in varying degrees in families, a general 
prognosis of the progression of HI can be given on the basis of the ARTA. Future 
research should focus on further development of normal values for the TFA of 
specific genotypes. 
GENETIC AND CLINICAL FEATURES OF USHER SYNDROME 
In Chapter 3 of this thesis, the clinical and genetic features of different subtypes of 
Usher syndrome are presented in several paragraphs. First, clinical characteristics 
of families with USHld or DFNB12 are described. It was shown that the 
truncating mutations in CDH23 causing USHld, lead to significantly more severe 
HI than the missense mutations that cause DFNB12. In USHld, the Cadherin 23 
molecules are probably absent or not functional and the stereocilia do not develop 
properly. Almost all the missense mutations identified in DFNB12 families affect 
the highly conserved Ca2+-binding sites in the extracellular Cadherin domains. 
Ca2* is necessary for the rigid elongated structure of the Cadherin molecule and 
enables homophilic lateral interactions.1 Abnormal development of the cochlear 
and vestibular stereocilia causes profound HI and vestibular areflexia in Usher 
syndrome type I. Recently, it was shown that a number of Usher syndrome type I 
proteins are likely to form a complex that shapes the stereocilia in the inner ear.23 
It can be hypothesised that similar interactions in a functional complex may be 
involved in the pathogenetic mechanism of RP, however, at the moment this is 
still not proven. Future research should therefore not only focus on family studies 
to identify new Usher syndrome type I genes, but also on the interactions of the 
currently identified Usher syndrome type I proteins in the stereocilia and the 
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retina in order to identify candidate genes. It can be hypothesised whether a 
similar complex of extracellular matrix proteins, encoded by USH2 genes, is 
involved in the pathogenetic mechanism underlying Usher syndrome type II. 
Usher syndrome type I is characterised by severe to profound deafness, whereas 
Usher syndrome type II shows moderate to severe HI. Usher syndrome type III is 
typically characterised by progressive HI. The present study has shown that 
patients with USH2a have progressive HI of about 0.5 dB/year. Reisser et al.4 
reported on clinically classified Usher syndrome type II patients with no mention 
of the related genotype and they concluded that there was no progression of HI in 
these patients. Nowadays however, analysis of pure tone audiograms should 
preferably be performed on patients with a confirmed genotype instead of on 
clinically classified patients.5 To further evaluate the HI in the genetic subtypes of 
Usher syndrome type II and type III, the number of clinically well examined 
patients with a confirmed genotype needs to be increased. 
Visual impairment is the most prominent handicap in most patients with Usher 
syndrome. It is assumed that Usher syndrome type I patients have more visual 
impairment than Usher syndrome type II patients and several clinical reports have 
emphasised confirmatory findings.6-8 The present study has shown that in cross-
sectional analysis there is no significant difference between the functional vision 
scores in USHlb and USH2a. However, longitudinal analysis in USH2a patients 
clearly showed a later onset of deterioration at a higher rate. Future studies, 
preferably performed in a multicentre approach on a large number of clinically 
well-examined Usher syndrome patients with a molecular diagnosis, will reveal 
whether or not there is a clear difference between USHlb and USH2a. Such 
studies may eventually also reveal differences in phenotype between different 
types of mutations in the same gene. 
In the present study we also performed mutation analysis of the USH2A gene. In 
63% (n=50) of 79 Dutch families, of which all patients (n=108) were clinically 
classified as Usher syndrome type II, we identified 1 or 2 mutations. In 29% (n=23) 
of the families both mutations were identified, whereas in 34% (n=27) the 
mutation in only one allele was found. It is hypothesised that the currently 
unknown USH2A mutations are likely to be intron mutations that affect splicing, 
represent mutations in regulatory sequences or intragenic deletions that remain 
undetected with the methods used for mutation analysis. It could, however, also 
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be possible that there are mutations in as yet unidentified coding sequences. Ten 
different mutations, 3 of which are new, were found in the 79 families. Future 
research will be focused on these issues and it will be attempted to identify all 
ÜSH2A mutations in the participating Usher syndrome type II families. 
Nowadays, patients with Usher syndrome are much more aware of the natural 
course of their disease than they were several decades ago. With the growing 
knowledge of genotype and phenotype, the Usher syndrome patients can receive 
information that is more specific for their own genetic subtype. To date, already 
several exons of USH2A and MY07A are routinely examined by the DNA 
diagnostics laboratory in Nijmegen. To facilitate fast and successful mutation 
analysis for Usher syndrome, the Nijmegen Otogenetic laboratory has in 2003 
initiated the development of the first Usher syndrome micro-array. This Usher 
chip will be a cost-effective high-throughput testing method, which soon will 
favour access to DNA-diagnostic facilities for most Usher syndrome patients 
worldwide. 
GENETIC AND CLINICAL FEATURES OF WOLFRAM 
SYNDROME 
In Chapter 4 the results of audiovestibular examinations in Wolfram syndrome 
patients are described. One of the most remarkable findings is that of the Wolfram 
syndrome patients with inactivating WFS1 mutations, the female patients had 
significantly more HI than the male patients, even within the same sibship. The 
WFSÎ gene encodes wolframin, which is a transmembrane domain protein. 
Wolframin is located in the canalicular reticulum, a specified type of the ER, in 
different cell types in the inner ear.9 Recently, it was shown that wolframin is 
involved in the homeostasis of intracellular Ca2+.10 The noticed gender difference 
in HI may be related to the involvement of sex hormones. In the next paragraphs a 
hypothesis of the function of wolframin is described, which suggests that 
nongenomic actions of estrogen are involved in intracellular Ca2+ homeostasis by 
wolframin. 
Estrogen influences differentiation, growth and function of the female 
reproductive tract. These actions are performed by binding to nuclear estrogen 
receptors, which function as hormone-dependent transcription factors with an 
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important role in the endocrine signalling system.11 Besides genomic actions, 
estrogen may also elicit nongenomic effects, which directly lead to activation of 
signal transduction pathways.12 Binding of estrogen to nongenomic estrogen 
receptors in the plasma membrane directly results in an intracellular Ca2+ 
increase.13 The rapidity of this increase is consistent with the activation of a cell 
surface receptor and is different from the conventional slow-acting nuclear 
estrogen receptors. Ca2+ is released from intracellular organels, such as the 
endoplasmic reticulum (ER). Ca2+-ATPase is located in the ER membrane and 
releases Ca2+. Wolframin is also located in the ER membrane and is involved in 
intracellular Ca2+ homeostasis.10 It may therefore be possible that nongenomic 
actions of estrogen may influence intracellular calcium homeostasis through 
wolframin. 
This hypothesis is in line with findings reported in several other studies. Patients 
with Wolfram syndrome have progressive high-frequency HI and similar 
audiometrie results have been reported for Turner syndrome patients.14 Turner 
syndrome is caused by total or partial deletion of one X chromosome (XO) in all or 
in some cells. HI in Turner syndrome patients is less progressive and severe than 
seen in patients with Wolfram syndrome and 72% of the Turner syndrome 
patients older than 34 years have mid- and high-frequency HI.15 Patients with 
Turner syndrome have estrogen deficiency, which requires long-term estrogen 
replacement therapy.16 In addition, a recent study by Lee and Marcus17 showed 
that estrogen decreases the secretion of K+ into the endolymph by inhibition of the 
IKS channels (KCNQ1/KCNE1) apical located in the marginal cells of the stria 
vascularis in the inner ear, through a nongenomic action mechanism. Decreased 
levels of estrogen thus affect inner ear ion homeostasis and causes mid- and high-
frequency HI in Turner syndrome patients. Possibly, wolframin is involved in the 
same pathogenic mechanism that causes progressive mid- and high- frequency HI 
due to a disturbance of the inner ear homeostasis, regulated by estrogen. 
Other studies showed that nongenomic actions of estrogen also may be involved 
in organs that are affected in Wolfram syndrome. A recent review by Garcia-
Segura18 has emphasised the role of estrogen in neuroprotection. Wolfram 
syndrome is a progressive neurodegenerative syndrome. It is also known that the 
ER Ca2+ ATPase inhibitor thapsigargin induces neuronal apoptosis, whereas the 
apoptosis is decreased by administration of estradiol and the phytoestrogen 
genistein.19 It thus might well be possible that estrogen is required to maintain 
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normal neuronal function by regulation of the intracellular Ca2+ homeostasis. 
Besides that, estrogen is also involved in psychiatric disease such as Alzheimer's 
disease and schizofrenia.20 Patients with Wolfram syndrome are also prone to the 
development of psychiatric diseases. 
In addition, Wolfram syndrome patients develop hypothalamic diabetes insipidus 
due to a lack of vasopressin. Truncated wolframin thus affects the release of 
vasopressin. Two studies have reported that estrogen is involved in vasopressin 
release as well. One study reported gender differences in plasma vasopressin 
concentrations and suggested a modulating role for estrogen in vasopressin 
releasing neurons.21 Another study demonstrated that estradiol inhibits the 
osmotically stimulated release of vasopressin.22 
Male patients with Wolfram syndrome have primary gonadal atrophy and 
produce less amounts of testosteron than do normal male subjects. Truncated 
wolframin in male patients thus disturbs normal testosteron production in the 
Leydig cells of testis. Ciocca et al.23 identified an estrogen-regulated protein in the 
cytoplasmic matrix, close to the cisternae of the rough and smooth ER of Leydig 
cells. This estrogen-regulated protein possibly interacts with wolframin in the 
regulation of testosteron production. 
The aforementioned data are compatible with our hypothesis. However, future 
research has to reveal whether there indeed is a link between wolframin and the 
estrogen-regulated calcium signalling pathways. 
CLINICAL FEATURES OF DFNA6/14 
In Chapter 5, the audiovestibular analyses of two families with low-frequency HI 
type DFNA6/14 are described. DFNA6/14 is caused by missense mutations in the 
WFSÏ gene. It is known that DFNA6/14 can easily be diagnosed when there is a 
medical history of autosomal dominantly inherited low-frequency HI.24 In most of 
these cases, mutations in the WFSl gene will be found. Another locus of 
nonsyndromic autosomal dominantly inherited low-frequency HI is DFNA1, 
which has been identified in a large Costa Rican family.25 It is still unclear why 
DFNA6/14 mutations mainly affect the low frequencies, whereas the high 
frequencies are affected in Wolfram syndrome. Although previous studies 
262 
GENERAL DISCUSSION 
suggested that DFNA6/14 is characterised by stable hearing loss, the present 
study has shown that the affected family members in two DFNA6/14 families do 
have progressive sensorineural HI. There was no substantial difference in pure 
tone audiogram findings between the Dutch III and Dutch IV family, although the 
2 kHz threshold appeared to be more affected in the Dutch III family. The 
evaluation of speech recognition scores showed significantly different scores for 
the performance-impairment plot, whereas the performance-age plot showed 
similar scores for both families. The performance-impairment plot difference may 
be related to the higher threshold values monitored in the 2 kHz frequency in the 
Dutch III family. 
FUTURE PERSPECTIVES IN HEREDITARY DEAFBLINDNESS 
Nowadays, many patients with congenital profound HI receive a cochlear implant 
at young age. These patients clearly benefit from their cochlear implant. Although 
this is a controversial issue, cochlear implantation may also be useful when 
applied at higher ages. Especially patients with an additional visual handicap, like 
Usher syndrome type I patients, might benefit from implantation. In these patients 
it may subserve as a signalling function when they have lost most of their visual 
abilities. Future research has to reveal whether or not this is really useful and 
satisfactory. 
An interesting development in the treatment of visual impairment due to retinal 
pathology is the development of retinal prostheses, which is inspired by the good 
results of the cochlear implants. Two interesting reviews on this subject were 
written by Margalit et al.26 and by Zrenner.27 Currently, 2 types of retinal implants 
that can be used in RP patients are being developed. The epiretinal implant can be 
introduced through the vitreous cavity and is attached to the inner retinal surface 
and electronically stimulates the inner retina. Recently, Humayun et al.28 reported 
the first details of testing with this type of implant in a blind RP patient. After 
implantation, the subject was able to see perceptions of light and by using a 
camera the subject was able to detect the presence of ambient light, to detect 
motion, and to recognise simple shapes.28 The subretinal implant can be placed in 
the potential space between the outer retinal layer and the retinal pigment 
epithelium and stimulates the outer retina. A lot of work still has to be done to 
safely implant large patients groups with RP and to date, the retinal implant 
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devices are being applied only as a research effort. Although still little is "seen" 
with the retinal implants, RP patients in the future may benefit as much from their 
retinal implant as do cochlear implant patients.26-27 
Future research may reveal the function of specific Usher syndrome proteins in 
the inner ear and retina. This would be useful for the development of new 
treatment modalities. Gene therapy may be one of these new therapies. Recent 
advances in transgenic and gene targeting technologies in mice that offer new 
opportunities to manipulate the expression of genes and study their role in vivo 
will support the development of gene therapy.29 The first steps towards 
application of cochlear gene therapy have been made and seem promising. Viral 
and non-viral vectors have been shown to be able to introduce and express 
exogenous genes in the peripheral auditory system.30 Not only cochlear gene 
therapies, but also retinal gene therapies are currently being developed and are 
ahead of the trials in the inner ear. Recently, some success in the delivery of 
potentially therapeutic genes to retinal tissues in case of recessive disease 
involving retinal degeneration was reported for experimental animal models.3134 
However, dominantly inherited retinal disorders show mutational heterogeneity, 
and it is challenging to see whether it is possible to develop mutation-independent 
therapeutic approaches that target the primary or secondary effects of the 
involved mutations. One of the promising concepts in this field is the mutation-
independent suppression utilising the degeneracy of the genetic code. In this 
concept, a ribozyme is designed to cleave a target transcript at a degenerate site. In 
parallel, a replacement gene is supplied that encodes wild-type protein but has 
been subtly modified at degenerate sites to such an extent that the ribozyme 
cannot cleave transcripts from the replacement gene.35 Other strategies are the 
modulation of secondary effects associated with disease pathology and the 
delivery of appropriate neurotrophic factors to photoreceptor cells in an attempt 
to improve the survival rates of these specialised neurons.35 
In addition, stem cell therapy is being developed as another type of treatment. A 
recent study36 identified cells that display characteristic features of stem cells in 
the adult utricular sensory epithelium. It is known that damaged vestibular organs 
can, to some extent, generate new hair cells. These inner ear stem cells have the 
capacity of self-renewal, are pluripotent and can give rise to a variety of cell types 
in vivo and in vitro, including cells representative for ectodermal, endodermal and 
mesodermal lineages. This finding implies a possible use of such cells for the 
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replacement of lost inner ear sensory cells.36 Another recent study3 7 has shown 
that it is possible to regenerate hair cells in mature mammalian inner ears by the 
application of adenoviral mediated overexpression of Hathl, a human atonal 
homolog. This study concluded that local adenoviral gene therapy in the inner ear 
may be a potential approach to treat hearing and balance disorders. Similar 
studies are being performed on retinal degenerations and dystrophies. One of 
those studies38 recently showed that it is possible to partially differentiate adult 
CD90+ marrow stromal cells into photoreceptors in vitro and in vivo. This may 
provide a promising therapeutic strategy for the treatment of some forms of 
hereditary retinal degenerations.38 
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SUMMARY AND CONCLUSIONS 

SUMMARY 
In this thesis, clinical and genetic aspects of hereditary types of hearing and visual 
impairment are delineated. This Ph.D. project forms part of the Nijmegen 
hereditary HI studies. 
SUMMARY 
Chapter 1 is a general introduction to the subject of this thesis. The first part of this 
chapter focuses on the historical, clinical and genetic characteristics of Usher 
syndrome. Usher syndrome is the most common deafblindness syndrome with a 
prevalence of about 3.5-6.2 per 100,000 individuals. It is believed to account for 
more than 50% of all deafblindness cases. It shows autosomal recessive inheritance 
and is classified into 3 different types on the basis of audiovestibular features. Not 
only is there clinical heterogeneity, but also genetic heterogeneity. Linkage studies 
have identified 11 loci and 7 corresponding genes were identified on the basis of 
positional cloning. At least 7 loci (USH1A-USH1G) and 5 corresponding genes 
(MY07A, USH1C, CDH23, PCDHIS, SANS) have been cloned so far for USH1. 
Patients with USH1 show congenital profound HI, vestibular areflexia and 
progressive RP. Three loci (USH2A-USH2C) and 1 gene (ÜSH2A) have so far been 
cloned for USH2. The USH2 patients show downsloping moderate-to-severe high-
frequency HI, intact vestibular responses and progressive RP. Worldwide, USH3 
is rare (2% of all Usher syndrome cases), however, it is relatively common in 
Finland (40%). It typically shows progressive HI, variable vestibular responses 
and progressive RP. One locus (USH3) and gene (USH3) have been reported for 
this specific type of Usher syndrome. 
The second part of Chapter 1 is a general introduction to Wolfram syndrome, 
which is a rare deafblindness syndrome (1:770,000 individuals in the UK). The 
acronym DIDMOAD covers the main features of the syndrome. Diabetes 
Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness. Other associated 
features are urologica! abnormalities, neuropsychiatrie abnormalities and 
hypogonadism. Patients with Wolfram syndrome are born without any 
symptoms. Progression of this neurodegenerative disease gradually leads to an 
increasing loss of organ functions. These patients die at young age; the median age 
at death is about 30 years (25-49 years). Wolfram syndrome shows autosomal 
recessive inheritance and is caused by mutations in the WFSl gene. 
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The third part of Chapter 1 concerns the molecular genetics of sensorineural HI. 
Many centres worldwide perform genetic studies in HI and the knowledge of the 
genes and function of the encoded proteins in the inner ear has emerged 
enormously in the past ten years. The currently known genes and the diseases 
they are causative for are presented. Based on their function, the genes are 
categorised into the following groups: 1. Hair cell structure and function, 2. Ion 
homeostasis and K+ recycling, 3. Transcription factors, 4. Extracellular matrix 
proteins, 5. Receptors and ligands, 6. Cellular trafficking proteins, 7. Genes whose 
function is currently unknown. 
The last part of Chapter 1 is a review of progressive phenotypes in nonsyndromic 
autosomal dominant HI. It focuses on the variability in phenotypic features as 
presented by the analysis of audiometrie profiles (ARTA) and of speech 
recognition scores of DFNA1, DFNA2, DFNA4, DFNA5, DFNA6/14, DFNA7, 
DFNA9, DFNA10, DFNA15, DFNA16, DFNA17, DFNA20/26 and DFNA21. 
Chapter 2 describes methods to analyse progressive HI traits. Cross-sectional and 
longitudinal regression analyses of pure tone thresholds are used to construct Age 
Related Typical Audiograms (ARTA) that present the data in an audiogram-like 
format. Where possible, these data cover decade steps in age. An additional newly 
developed tool is the Threshold Features Array (TFA). This one-dimensional array 
is used for statistical tests involving different forms of HI. In the ongoing 
Nijmegen family studies of progressive nonsyndromic HI, the ARTA and TFA are 
used where possible for guiding genetic analyses. 
Chapter 3 is dedicated to Usher syndrome. This part of the study is the 
continuation of two previous Usher syndrome PhD projects by Annelies van 
Aarem and Manette Wagenaar. In six parts of this chapter studies on the clinical 
and genetic features of this syndrome are described. 
The first part of this chapter presents the phenotypic features of Usher syndrome 
type Id (3 families, 6 patients) and DFNB12 (1 family, 4 patients), both caused by 
mutations in the CDH23 gene. The USHld patients had significantly worse HI 
than the DFNB12 patients. Missense mutations in CDH23 caused DFNB12 and 
these patients had normal retinal and vestibular function. The USHld patients all 
had splice site mutations in CDH23 that lead to truncation of the protein. Besides 
profound HI, these patients also have vestibular areflexia and RP. In one DFNB12 
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patient abnormal flecks in the posterior pole of the eye could be seen. Another 
DFNB12 patient had increased reflexes and minifolds of the internal limiting 
membrane in the macular area on funduscopy. 
In part 3.2 the deterioration of visual function in patients with Usher syndrome 
type lb and Usher syndrome type Ha is addressed. The visual functions of 19 
USHlb and 40 USH2a patients, identified by at least 1 mutation in MY07A and 
USH2A respectively, were evaluated by measuring the best-corrected visual acuity 
and using Goldmann perimetry to assess the visual fields. The functional acuity 
score (FAS), functional field score (FFS) and the functional vision score (FVS) were 
evaluated according to the descriptions of the American Medical Association 
Guides for the Evaluation of Permanent Impairment. Cross-sectional analyses 
revealed no significant difference in the deterioration of any of the functional 
scores with advancing age between USHlb and USH2a. The FAS, FFS and FVS 
deteriorated by on average 0.7%, 1.0% and 1.5% per year, respectively. The mean 
onset age, estimated on the basis of longitudinal analyses in the USH2a patients, 
was 37, 18 and 14 years for FAS, FFS and FVS, respectively. The estimates of the 
rate of deterioration were higher then those found in cross-sectional analyses 
(FAS: 5.2%/y, FFS: 2.5%/y, FVS: 2.4%/y). 
The third part of this chapter describes the audiometrie profile of 36 patients with 
Usher syndrome type IIa, identified by at least one pathogenic mutation in the 
USH2A gene. It was shown that USH2a patients in general have a moderate to 
severe downsloping audiogram with threshold progression of about 0.5 dB/year. 
In 30 patients speech recognition scores were evaluated and it appeared that they 
started to deteriorate from 38 years of age onwards (90% recognition) at a rate of 
0.4% per year. The 90% recognition level was attained at 69 dB hearing level and 
deteriorated with increasing level of HI by 0.6%/dB HL. 
In part 3.4, the vestibular function in relation to deteriorating visual function in 29 
Usher syndrome type Ha patients, all identified by at least one pathogenic 
mutation in the USH2A gene, was analysed. The optokinetic nystagmus (OKN) 
response level and the vestibulo-ocular reflex (VOR) were analysed. Remarkably, 
the VOR was intact but seldom normal. The VOR gain and time constant (T) were 
more often significantly higher or lower than could have been expected on the 
basis of chance alone. The OKN response level and the functional vision scores all 
decreased significantly, whereas Τ increased significantly with advancing age. 
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The fifth part of this chapter describes the results of USH2A mutation analysis in 
79 Dutch families with Usher syndrome type II. In 63% of the families at least 1 
pathogenic USH2A mutation was detected. In 23 families (29%) the mutations in 
both alleles were identified and in 27 families (34%) the mutation in only one allele 
was identified. It is hypothesised that intron mutations that affect splicing, 
mutations in regulatory sequences or deletions of parts of the gene account for the 
remaining unidentified genetic defects. Assuming that all USH2 patients with 1 
mutated USH2A allele are in fact USH2a patients, it is estimated that 23% of the 
Dutch USH2 patients have mutations in a different USH2 gene. Three new 
pathogenic mutations (R317R, Q748X and Q1468X) are described to cause USH2a. 
A total of 10 different mutations, detected in 6 exons, are found to be causative for 
USH2a in the Netherlands. Typical Dutch Ιί5Η2Λ mutations are C419F, W409X 
and R317R presently identified in 16, 7 and 4 alleles of 15, 6 and 4 families, 
respectively. It is very likely that the C419F mutation has an ancestral origin on the 
basis of a core haplotype deduced from 10 single nucleotide polymorphisms, 
whereas this was not conclusively possible for the W409X and R317R mutations. 
The last part of this chapter describes the clinical and genetic features of the first 
USH3 family identified in the Netherlands. Two patients from this family were 
found to be homozygous for a new USH3 mutation (149-152delCAGG + ins 
TGTCCAAT). One individual had profound HI with normal vesibular function 
and retinitis punctata albescens. The other individual also had HI, but with well-
developed speech, vestibular areflexia and retinitis pigmentosa sine pigmento. On 
the basis of these findings, it was concluded that Usher syndrome type III can 
easily be misdiagnosed as Usher syndrome type I or II. 
Chapter 4 focuses on the audiovestibular presentation of Wolfram syndrome. This 
study included 11 Wolfram syndrome patients (4 male, 7 female) and 17 related 
heterozygous carriers. Patients and carriers were identified by pathogenic 
mutations in the Wolfram syndrome 1 gene (WFS1). None of the carriers had 
sensorineural hearing loss. The patients in general showed a downsloping 
audiogram and progressive HI. Two patients with missense mutations in WFS1 
had normal hearing for their age and relatively mild Wolfram syndrome 
symptoms. These 2 patients were excluded from further analyses. The remaining 9 
patients all had inactivating mutations in the WFS1 gene and it was shown that 
the female patients had significantly more severe HI than the male patients. The 
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female patients showed progression of HI by 1.5-2.0 dB HL per year for the low 
frequencies and 4.0-4.5 dB HL per year for the mid and high frequencies. Speech 
recognition started to deteriorate (90% score) at age 21 at a HI level of 78 dB HL. 
The deterioration rate was 4.0% per year and the deterioration gradient was 
1.4%/dB HL. One of the 6 patients examined had vestibular areflexia. 
Chapter 5 describes the audiometrie profile of low-frequency HI (DFNA6/14) 
occurring in two families (Dutch III, 9 patients and Dutch IV, 4 patients). 
Heterozygous mutations in the WFSl gene were found to cause this type of 
autosomal dominantly inherited nonsyndromic sensorineural HI. Progression of 
HI beyond presbyacusis was found in affected persons from both families. The 
annual threshold deterioration was between 0.6 and 1 dB at all frequencies. 
Remarkably, the speech recognition scores in family Dutch III showed 
significantly more deterioration at increasing levels of HI than those reported for 
family Dutch IV. 
CONCLUSIONS 
This Ph.D. project has succeeded to report on new clinical and molecular genetic 
features of Usher syndrome. Wolfram syndrome and DFNA6/14. In addition, 
methods to analyse progression of HI were developed. Several interesting 
conclusions can be drawn from this study. The study on HI in USH2a patients 
showed that these patients have progression of HI by about 0.5 dB/y. In general, it 
was previously thought that Usher syndrome type II patients had no progression 
of HI other than presbyacusis. In addition, it was shown that the visual 
impairment in 19 USHlb patients did not statistically differ in cross-sectional 
analysis from that of 40 USH2a patients. However, longitudinal analysis of visual 
functions in the USH2a patient group revealed that the deterioration may have 
developed at a more advanced age and that the rate of deterioration was much 
higher in USH2a than was reported in the cross-sectional analysis. The visual 
impairment in USH2a and USHlb was quite similar by age 40-50 years. It was also 
shown that the USH2a patients seldom showed normal vestibular responses and 
that the OKN response level decreased significantly whereas the time constant Τ 
increased significantly with advancing age. Another remarkable finding was the 
gender difference in HI in Wolfram syndrome patients, who had been identified 
by inactivating WFS2 mutations. 
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The importance of performing studies such as the present one is best illustrated by 
the enormous advance in knowledge that has been made over the past decade. 
Ten years ago only a few deafness genes had been cloned and only little was 
known about the function of their protein products within the inner ear. Without 
elaborate family studies, this type of knowledge would never have developed so 
rapidly. By performing linkage studies on families, showing syndromic or 
nonsyndromic HI, new genes can be identified and their role and function in the 
inner ear can be studied. The enormous development in knowledge of inner ear 
genes is best illustrated in the third part of the introduction (1.3), which is focused 
on the molecular genetics of sensorineural HI. Certainly now that most of the 
more prevalent genes have been identified, it is crucial to perform thorough 
analyses of the clinical features seen within these families to optimally assist the 
molecular geneticists. 
Studies like the present one are also important for patients and their relatives 
because they can be informed more precisely about their disease. Certainly 
nowadays, when patients are increasingly asking for specific information about 
their disease, we should be able to respond properly. Mutation analysis has 
become available and provides a more exact diagnosis. To remain cost-effective, it 
is imperative that a correct clinical diagnosis accompanies the request for mutation 
analysis. Genotype-phenotype correlation studies such as those performed in this 
thesis are necessary to obtain correct clinical diagnoses. When mutation analysis is 
available, it is also possible to evaluate carriership within affected families and 
even prenatal DNA diagnostics can be offered. Such new opportunities favour the 
quality of genetic counseling. 
The attitude of affected individuals towards the type of studies and their 
willingness to participate clearly demonstrate the socio-emotional importance for 
these patients. Hopefully, this and future projects will finally result in proper 
treatment of this and many other types of hereditary syndromic and 
nonsyndromic HI. 
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In dit proefschrift worden klinische en genetische aspecten van erfelijke 
slechthorendheid en slechtziendheid beschouwd. Dit promotieproject is onderdeel 
van de Nijmeegse erfelijke slechthorendheidsstudies. 
SAMENVATTING 
In Hoofdstuk 1 wordt een algemene inleiding over het onderwerp van dit 
proefschrift gegeven. Het eerste deel van dit hoofdstuk beschrijft de historische 
achtergronden en de klinische en genetische kenmerken van Usher syndroom. 
Usher syndroom is het meest voorkomende doofblindheidssyndroom met een 
prevalentie van ongeveer 3,5-6,2 per 100.000 personen. Er wordt geschat dat het 
meer dan 50% van alle doofblindheid veroorzaakt. Het erft autosomaal recessief 
over en wordt ingedeeld in 3 verschillende typen op grond van audiovestibulaire 
kenmerken. Usher syndroom is zowel klinisch als genetisch heterogeen. 
Koppelingsstudies hebben 11 loei en 7 corresponderende genen, waarin mutaties 
gevonden worden die het syndroom veroorzaken, geïdentificeerd. Voor Usher 
syndroom type I zijn er momenteel 7 chromosomale loei (USH1A-USH1G) en 5 
genen (MY07A, USH1C, CDH23,PCDHÏ5, SANS) bekend. Patiënten met USH1 
zijn vanaf hun geboorte volledig doof, vertonen vestibulaire areflexie en 
ontwikkelen progressieve RP. Voor USH2 zijn er momenteel 3 chromosomale loei 
(USH2A-USH2C) en 1 corresponderend gen {USH2A) bekend. USH2 wordt 
klinisch gekenmerkt door een matig ernstig gehoorverlies in de hoge frequenties, 
intacte vestibulaire reflexen en progressieve RP. USH3 is wereldwijd zeldzaam 
(2% van alle Usher syndroom patiënten), maar komt veelvuldig voor in Finland 
(40%). USH3 wordt gekenmerkt door evidente progressie van het gehoorverlies, 
aanwezige maar variabele vestibulaire reflexen en progressieve RP. Het USH3 
locus en het bijbehorende gen (ÜSH3) zijn gevonden en vooralsnog is dit het enige 
locus voor dit type Usher syndroom. 
Het tweede deel van Hoofdstuk 1 bevat een algemene inleiding van het Wolfram 
syndroom, een zeldzaam doofblindheidssyndroom (1 op de 770.000 personen in 
Groot-Brittanië). Een acroniem voor dit syndroom is DIDMOAD, vernoemt naar 
de belangrijkste kenmerken van het syndroom: Diabetes Insipidus, Diabetes 
Mellitus, Opticus Atrofie en Doofheid (slechthorendheid). Andere optredende 
kenmerken zijn urologische afwijkingen, neuropsychiatrische stoornissen en 
hypogonadisme. Patiënten met het Wolfram syndroom worden gezond geboren 
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zonder enige symptomen. Gedurende hun leven zorgt de progressie van deze 
neurodegeneratieve aandoening ervoor dat steeds meer organen problemen gaan 
vertonen. Deze patiënten worden niet oud en de mediane leeftijd bij overlijden is 
ongeveer 30 jaar (25-49 jaar). Dit syndroom erft autosomaal recessief over en 
wordt veroorzaakt door mutaties in het WFS1 gen. 
Het derde deel van Hoofdshik 1 beschrijft de huidige kennis van de moleculaire 
genetica van erfelijke perceptieve slechthorendheid. Meerdere centra in de wereld 
verrichten genetische studies naar erfelijke slechthorendheid en de kennis van 
genen en de oorfunctie van de door deze genen gecodeerde eiwitten in het 
binnenoor is enorm toegenomen in de afgelopen tien jaar. De momenteel bekende 
genen en aanverwante syndromale en niet-syndromale slechthorendheidsbeelden 
worden in dit deel van het hoofdstuk gepresenteerd en ingedeeld naar de 
betrokken functies in het binnenoor. De genen worden beschreven in de volgende 
categorieën: 1. Haarcelfunctie/mechanotransductie, 2. lonenhomeostase en K+ 
recycling, 3. Transcriptiefactoren, 4. Extracellulaire matrix eiwitten, 5. Receptoren 
en liganden, 6. Eiwitten betrokken bij cellulair transport, 7. Genen met een 
momenteel nog onbekende functie. 
Het laatste deel van Hoofdstuk 1 is een review betreffende autosomaal dominant 
overervende progressieve nietsyndromale slechthorendheidsbeelden. De 
fenotypische kenmerken worden beschreven met behulp van leeftijdsgerelateerde 
audiogrammen (ARTA) en analyses van spraakverstaanbaarheidsscores voor de 
volgende beelden: DFNA1, DFBA2, DFNA4, DFNA5, DFNA6/14, DFNA7, 
DFNA9, DFNA10, DFNA15, DFNA16, DFNA17, DFNA20/26 en DFNA21. 
Hoofdstuk 2 beschrijft de statistische methoden die gebruikt worden om de 
fenotypes van progressieve erfelijke slechthorendheid te analyseren. Cross-
sectionele en longitudinale regressie-analyse van de gehoordrempels ten opzichte 
van de leeftijd worden gemaakt om een leeftijdsgerelateerd audiogram (Age 
Related Typical Audiograms: ARTA) af te leiden. De ARTA tonen de progressie 
van het gehoorverlies in een audiogram-lay out waarbij de data, indien mogelijk, 
worden weergegeven in leeftijdsdecennia. Een nieuw ontwikkelde methode is de 
"drempelkenmerkenvector" (Threshold Features Array: TFA). Deze 
ééndimensionele vector wordt gebruikt om verschillende erfelijke 
slechthorendheidsbeelden statistisch tegen elkaar te toetsen. De ARTA en de TFA 
die afgeleid worden voor een onderzochte familie worden gebruikt voor het 
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maken van strategische keuzes om primair mutatie-analyse van een gen met een 
bekend en gelijkend phenotype te verrichten of juist te kiezen voor een 
genkoppelingsstudie. 
Hoofdstuk 3 van dit proefschrift is gewijd aan het Usher syndroom. Dit hoofdstuk 
sluit aan bij de twee eerdere proefschriften die door Annelies van Aarem en 
Mariette Wagenaar over dit syndroom zijn geschreven. In zes onderdelen wordt 
aandacht besteed aan de klinische en genetische kenmerken van dit syndroom. 
Het eerste deel van dit hoofdstuk beschrijft de fenotypische kenmerken van Usher 
syndroom type ld (3 families, 6 patiënten) en DFNB12 (1 familie, 4 patiënten). 
Beide ziektebeelden worden veroorzaakt door mutaties in het CDH23 gen. De 
USHld patiënten hebben significant slechtere gehoordrempels dan de DFNB12 
patiënten. Missense mutaties in het CDH23 gen veroorzaken DFNB12 en deze 
patiënten hebben een normale retinale en vestibulaire functie. Alle USHld 
patiënten hebben splice-site mutaties in het CDH23 gen die leiden tot truncatie 
van het eiwit. Naast de congenitale totale doofheid hebben deze patiënten 
vestibulaire areflexie en RP. Bij één DFNB12 patiënt werden abnormale vlekken in 
de achterpool van het oog gezien. 
In deel 3.2 wordt aandacht besteed aan de afname van de visus bij patiënten met 
Usher syndroom type Ib en Usher syndroom type IIa. Bij 19 USHlb en 40 USH2a 
patiënten werd de gecorrigeerde gezichtsscherpte (Snellen kaart) en de grootte 
van de gezichtsvelden (Goldmann perimetrie) opgemeten. Alle patiënten hebben 
tenminste 1 mutatie in respectievelijk het MY07A of LÌSH2A gen. De functionele 
gezichtsscherpte score (Functional Acuity Score, FAS), de functionele 
gezichtsveldscore (Functional Field Score, FFS) en de functionele visus score 
(Functional Vision Score, FVS) werden bepaald volgens de beschrijvingen van de 
American Medical Association Guides for the Evaluation of Permanent 
Impairment. Cross-sectionele analyse van de functionele scores in relatie tot de 
leeftijd liet geen significant verschil in verslechtering zien bij toenemende leeftijd 
tussen USHlb en USH2a. De FAS, FFS en FVS namen gemiddeld af met 
respectievelijk 0,7%, 1,0% en 1,5% per jaar. Longitudinale regressie-analyse van de 
scores van USH2a patiënten liet echter zien dat de afname van de scores 
weliswaar op een hogere leeftijd begon maar dat de mate van afname groter was. 
De gemiddelde beginleeftijden voor de FAS, FFS en FVS die zijn afgeleid via 
longitudinale analyses bij USH2a patiënten, waren respectievelijk 37,18 en 14 jaar. 
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De schattingen van de jaarlijkse afname waren hoger dan gerapporteerd voor de 
cross-sectionele analyses (FAS: 5,2% per jaar, FFS: 2,5% per jaar, FVS: 2,4% per 
jaar). 
Het derde deel van dit hoofdstuk beschrijft het audiometrisch profiel van 36 
patiënten met USH2a. Alle patiënten hebben tenminste 1 mutatie in het USH2A 
gen. Uit dit onderzoek bleek dat USH2a patiënten in het algemeen een matig-
ernstig gehoorverlies in de hoge frequenties hebben dat langzaam verergert met 
ongeveer 0,5 decibel per jaar. Bij 30 patiënten zijn de spraakherkennningsscores 
geëvalueerd en is aangetoond dat vanaf de leeftijd van 38 jaar de 
spraakherkenningscores (<90%) verslechteren met een snelheid van 0,4% per jaar. 
De 90% spraakherkenningsdrempel wordt bereikt bij een gemiddelde drempel 
van 69 decibel en neemt dan af met 0,6% per decibel. 
In deel 3.4 wordt de vestibulaire functie in relatie tot de afname van de visus 
beschreven voor 29 USH2a patiënten. Alle patiënten hebben tenminste 1 mutatie 
in het USH2A gen. De optokinetische nystagmus (OKN) respons en de vestibulo-
oculaire reflex (VOR) zijn geanalyseerd. Het viel op dat de VOR intact was maar 
zelden normale waarden vertoonde. De VOR-gain en de VOR-tijdconstante (T) 
waren vaker significant hoger of lager dan op basis van kansberekening verwacht 
mag worden. De OKN-gain en de functionele visus scores namen beide significant 
af, terwijl Τ significant toenam met toenemende leeftijd. 
Het vijfde deel van dit hoofdstuk beschrijft de resultaten van (Λ5Η2Α mutatie 
analyse verricht bij 79 Nederlandse families met Usher syndroom type II. Bij 63% 
van de families werden mutaties in het USH2A gen gevonden. Bij 23 families 
(29%) zijn de mutaties in beide allelen geïdentificeerd en bij 27 families (34%) werd 
maar 1 mutatie in 1 allei gevonden. Waarschijnlijk zijn intronmutaties die de 
splicing van het gen beïnvloeden of mutaties in de regulatoire sequenties of 
deleties van delen van het gen verantwoordelijk voor de ontbrekende genetische 
defecten. Wanneer we aannemen dat alle USH2 patiënten met minimaal 1 
gemuteerd USH2A allei in feite USH2a patiënten zijn dan kan worden afgeleid dat 
23% van de Nederlandse USH2 patiënten pathogène mutaties in een ander USH2 
gen moeten hebben. Drie nieuwe, niet eerder beschreven, USH2a veroorzakende 
mutaties (R317R, Q748X en Q1468X) worden beschreven. In totaal zijn er 10 
verschillende mutaties gevonden die USH2a in Nederland veroorzaken. Typisch 
Nederlandse mutaties zijn de C419F, W409X en de R317R mutatie, die tot nu toe 
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geïdentificeerd zijn bij 16, 7 en 4 allelen in respectievelijk 15, 6 en 4 families. De 
C419F en E767fs mutatie zijn foundermutaties op basis van een haplotype dat 
afgeleid is van 10 verschillende nucleotide polymorfismen. 
Het laatste deel van dit hoofdstuk beschrijft de klinische en genetische kenmerken 
van de eerste USH3 familie die in Nederland is geïdentificeerd. Twee patiënten 
van deze familie hebben een nieuwe homozygote liSH3 mutatie: 149-152delCAGG 
+ ins TGTCCAAT. Eén patiënt is volledig doof in aanwezigheid van een normale 
vestibulaire functie en retinitis punctata albescens, terwijl de andere patiënt een 
zelfde type gehoorverlies heeft met een goed ontwikkelde spraak en daarbij 
vestibulaire areflexie en retinitis pigmentosa sine pigmento heeft. Op basis van 
deze bevindingen kan geconcludeerd worden dat USH3 gemakkelijk kan worden 
verward met zowel USH1 als USH2. 
Hoofdstuk 4 is gericht op de audiovestibulaire kenmerken van het Wolfram 
syndroom. Bij deze studie zijn 11 Wolfram syndroom patiënten (4 mannen en 7 
vrouwen) en 17 familieleden betrokken die heterozygote mutatiedrager zijn. 
Zowel de patiënten als de mutatiedragers zijn geïdentificeerd op basis van 
pathogène mutaties in het WFS1 gen. Geen van de mutatiedragers heeft een 
perceptief gehoorverlies. De patiënten hebben over het algemeen een perceptief 
gehoorverlies in de hoge frequenties dat in de loop der jaren toeneemt. De enige 
twee patiënten met missense mutaties in het WFS1 gen hadden een normaal 
gehoor voor hun leeftijd en opvallend milde Wolfram kenmerken. Deze twee 
patiënten zijn daarom uitgesloten van verdere analyse. De 9 overgebleven 
patiënten hebben inactiverende WFS1 mutaties, en voor hen is aangetoond dat de 
5 vrouwelijke patiënten significant slechter horen dan de 4 mannelijke patiënten. 
De vrouwelijke patiënten vertoonden een jaarlijkse toename van hun 
gehoorverlies van 1,5-2,0 decibel voor de lage frequenties en 4,0-4,5 decibel voor 
de midden en hoge frequenties. Het spraakverstaan van de vrouwelijke patiënten 
begon af te nemen (90% score) vanaf de leeftijd van 21 jaar bij een gemiddelde 
gehoordrempel van 78 decibel. Het spraakverstaan verslechterde met 4,0% per jaar 
bij een afname van 1,4% per decibel. Eén van de 6 vestibulair onderzochte 
patiënten bleek vestibulaire areflexie te vertonen. 
Hoofdstuk 5 beschrijft het audiometrisch profiel van twee families (Dutch III, 9 
patiënten en Dutch IV, 4 patiënten) waarbij slechthorendheid in de lage 
frequenties (DFNA6/14) voorkomt. Heterozygote mutaties in het WFSÎ gen zijn 
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verantwoordelijk voor dit type van autosomaal dominant overervende 
nietsyndromale perceptieve slechthorendheid. De aangedane familieleden van 
deze 2 families vertonen een progressie van het gehoorverlies die groter is dan op 
basis van presbyacusis verwacht zou mogen worden. De toondrempel neemt 
tussen de 0,6 en 1,0 decibel per jaar toe bij alle frequenties. Opvallend is ook dat de 
spraakverstaanscores in familie Dutch III significant meer afnemen bij toenemende 
gehoordrempel dan de scores in familie Dutch IV. 
CONCLUSIES 
Dit promotieproject is erin geslaagd om te rapporteren over nieuwe klinische en 
genetische kenmerken van Usher syndroom. Wolfram syndroom en DFNA6/14. 
Daarnaast zijn er methodes voor het analyseren van progressief gehoorverlies 
ontwikkeld en beschreven. Een aantal interessante conclusies kunnen getrokken 
worden uit dit onderzoek. Het onderzoek naar het gehoorverlies van USH2a 
patiënten heeft aangetoond dat dit progressief is met een jaarlijkse toename van 
het gehoorverlies van ongeveer 0,5 decibel. Over het algemeen wordt echter 
aangenomen dat USH2a patiënten een stabiel gehoorverlies met lichte toename 
door presbyacusis hebben. Daarnaast is aangetoond dat de visus bij 19 USHlb 
patiënten niet significant verschilde van de visus bij 40 USH2a patiënten. 
Longitudinale analyses van de visus bij USH2a patiënten liet echter zien dat de 
visus-afname bij hogere leeftijd begint maar dan sterker is dan op basis van de 
cross-sectionele studies is berekend. De visus is rond 40-50 jarige leeftijd voor 
USHlb en USH2a ongeveer gelijk. Tevens is aangetoond dat USH2a patiënten 
zelden normale vestibulaire responsies hebben en dat de OKN gain significant 
afneemt en de tijdconstante Τ significant toeneemt met de leeftijd. Een andere 
opvallende bevinding was het verschil in gehoorverlies tussen mannelijke en 
vrouwelijke patiënten met Wolfram syndroom en inactiverende mutaties in het 
WFSI gen. De vrouwelijke patiënten hadden significant meer gehoorverlies dan 
de mannelijke patiënten. 
Het belang van het verrichten van dit soort studies kan het beste geïllustreerd 
wordenaan de hand van de enorme toename aan kennis van de afgelopen jaren. 
Tien jaar geleden waren nog maar een paar slechthorendheidsgenen 
geïdentificeerd en was nog maar weinig bekend over de functie van de 
corresponderende eiwitten in het binnenoor. Zonder uitgebreide familiestudies 
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zou deze kennis nooit zo snel verkregen kunnen zijn. Door het uitvoeren van 
koppelingsanalyse bij families met erfelijke nietsyndromale of syndromale 
slechthorendheid kunnen nieuwe genen geïdentificeerd worden en kan de rol van 
de betrokken eiwitten in het binnenoor onderzocht worden. De enorme 
ontwikkeling in kennis van binnenoorgenen wordt het best geïllustreerd in 
paragraaf 1.3, waarin de moleculaire genetica van perceptieve slechthorendheid 
beschreven wordt. Het analyseren van de klinische kenmerken van families met 
erfelijke slechthorendheid zal echter steeds belangrijker worden om de 
moleculaire genetici zo optimaal mogelijk te kunnen assisteren, zeker gezien het 
feit dat de meeste van de veel voorkomende genen al geïdentificeerd zijn. 
Studies zoals de huidige zijn dan ook van belang voor de patiënten en hun 
familieleden omdat ze uitgebreider en nauwkeuriger geïnformeerd kunnen 
worden over de aandoening waaraan ze leiden. In een maatschappij waarin de 
patiënten steeds mondiger worden en steeds meer willen weten over hun ziekte, 
moeten we in staat zijn deze informatie te verschaffen. Daarnaast is diagnostische 
mutatie-analyse tegenwoordig ook beschikbaar en kan er een preciese diagnose 
gesteld worden. Om kosteneffectief te blijven, dient een correcte klinische 
diagnose de aanvraag voor diagnostische mutatie-analyse te vergezellen. Voor het 
stellen van deze klinische diagnose is het van belang dat er grondige fenotype-
genotype correlatiestudies zijn of worden uitgevoerd. Wanneer mutatie-analyse 
voor handen is, is het zelfs mogelijk om dragerschap van niet-aangedane 
familieleden te laten onderzoeken en kan er zelfs prenatale DNA-diagnostiek 
aangeboden worden. Concluderend kunnen we dan ook stellen dat dergelijke 
ontwikkelingen de kwaliteit van de genetische counseling ten goede komen. 
De houding en bereidheid van patiënten om mee te werken aan het soort 
onderzoek dat in dit proefschrift wordt beschreven toont het sociaal-emotionele 
belang voor hen duidelijk aan. Het valt te hopen dat dit project en toekomstige 
soortgelijke projecten uiteindelijk dan ook zullen leiden tot toepasbare 
behandelingen van deze en vele andere vormen van erfelijk syndromaal en 
nietsyndromaal gehoorverlies. 
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Hereditary Deaf-Blindness 
clinical and genetic aspects 
Ronald Pennings, 29 april 2004 
1. Vrouwelijke patiënten met Wolfram syndroom dat wordt veroor-
zaakt door truncerende WFS1 mutaties horen significant slechter dan 
mannelijke patiënten met Wolfram syndroom, (dit proefschrift) 
2. Cross-sectionele analyse van het gezichtsveld en de gezichtsscherpte 
bij USHlb en USH2a patiënten laat geen significant verschil in 
progressie zien tussen deze groepen patiënten, (dit proefschrifl) 
3. De slechthorendheid bij patiënten met DFNA6/14 kan ook een 
progressief karakter hebben, (dit proeßchrift) 
4. Mutaties in het USH2A gen zijn verantwoordelijk voor ongeveer 72% 
van de in Nederland voorkomende Usher syndroom type II families. 
(dit proefschrifl) 
5. Het USH2A gen bestaat uit 72 en niet zoals eerder beschreven 21 
exonen. (van Y/ijk et al. Am J Hum Genet 2004, in druk) 
6. De variatie in aanvang en progressie van het gehoorverlies bij 
patiënten met Usher syndroom type ΠΙ zorgt er voor dat het klinisch 
zowel kan imponeren als Usher syndroom type I als Usher 
syndroom type Π. (Plantinga et al. Audiol Neurootol 2004, in druk) 
7. De analyse van het audiometrisch phenotype met behulp van de age-
related typical audiograms (ARTA) en de threshold features array 
(TFA) is vooral zinvol indien er sprake is van een goede 
samenwerking met de onderzoekers die het genotype bestuderen. 
8. De hoogte van de citation index van wetenschappelijke tijdschriften 
wordt in het huidige tijdperk mede bepaald door de elektronische 
beschikbaarheid van deze tijdschriften via internet. 
9. Er is een sekseverschil in het plezier dat mensen ervaren wanneer zij 
gaan winkelen ("shoppen"). Mannen (de jagers) vinden het 
gemiddeld 72 minuten leuk om te winkelen. Vrouwen (de 
verzamelaars) vinden dit gemiddeld 100 minuten leuk. Stellen 
krijgen dan ook na gemiddeld 1 uur en 12 minuten shoppen ruzie. 
(YouGov Research, September 2003, www.YouGov.com) 
10. Carpe diem 
Stellingen 
behorende bij het proefschrift 
Characterizations of LP-spaces with ρ G (0, oo) 
van Steven Teerenstra 
1. Laat X een compacte HausdorfFruimte zijn. 
Dan zijn de volgende uitspraken equivalent: 
{α) X is nul-dimensionaal i.e. de topologie van X heeft een 
basis van open-gesloten deelverzamelingen. 
(/?) Als 0 < <7i,02 < ƒ in C{X) met <?i,c72 disjunct, en ε > 0 
gegeven zijn, dan bestaan er 0 < fi, f? in C(X) zodanig dat 
ƒ = fi + f2 met /i en ƒ2 disjunct en ft>gt- ε f (i = 1,2). 
2. De implementatie van referentiële integriteit binnen MS Access 
is een farce. 
3. Er bestaat geen quantum wereld. 
Er zijn slechts de verschijnselen. 
4. Reïficatie, het toedichten van werkelijksheidgehalte aan theorie-
geladen concepten, objecten en/of relaties, is een vorm van 
hubris. 
5. Een formule zegt meer dan 1000 woorden. 
6. De vorming van de promovendus of promovenda is een belang-
rijker resultaat van het promotietraject dan de door hem of 
haar geschreven artikelen. 
7. In het boek dat leven heet, heeft God letterlijk geen betekenis. 
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